Protein(poly)peptide libraries

ABSTRACT

The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.

This is a divisional of application Ser. No. 09/025,769 now U.S. Pat. No. 6,300,064, filed Feb. 18, 1998 which is a continuation of PCT/EP96/03647, filed Aug. 19, 1995.

FIELD OF THE INVENTION

The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.

BACKGROUND TO THE INVENTION

All current recombinant methods which use libraries of proteins/(poly)peptides, e.g. antibodies, to screen for members with desired properties, e.g. binding a given ligand, do not provide the possibility to improve the desired properties of the members in an easy and rapid manner. Usually a library is created either by inserting a random oligonucleotide sequence into one or more DNA sequences cloned from an organism, or a family of DNA sequences is cloned and used as the library. The library is then screened, e.g. using phage display, for members which show the desired property. The sequences of one or more of these resulting molecules are then determined. There is no general procedure available to improve these molecules further on.

Winter (EP 0 368 684 B1) has provided a method for amplifying (by PCR), cloning, and expressing antibody variable region genes. Starting with these genes he was able to create libraries of functional antibody fragments by randomizing the CDR3 of the heavy and/or the light chain. This process is functionally equivalent to the natural process of VJ and VDJ recombination which occurs during the development of B-cells in the immune system.

However the Winter invention does not provide a method for optimizing the binding affinities of antibody fragments further on, a process which would be functionally equivalent to the naturally occurring phenomenon of “affinity maturation”, which is provided by the present invention. Furthermore, the Winter invention does not provide for artificial variable region genes, which represent a whole family of structurally similar natural genes, and which can be assembled from synthetic DNA oligonucleotides. Additionally, Winter does not enable the combinatorial assembly of portions of antibody variable regions, a feature which is provided by the present invention. Furthermore, this approach has the disadvantage that the genes of all antibodies obtained in the screening procedure have to be completely sequenced, since, except for the PCR priming regions, no additional sequence information about the library members is available. This is time and labor intensive and potentially leads to sequencing errors.

The teaching of Winter as well as other approaches have tried to create large antibody libraries having high diversity in the complementarity determining regions (CDRs) as well as in the frameworks to be able to find antibodies against as many different antigens as possible. It has been suggested that a single universal framework may be useful to build antibody libraries, but no approach has yet been successful.

Another problem lies in the production of reagents derived from antibodies. Small antibody fragments show exciting promise for use as therapeutic agents, diagnostic reagents, and for biochemical research. Thus, they are needed in large amounts, and the expression of antibody fragments, e.g. Fv, single-chain Fv (scFv), or Fab in the periplasm of E. coli (Skerra & Plückthun, 1988; Better et al., 1988) is now used routinely in many laboratories. Expression yields vary widely, however. While some fragments yield up to several mg of functional, soluble protein per liter and OD of culture broth in shake flask culture (Carter et al., 1992, Plückthun et al. 1996), other fragments may almost exclusively lead to insoluble material, often found in so-called inclusion bodies. Functional protein may be obtained from the latter in modest yields by a laborious and time-consuming refolding process. The factors influencing antibody expression levels are still only poorly understood. Folding efficiency and stability of the antibody fragments, protease lability and toxicity of the expressed proteins to the host cells often severely limit actual production levels, and several attempts have been tried to increase expression yields. For example, Knappik & Plückthun (1995) could show that expression yield depends on the antibody sequence. They identified key residues in the antibody framework which influence expression yields dramatically. Similarly, Ullrich et al. (1995) found that point mutations in the CDRs can increase the yields in periplasmic antibody fragment expression. Nevertheless, these strategies are only applicable to a few antibodies. Since the Winter invention uses existing repertoires of antibodies, no influence on expressibility of the genes is possible.

Furthermore, the findings of Knappik & Plückthun and Ullrich demonstrate that the knowledge about antibodies, especially about folding and expression is still increasing. The Winter invention does not allow to incorporate such improvements into the library design.

The expressibility of the genes is important for the library quality as well, since the screening procedure relies in most cases on the display of the gene product on a phage surface, and efficient display relies on at least moderate expression of the gene.

These disadvantages of the existing methodologies are overcome by the present invention, which is applicable for all collections of homologous proteins. It has the following novel and useful features illustrated in the following by antibodies as an example:

Artificial antibodies and fragments thereof can be constructed based on known antibody sequences, which reflect the structural properties of a whole group of homologous antibody genes. Therefore it is possible to reduce the number of different genes without any loss in the structural repertoire. This approach leads to a limited set of artificial genes, which can be synthesized de novo, thereby allowing introduction of cleavage sites and removing unwanted cleavages sites. Furthermore, this approach enables (i), adapting the codon usage of the genes to that of highly expressed genes in any desired host cell and (ii), analyzing all possible pairs of antibody light (L) and heavy (H) chains in terms of interaction preference, antigen preference or recombinant expression titer, which is virtually impossible using the complete collection of antibody genes of an organism and all combinations thereof.

The use of a limited set of completely synthetic genes makes it possible to create cleavage sites at the boundaries of encoded structural sub-elements. Therefore, each gene is built up from modules which represent structural sub-elements on the protein/(poly)peptide level. In the case of antibodies, the modules consist of “framework” and “CDR” modules. By creating separate framework and CDR modules, different combinatorial assembly possibilities are enabled. Moreover, if two or more artificial genes carry identical pairs of cleavage sites at the boundaries of each of the genetic sub-elements, pre-built libraries of sub-elements can be inserted in these genes simultaneously, without any additional information related to any particular gene sequence. This strategy enables rapid optimization of, for example, antibody affinity, since DNA cassettes encoding libraries of genetic sub-elements can be (i), pre-built, stored and reused and (ii), inserted in any of these sequences at the right position without knowing the actual sequence or having to determine the sequence of the individual library member.

Additionally, new information about amino acid residues important for binding, stability, or solubility and expression could be integrated into the library design by replacing existing modules with modules modified according to the new observations.

The limited number of consensus sequences used for creating the library allows to speed up the identification of binding antibodies after screening. After having identified the underlying consensus gene sequence, which could be done by sequencing or by using fingerprint restriction sites, just those part(s) comprising the random sequence(s) have to be determined. This reduces the probability of sequencing errors and of false-positive results.

The above mentioned cleavage sites can be used only if they are unique in the vector system where the artificial genes have been inserted. As a result, the vector has to be modified to contain none of these cleavage sites. The construction of a vector consisting of basic elements like resistance gene and origin of replication, where cleavage sites have been removed, is of general interest for many cloning attempts. Additionally, these vector(s) could be part of a kit comprising the above mentioned artificial genes and pre-built libraries.

The collection of artificial genes can be used for a rapid humanization procedure of non-human antibodies, preferably of rodent antibodies. First, the amino acid sequence of the non-human, preferably rodent antibody is compared with the amino acid sequences encoded by the collection of artificial genes to determine the most homologous light and heavy framework regions. These genes are then used for insertion of the genetic sub-elements encoding the CDRs of the non-human, preferably rodent antibody.

Surprisingly, it has been found that with a combination of only one consensus sequence for each of the light and heavy chains of a scFv fragment an antibody repertoire could be created yielding antibodies against virtually every antigen. Therefore, one aspect of the present invention is the use of a single consensus sequence as a universal framework for the creation of useful (poly)peptide libraries and antibody consensus sequences useful therefor.

DETAILED DESCRIPTION OF THE INVENTION

The present invention enables the creation of useful libraries of (poly)peptides. In a first embodiment, the invention provides for a method of setting up nucleic acid sequences suitable for the creation of said libraries. In a first step, a collection of at least three homologous proteins is identified and then analyzed. Therefore, a database of the protein sequences is established where the protein sequences are aligned to each other. The database is used to define subgroups of protein sequences which show a high degree of similarity in both the sequence and, if information is available, in the structural arrangement. For each of the subgroups a (poly)peptide sequence comprising at least one consensus sequence is deduced which represents the members of this subgroup; the complete collection of (poly)peptide sequences represent therefore the complete structural repertoire of the collection of homologous proteins. These artificial (poly)peptide sequences are then analyzed, if possible, according to their structural properties to identify unfavorable interactions between amino acids within said (poly)peptide sequences or between said or other (poly)peptide sequences, for example, in multimeric proteins. Such interactions are then removed by changing the consensus sequence accordingly. The (poly)peptide sequences are then analyzed to identify sub-elements such as domains, loops, helices or CDRs. The amino acid sequence is backtranslated into a corresponding coding nucleic acid sequence which is adapted to the codon usage of the host planned for expressing said nucleic acid sequences. A set of cleavage sites is set up in a way that each of the sub-sequences encoding the sub-elements identified as described above, is flanked by two sites which do not occur a second time within the nucleic acid sequence. This can be achieved by either identifying a cleavage site already flanking a sub-sequence of by changing one or more nucleotides to create the cleavage site, and by removing that site from the remaining part of the gene. The cleavage sites should be common to all corresponding sub-elements or sub-sequences, thus creating a fully modular arrangement of the sub-sequences in the nucleic acid sequence and of the sub-elements in the corresponding (poly)peptide.

In a further embodiment, the invention provides for a method which sets up two or more sets of (poly)peptides, where for each set the method as described above is performed, and where the cleavage sites are not only unique within each set but also between any two sets. This method can be applied for the creation of (poly)peptide libraries comprising for example two ex-helical domains from two different proteins, where said library is screened for novel hetero-association domains.

In yet a further embodiment, at least two of the sets as described above, are derived from the same collection of proteins or at least a part of it. This describes libraries comprising for example, but not limited to, two domains from antibodies such as VH and VL, or two extracellular loops of transmembrane receptors.

In another embodiment, the nucleic acid sequences set up as described above, are synthesized. This can be achieved by any one of several methods well known to the practitioner skilled in the art, for example, by total gene synthesis or by PCR-based approaches.

In one embodiment, the nucleic acid sequences are cloned into a vector. The vector could be a sequencing vector, an expression vector or a display (e.g. phage display) vector, which are well known to those skilled in the art. Any vector could comprise one nucleic acid sequence, or two or more nucleic sequences, either in different or the same operon. In the last case, they could either be cloned separately or as contiguous sequences.

In one embodiment, the removal of unfavorable interactions as described above, leads to enhanced expression of the modified (poly)peptides.

In a preferred embodiment, one or more sub-sequences of the nucleic acid sequences are replaced by different sequences. This can be achieved by excising the sub-sequences using the conditions suitable for cleaving the cleavage sites adjacent to or at the end of the sub-sequence, for example, by using a restriction enzyme at the corresponding restriction site under the conditions well known to those skilled in the art, and replacing the sub-sequence by a different sequence compatible with the cleaved nucleic acid sequence. In a further preferred embodiment, the different sequences replacing the initial sub-sequence(s) are genomic or rearranged genomic sequences, for example in grafting CDRs from non-human antibodies onto consensus antibody sequences for rapid humanization of non-human antibodies. In the most preferred embodiment, the different sequences are random sequences, thus replacing the sub-sequence by a collection of sequences to introduce variability and to create a library. The random sequences can be assembled in various ways, for example by using a mixture of mononucleotides or preferably a mixture of trinucleotides (Virnekäs et al., 1994) during automated oligonucleotide synthesis, by error-prone PCR or by other methods well known to the practitioner in the art. The random sequences may be completely randomized or biased towards or against certain codons according to the amino acid distribution at certain positions in known protein sequences. Additionally, the collection of random sub-sequences may comprise different numbers of codons, giving rise to a collection of sub-elements having different lengths.

In another embodiment, the invention provides for the expression of the nucleic acid sequences from a suitable vector and under suitable conditions well known to those skilled in the art.

In a further preferred embodiment, the (poly)peptides expressed from said nucleic acid sequences are screened and, optionally, optimized. Screening may be performed by using one of the methods well known to the practitioner in the art, such as phage-display, selectively infective phage, polysome technology to screen for binding, assay systems for enzymatic activity or protein stability. (Poly)peptides having the desired property can be identified by sequencing of the corresponding nucleic acid sequence or by amino acid sequencing or mass spectrometry. In the case of subsequent optimization, the nucleic acid sequences encoding the initially selected (poly)peptides can optionally be used without sequencing. Optimization is performed by repeating the replacement of sub-sequences by different sequences, preferably by random sequences, and the screening step one or more times.

The desired property the (poly)peptides are screened for is preferably, but not exclusively, selected from the group of optimized affinity or specificity for a target molecule, optimized enzymatic activity, optimized expression yields, optimized stability and optimized solubility.

In one embodiment, the cleavage sites flanking the sub-sequences are sites recognized and cleaved by restriction enzymes, with recognition and cleavage sequences being either identical or different, the restricted sites either having blunt or sticky ends.

The length of the sub-elements is preferably, but not exclusively ranging between 1 amino acid, such as one residue in the active site of an enzyme or a structure-determining residue, and 150 amino acids, as for whole protein domains. Most preferably, the length ranges between 3 and 25 amino acids, such as most commonly found in CDR loops of antibodies.

The nucleic acid sequences could be RNA or, preferably, DNA.

In one embodiment, the (poly)peptides have an amino acid pattern characteristic of a particular species. This can for example be achieved by deducing the consensus sequences from a collection of homologous proteins of just one species, most preferably from a collection of human proteins. Since the (poly)peptides comprising consensus sequences are artificial, they have to be compared to the protein sequence(s) having the closest similarity to ensure the presence of said characteristic amino acid pattern.

In one embodiment, the invention provides for the creation of libraries of (poly)peptides comprising at least part of members or derivatives of the immunoglobulin superfamily, preferably of member or derivatives of the immunoglobulins. Most preferably, the invention provides for the creation of libraries of human antibodies, wherein said (poly)peptides are or are derived from heavy or light chain variable regions wherein said structural sub-elements are framework regions (FR) 1, 2, 3, or 4 or complementary determining regions (CDR) 1, 2, or 3. In a first step, a database of published antibody sequences of human origin is established where the antibody sequences are aligned to each other. The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold of CDR loops (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.

These artificial genes are then constructed e.g. by total gene synthesis or by the use of synthetic genetic subunits. These genetic subunits correspond to structural sub-elements on the (poly)peptide level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the sub-elements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of corresponding genetic sub-sequences. Most preferably, said (poly)peptides are or are derived from the HuCAL consensus genes: Vκ1, Vκ2, Vκ3, Vκ4, Vλ1, Vλ2, Vλ3, VH1A, VH1B, VH2, VH3, VH4, VH5, VH6, Cκ, Cλ, CH1 or any combination of said HuCAL consensus genes.

This collection of DNA molecules can then be used to create libraries of antibodies or antibody fragments, preferably Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments, which may be used as sources of specificities against new target antigens. Moreover, the affinity of the antibodies can be optimized using pre-built library cassettes and a general procedure. The invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule. Preferably, an scFv fragment library comprising the combination of HuCAL VH3 and HuCAL Vλ2 consensus genes and at least a random sub-sequence encoding the heavy chain CDR3 sub-element is screened for binding antibodies. If necessary, the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements. The expression and screening steps can then be repeated until an antibody having the desired affinity is generated.

Particularly preferred is a method in which one or more of the genetic subunits (e.g. the CDRs) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are selected, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomized as described above.

A further embodiment of the present invention relates to fusion proteins by providing for a DNA sequence which encodes both the (poly)peptide, as described above, as well as an additional moiety. Particularly preferred are moieties which have a useful therapeutic function. For example, the additional moiety may be a toxin molecule which is able to kill cells (Vitetta et al., 1993). There are numerous examples of such toxins, well known to the one skilled in the art, such as the bacterial toxins Pseudomonas exotoxin A, and diphtheria toxin, as well as the plant toxins ricin, abrin, modeccin, saporin, and gelonin. By fusing such a toxin for example to an antibody fragment, the toxin can be targeted to, for example, diseased cells, and thereby have a beneficial therapeutic effect. Alternatively, the additional moiety may be a cytokine, such as IL-2 (Rosenberg & Lotze, 1986), which has a particular effect (in this case a T-cell proliferative effect) on a family of cells. In a further embodiment, the additional moiety may confer on its (poly)peptide partner a means of detection and/or purification. For example, the fusion protein could comprise the modified antibody fragment and an enzyme commonly used for detection purposes, such as alkaline phosphatase (Blake et al., 1984). There are numerous other moieties which can be used as detection or purification tags, which are well known to the practitioner skilled in the art. Particularly preferred are peptides comprising at least five histidine residues (Hochuli et al., 1988), which are able to bind to metal ions, and can therefore be used for the purification of the protein to which they are fused (Lindner et al., 1992). Also provided for by the invention are additional moieties such as the commonly used C-myc and FLAG tags (Hopp et al., 1988; Knappik & Plückthun, 1994).

By engineering one or more fused additional domains, antibody fragments or any other (poly)peptide can be assembled into larger molecules which also fall under the scope of the present invention. For example, mini-antibodies (Pack, 1994) are dimers comprising two antibody fragments, each fused to a self-associating dimerization domain. Dimerization domains which are particularly preferred include those derived from a leucine zipper (Pack & Plückthun, 1992) or helix-turn-helix motif (Pack et al., 1993).

All of the above embodiments of the present invention can be effected using standard techniques of molecular biology known to anyone skilled in the art.

In a further embodiment, the random collection of sub-sequences (the library) is inserted into a singular nucleic acid sequence encoding one (poly)peptide, thus creating a (poly)peptide library based on one universal framework. Preferably a random collection of CDR sub-sequences is inserted into a universal antibody framework, for example into the HuCAL H3κ2 single-chain Fv fragment described above.

In further embodiments, the invention provides for nucleic acid sequence(s), vector(s) containing the nucleic acid sequence(s), host cell(s) containing the vector(s), and (poly)peptides, obtainable according to the methods described above.

In a further preferred embodiment, the invention provides for modular vector systems being compatible with the modular nucleic acid sequences encoding the (poly)peptides. The modules of the vectors are flanked by restriction sites unique within the vector system and essentially unique with respect to the restriction sites incorporated into the nucleic acid sequences encoding the (poly)peptides, except for example the restriction sites necessary for cloning the nucleic acid sequences into the vector. The list of vector modules comprises origins of single-stranded replication, origins of double-stranded replication for high- and low copy number plasmids, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, purification and detection tags, and sequences of additional moieties. The vectors are preferably, but not exclusively, expression vectors or vectors suitable for expression and screening of libraries.

In another embodiment, the invention provides for a kit, comprising one or more of the list of nucleic acid sequence(s), recombinant vector(s), (poly)peptide(s), and vector(s) according to the methods described above, and suitable host cell(s) for producing the (poly)peptide(s).

In a preferred embodiment, the invention provides for the creation of libraries of human antibodies. In a first step, a database of published antibody sequences of human origin is established. The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.

These artificial genes are then constructed by the use of synthetic genetic subunits. These genetic subunits correspond to structural sub-elements on the protein level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the subelements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of said genetic subunits.

This collection of DNA molecules can then be used to create libraries of antibodies which may be used as sources of specificities against new target antigens. Moreover, the affinity of the antibodies can be optimised using pre-built library cassettes and a general procedure. The invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule. If necessary, the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements. The expression and screening steps can then be repeated until an antibody having the desired affinity is generated.

Particularly preferred is a method in which one or more of the genetic subunits (e.g. the CDR's) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are eluted, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomised as described above.

DEFINITIONS

Protein:

The term protein comprises monomeric polypeptide chains as well as homo- or heteromultimeric complexes of two or more polypeptide chains connected either by covalent interactions (such as disulphide bonds) or by non-covalent interactions (such as hydrophobic or electrostatic interactions).

Analysis of Homologous Proteins:

The amino acid sequences of three or more proteins are aligned to each other (allowing for introduction of gaps) in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous if the percentage of the sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15% of the amino acids in the aligned genes are identical, and at least 30% are similar. Examples for families of homologous proteins are: immunoglobulin superfamily, scavenger receptor superfamily, fibronectin superfamilies (e.g. type II and III), complement control protein superfamily, cytokine receptor superfamily, cystine knot proteins, tyrosine kinases, and numerous other examples well known to one of ordinary skill in the art.

Consensus Sequence:

Using a matrix of at least three aligned amino acid sequences, and allowing for gaps in the alignment, it is possible to determine the most frequent amino acid residue at each position. The consensus sequence is that sequence which comprises the amino acids which are most frequently represented at each position. In the event that two or more amino acids are equally represented at a single position, the consensus sequence includes both or all of those amino acids.

Removing Unfavorable Interactions:

The consensus sequence is per se in most cases artificial and has to be analyzed in order to change amino acid residues which, for example, would prevent the resulting molecule to adapt a functional tertiary structure or which would block the interaction with other (poly)peptide chains in multimeric complexes. This can be done either by (i) building a three-dimensional model of the consensus sequence using known related structures as a template, and identifying amino acid residues within the model which may interact unfavorably with each other, or (ii) analyzing the matrix of aligned amino acid sequences in order to detect combinations of amino acid residues within the sequences which frequently occur together in one sequence and are therefore likely to interact with each other. These probable interaction-pairs are then tabulated and the consensus is compared with these “interaction maps”. Missing or wrong interactions in the consensus are repaired accordingly by introducing appropriate changes in amino acids which minimize unfavorable interactions.

Identification of Structural Sub-Elements:

Structural sub-elements are stretches of amino acid residues within a protein/(poly)peptide which correspond to a defined structural or functional part of the molecule. These can be loops (e.g. CDR loops of an antibody) or any other secondary or functional structure within the protein/(poly)peptide (domains, α-helices, β-sheets, framework regions of antibodies, etc.). A structural sub-element can be identified using known structures of similar or homologous (poly)peptides, or by using the above mentioned matrices of aligned amino acid sequences. Here the variability at each position is the basis for determining stretches of amino acid residues which belong to a structural sub-element (e.g. hypervariable regions of an antibody).

Sub-Sequence:

A sub-sequence is defined as a genetic module which is flanked by unique cleavage sites and encodes at least one structural sub-element. It is not necessarily identical to a structural sub-element.

Cleavage Site:

A short DNA sequence which is used as a specific target for a reagent which cleaves DNA in a sequence-specific manner (e.g. restriction endonucleases).

Compatible Cleavage Sites:

Cleavage sites are compatible with each other, if they can be efficiently ligated without modification and, preferably, also without adding an adapter molecule.

Unique Cleavage Sites:

A cleavage site is defined as unique if it occurs only once in a vector containing at least one of the genes of interest, or if a vector containing at least one of the genes of interest could be treated in a way that only one of the cleavage sites could be used by the cleaving agent.

Corresponding (Poly)Peptide Sequences:

Sequences deduced from the same part of one group of homologous proteins are called corresponding (poly)peptide sequences.

Common Cleavage Sites:

A cleavage site in at least two corresponding sequences, which occurs at the same functional position (i.e. which flanks a defined sub-sequence), which can be hydrolyzed by the same cleavage tool and which yields identical compatible ends is termed a common cleavage site.

Excising Genetic Sub-Sequences:

A method which uses the unique cleavage sites and the corresponding cleavage reagents to cleave the target DNA at the specified positions in order to isolate, remove or replace the genetic sub-sequence flanked by these unique cleavage sites.

Exchanging Genetic Sub-Sequences:

A method by which an existing sub-sequence is removed using the flanking cleavage sites of this sub-sequence, and a new sub-sequence or a collection of sub-sequences, which contain ends compatible with the cleavage sites thus created, is inserted.

Expression of Genes:

The term expression refers to in vivo or in vitro processes, by which the information of a gene is transcribed into mRNA and then translated into a protein/(poly)peptide. Thus, the term expression refers to a process which occurs inside cells, by which the information of a gene is transcribed into mRNA and then into a protein. The term expression also includes all events of post-translational modification and transport, which are necessary for the (poly)peptide to be functional.

Screening of Protein (Poly)Peptide Libraries:

Any method which allows isolation of one or more proteins/(poly)peptides having a desired property from other proteins/(poly)peptides within a library.

Amino Acid Pattern Characteristic for a Species:

A (poly)peptide sequence is assumed to exhibit an amino acid pattern characteristic for a species if it is deduced from a collection of homologous proteins from just this species.

Immunoglobulin Superfamily (IgSF):

The IgSF is a family of proteins comprising domains being characterized by the immunoglobulin fold. The IgSF comprises for example T-cell receptors and the immunoglobulins (antibodies).

Antibody Framework:

A framework of an antibody variable domain is defined by Kabat et al. (1991) as the part of the variable domain which serves as a scaffold for the antigen binding loops of this variable domain.

Antibody CDR:

The CDRs (complementarity determining regions) of an antibody consist of the antigen binding loops, as defined by Kabat et al. (1991). Each of the two variable domains of an antibody Fv fragment contain three CDRs.

HuCAL:

Acronym for Human Combinatorial Antibody Library. Antibody Library based on modular consensus genes according to the invention (see Example 1).

Antibody Fragment:

Any portion of an antibody which has a particular function, e.g. binding of antigen. Usually, antibody fragments are smaller than whole antibodies. Examples are Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments. Additionally, antibody fragments are often engineered to include new functions or properties.

Universal Framework:

One single framework which can be used to create the full variability of functions, specificities or properties which is originally sustained by a large collection of different frameworks, is called universal framework.

Binding of an Antibody to its Target:

The process which leads to a tight and specific association between an antibody and a corresponding molecule or ligand is called binding. A molecule or ligand or any part of a molecule or ligand which is recognized by an antibody is called the target.

Replacing Genetic Sub-Sequences

A method by which an existing sub-sequence is removed using the flanking cleavage sites of this sub-sequence, and a new sub-sequence or collection of sub-sequences, which contains ends compatible with the cleavage sites this creates, is inserted inserted.

Assembling of Genetic Sequences:

Any process which is used to combine synthetic or natural genetic sequences in a specific manner in order to get longer genetic sequences which contain at least parts of the used synthetic or natural genetic sequences.

Analysis of Homologous Genes:

The corresponding amino acid sequences of two or more genes are aligned to each other in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous if the percentage of the sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15 percent of the amino acids in the aligned genes are identical, and at least 30 percent are similar.

LEGENDS TO FIGURES AND TABLES

FIG. 1: Flow chart outlining the process of construction of a synthetic human antibody library based on consensus sequences.

FIGS. 2A–2G: Alignment of consensus sequences designed for each subgroup (amino acid residues are shown with their standard one-letter abbreviation). (2A–2B) kappa sequences, (2C–2D) lambda sequences and (2E–2G), heavy chain sequences. The positions are numbered according to Kabat (1991). In order to maximize homology in the alignment, gaps (−) have been introduced in the sequence at certain positions.

FIGS. 3A–3K: Gene sequences of the synthetic V kappa consensus genes. The corresponding amino acid sequences (see FIGS. 2A–2B) as well as the unique cleavage sites are also shown.

FIGS. 4A–4I: Gene sequences of the synthetic V lambda consensus genes. The corresponding amino acid sequences (see FIGS. 2C–2D) as well as the unique cleavage sites are also shown.

FIGS. 5A–5U: Gene sequences of the synthetic V heavy chain consensus genes. The corresponding amino acid sequences (see FIGS. 2E–2G) as well as the unique cleavage sites are also shown.

FIGS. 6A–6G: Oligonucleotides used for construction of the consensus genes. The oligos are named according to the corresponding consensus gene, e.g. the gene Vκ1 was constructed using the six oligonucleotides O1K1 to O1K6. The oligonucleotides used for synthesizing the genes encoding the constant domains Cκ (OCLK1 to 8) and CH1 (OCH1 to 8) are also shown.

FIGS. 7A–7D: Sequences of the synthetic genes encoding the constant domains Cκ (7A–7B) and CH1 (7C–7D). The corresponding amino acid sequences as well as unique cleavage sites introduced in these genes are also shown.

FIGS. 7E–7H: Functional map and sequence of module M24 comprising the synthetic Cλ gene segment (huCL lambda).

FIGS. 7I–7J: Oligonucleotides used for synthesis of module M24.

FIGS. 8A–8E: Sequence and restriction map of the synthetic gene encoding the consensus single-chain fragment VH3-Vκ2. The signal sequence (amino acids 1 to 21) was derived from the E. coli phoA gene (Skerra & Plückthun, 1988). Between the phoA signal sequence and the VH3 domain, a short sequence stretch encoding 4 amino acid residues (amino acid 22 to 25) has been inserted in order to allow detection of the single-chain fragment in Western blot or ELISA using the monoclonal antibody M1 (Knappik & Plückthun, 1994). The last 6 basepairs of the sequence were introduced for cloning purposes (EcoRI site).

FIG. 9: Plasmid map of the vector pIG10.3 used for phage display of the H3κ2 scFv fragment. The vector is derived from pIG10 and contains the gene for the lac operon repressor, lac1, the artificial operon encoding the H3κ2-gene3ss fusion under control of the lac promoter, the 1pp terminator of transcription, the single-strand replication origin of the E. coli phage f1 (F1_ORI), a gene encoding β-lactamase (bla) and the ColEI derived origin of replication.

FIGS. 10A–10B: Sequencing results of independent clones from the initial library, translated into the corresponding amino acid sequences. (A) Amino acid sequence of the VH3 consensus heavy chain CDR3 (position 93 to 102, Kabat numbering). (B) Amino acid sequences of 12 clones of the 10-mer library. (C) Amino acid sequences of 11 clones of the 15-mer library, *: single base deletion.

FIG. 11: Expression test of individual library members. (A) Expression of 9 independent clones of the 10-mer library. (B) Expression of 9 independent clones of the 15-mer library. The lane designated with M contains the size marker. Both the gp3-scFv fusion and the scFv monomer are indicated.

FIG. 12: Enrichment of specific phage antibodies during the panning against FITC-BSA. The initial as well as the subsequent fluorescein-specific sub-libraries were panned against the blocking buffer and the ratio of the phage eluted from the FITC-BSA coated well vs. that from the powder milk coated well from each panning round is presented as the “specificity factor”.

FIG. 13: Phage ELISA of 24 independent clones after the third round of panning tested for binding on FITC-BSA.

FIG. 14: Competition ELISA of selected FITC-BSA binding clones. The ELISA signals (OD.sub.405 nm) of scFv binding without inhibition are taken as 100%.

FIG. 15: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against FITC-BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 203–218 respectively) (position 93 to 102, Kabat numbering).

FIG. 16: Coomassie-Blue stained SDS-PAGE of the purified anti-fluorescein scFv fragments: M: molecular weight marker, A: total soluble cell extract after induction, B: fraction of the flow-through, C, D and E: purified scFv fragments 1HA-3E4, 1HA-3E5 and 1HA-3E10, respectively.

FIG. 17: Enrichment of specific phage antibodies during the panning against β-estradiol-BSA, testosterone-BSA, BSA, ESL-1, interleukin-2, lymphotoxin-β and, LeY-BSA after three rounds of panning.

FIG. 18: ELISA of selected ESL-1 and .beta.-estradiol binding clones.

FIG. 19: Selectivity and cross-reactivity of HuCAL antibodies: in the diagonal specific binding of HuCAL antibodies can be seen, off-diagonal signals show non-specific cross-reactivity.

FIG. 20: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against β-estradiol-BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 219–230 respectively) (position 93 to 102, Kabat numbering). One clone is derived from the 10mer library.

FIG. 21: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against testosterone-BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 231–236 respectively) (position 93 to 102, Kabat numbering).

FIG. 22: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against lymphotoxin-.beta., translated into the corresponding amino acid sequences (SEQ ID NOS 237–244 respectively) (position 93 to 102, Kabat numbering). One clone comprises a 14mer CDR, presumably introduced by incomplete coupling of the trinucleotide mixture during oligonucleotide synthesis.

FIG. 23: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against ESL-1, translated into the corresponding amino acid sequences (SEQ ID NOS 245–256 respectively) (position 93 to 102, Kabat numbering). Two clones are derived from the 10mer library. One clone comprises a 16mer CDR, presumably introduced by chain elongation during oligonucleotide synthesis using trinucleotides.

FIG. 24: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 257–262 respectively) (position 93 to 102, Kabat numbering).

FIG. 25A: Schematic representation of the modular pCAL vector system.

FIGS. 25B–25C: List of restriction sites already used in or suitable for the modular HuCAL genes and pCAL vector system.

FIGS. 26A–26D: List of the modular vector elements for the pCAL vector series: shown are only those restriction sites which are part of the modular system.

FIGS. 27A–27B: Functional map and sequence of the multi-cloning site module (MCS).

FIGS. 28A–28G: Functional map and sequence of the pMCS cloning vector series.

FIGS. 29A–29B: Functional map and sequence of the pCAL module M1 (see FIGS. 26A–26D).

FIGS. 30A–30C: Functional map and sequence of the pCAL module M7-III (see FIGS. 26A–26D).

FIGS. 31A–31B: Functional map and sequence of the pCAL module M9-II (see FIGS. 26A–26D).

FIGS. 32A–32C: Functional map and sequence of the pCAL module M11-II (see FIGS. 26A–26D).

FIGS. 33A–33D: Functional map and sequence of the pCAL module M14-Ext2 (see FIGS. 26A–26D).

FIGS. 34A–34D: Functional map and sequence of the pCAL module M17 (see FIGS. 26A–26D).

FIGS. 35 to 35A-8: functional map and sequence module vector pCAL4.

FIGS. 35A-9 to 35A-75: Functional maps and sequences of additional pCAL modules (M2, M3, M7I, M7II, M8, M10II, M11II, M12, M13, M19, M20, M21, M41) and of low-copy number plasmid vectors (pCALO1 to pCALO3).

FIGS. 35A-76 to 35A-80: List of oligonucleotides and primers used for synthesis of pCAL vector modules.

FIGS. 36A–36F: Functional map and sequence of the β-lactamase cassette for replacement of CDRs for CDR library cloning.

FIGS. 37A–37D: Oligo and primer design for Vκ CDR3 libraries.

FIGS. 38A–38D: Oligo and primer design for Vλ CDR3 libraries.

FIG. 39: Functional map of the pBS13 expression vector series.

FIGS. 40A–40B: Expression of all 49 HuCAL scFvs obtained by combining each of the 7 VH genes with each of the 7 VL genes (pBS 13, 30° C.): Values are given for the percentage of soluble vs. insoluble material, the total and the soluble amount compared to the combination H3P2, which was set to 100%. In addition, the corresponding values for the McPC603 scFv are given.

TABLE 1 Summary of human immunoglobulin germline sequences used for computing the germline membership of rearranged sequences. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. (1) The germline name used in the various calculations, (2) the references number for the corresponding sequence (see appendix for sequence related citations), (3) the family where each sequence belongs to and (4), the various names found in literature for germline genes with identical amino acid sequences.

TABLE 2 Rearranged human sequences used for the calculation of consensus sequences. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The table summarized the name of the sequence (1), the length of the sequence in amino acids (2), the germline family (3) as well as the computed germline counterpart (4). The number of amino acid exchanges between the rearranged sequence and the germline sequence is tabulated in (5), and the percentage of different amino acids is given in (6). Column (7) gives the references number for the corresponding sequence (see appendix for sequence related citations).

TABLE 3 Assignment of rearranged V sequences to their germline counterparts. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The germline genes are tabulated according to their family (1), and the number of rearranged genes found for every germline gene is given in (2).

TABLE 4 Computation of the consensus sequence of the rearranged V kappa sequences. (A) (SEQ ID NO: 14), V kappa subgroup 1, (B) (SEQ ID NO: 15), V kappa subgroup 2, (C) (SEQ ID NO: 16), V kappa subgroup 3 and (D) (SEQ ID NO: 17), V kappa subgroup 4. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. (1) Amino acids are given with their standard one-letter abbreviations (and B means D or N, Z means E or Q and X means any amino acid). The statistical analysis summarizes the number of sequences found at each position (2), the number of occurrences of the most common amino acid (3), the amino acid residue which is most common at this position (4), the relative frequency of the occurrence of the most common amino acid (5) and the number of different amino acids found at each position (6).

TABLE 5 Computation of the consensus sequence of the rearranged V lambda sequences. (A) (SEQ ID NO: 18), V lambda subgroup 1, (B) (SEQ ID NO: 19), V lambda subgroup 2, and (C) (SEQ ID NO: 20), V lambda subgroup 3. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.

TABLE 6 Computation of the consensus sequence of the rearranged V heavy chain sequences. (A) (SEQ ID NO: 21), V heavy chain subgroup 1A, (B) (SEQ ID NO: 22), V heavy chain subgroup 1B, (C) (SEQ ID NO: 23), V heavy chain subgroup 2, (D) (SEQ ID NO: 24), V heavy chain subgroup 3, (E) (SEQ ID NO: 25), V heavy chain subgroup 4, (F) (SEQ ID NO: 26), V heavy chain subgroup 5, and (G) (SEQ ID NO: 27), V heavy chain subgroup 6. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.

EXAMPLES Example 1 Design of a Synthetic Human Combinatorial Antibody Library (HuCAL)

The following example describes the design of a fully synthetic human combinatorial antibody library (HuCAL), based on consensus sequences of the human immunoglobulin repertoire, and the synthesis of the consensus genes. The general procedure is outlined in FIG. 1.

1.1 Sequence Database

1.1.1 Collection and Alignment of Human Immunoglobulin Sequences

In a first step, sequences of variable domains of human immunoglobulins have been collected and divided into three sub bases: V heavy chain (VH), V kappa (Vκ) and V lambda (Vλ). For each sequence, the gene sequence was then translated into the corresponding amino acid sequence. Subsequently, all amino acid sequences were aligned according to Kabat et al. (1991). In the case of Vλ sequences, the numbering system of Chuchana et al. (1990) was used. Each of the three main databases was then divided into two further sub bases: the first sub base contained all sequences derived from rearranged V genes, where more than 70 positions of the sequence were known. The second sub base contained all germline gene segments (without the D- and J-minigenes; pseudogenes with internal stop codons were also removed). In all cases, where germline sequences with identical amino acid sequence but different names were found, only one sequence was used (see Table 1). The final databases of rearranged sequences contained 386, 149 and 674 entries for Vκ, Vλ and VH, respectively. The final databases of germline sequences contained 48, 26 and 141 entries for Vκ, Vλ and VH, respectively.

1.1.2 Assignment of Sequences to Subgroups

The sequences in the three germline databases where then grouped according to sequence homology (see also Tomlinson et al., 1992, Williams & Winter, 1993, and Cox et al., 1994). In the case of Vκ, 7 families could be established. Vλ was divided into 8 families and VH into 6 families. The VH germline genes of the VH7 family (Van Dijk et al., 1993) were grouped into the VH1 family, since the genes of the two families are highly homologous. Each family contained different numbers of germline genes, varying from 1 (for example VH6) to 47 (VH3).

1.2 Analysis of Sequences

1.2.1 Computation of Germline Membership

For each of the 1209 amino acid sequences in the databases of rearranged genes, the nearest germline counterpart, i.e. the germline sequence with the smallest number of amino acid differences was then calculated. After the germline counterpart was found, the number of somatic mutations which occurred in the rearranged gene and which led to amino acid exchanges could be tabulated. In 140 cases, the germline counterpart could not be calculated exactly, because more than one germline gene was found with an identical number of amino acid exchanges. These rearranged sequences were removed from the database. In a few cases, the number of amino acid exchanges was found to be unusually large (>20 for VL and >25 for VH), indicating either heavily mutated rearranged genes or derivation from germline genes not present in the database. Since it was not possible to distinguish between these two possibilities, these sequences were also removed from the database. Finally, 12 rearranged sequences were removed from the database because they were found to have very unusual CDR lengths and composition or unusual amino acids at canonical positions (see below). In summary, 1023 rearranged sequences out of 1209 (85%) could be clearly assigned to their germline counterparts (see Table 2).

After this calculation, every rearranged gene could be arranged in one of the families established for the germline genes. Now the usage of each germline gene, i.e. the number of rearranged genes which originate from each germline gene, could be calculated (see Table 2). It was found that the usage was strongly biased towards a subset of germline genes, whereas most of the germline genes were not present as rearranged genes in the database and therefore apparently not used in the immune system (Table 3). This observation had already been reported in the case of Vκ (Cox, et al., 1994). All germline gene families, where no or only very few rearranged counterparts could be assigned, were removed from the database, leaving 4 Vκ, 3 Vλ, and 6 VH families.

1.2.2 Analysis of CDR Conformations

The conformation of the antigen binding loops of antibody molecules, the CDRs, is strongly dependent on both the length of the CDRs and the amino acid residues located at the so-called canonical positions (Chothia & Lesk, 1987). It has been found that only a few canonical structures exist, which determine the structural repertoire of the immunoglobulin variable domains (Chothia et al., 1989). The canonical amino acid positions can be found in CDR as well as framework regions. The 13 used germline families defined above (7 VL and 6 VH) were now analyzed for their canonical structures in order to define the structural repertoire encoded in these families.

In 3 of the 4 Vκ families (Vκ1, 2 and 4), one different type of CDR1 conformation could be defined for every family. The family Vκ3 showed two types of CDR1 conformation: one type which was identical to Vκ1 and one type only found in Vκ3. All Vκ CDR2s used the same type of canonical structure. The CDR3 conformation is not encoded in the germline gene segments. Therefore, the 4 Vκ families defined by sequence homology and usage corresponded also to 4 types of canonical structures found in Vκ germline genes.

The 3 Vκ families defined above showed 3 types of CDR1 conformation, each family with one unique type. The Vκ1 family contained 2 different CDR1 lengths (13 and 14 amino acids), but identical canonical residues, and it is thought that both lengths adopt the same canonical conformation (Chothia & Lesk, 1987). In the CDR2 of the used Vλ germlines, only one canonical conformation exists, and the CDR3 conformation is not encoded in the germline gene segments. Therefore, the 3 Vλ families defined by sequence homology and usage corresponded also to 3 types of canonical structures.

The structural repertoire of the human VH sequences was analyzed in detail by Chothia et al., 1992. In total, 3 conformations of CDR1 (H1-1, H1-2 and H1-3) and 6 conformations of CDR2 (H2-1, H2-2, H2-3, H2-4, H2-5 and H2-x) could be defined. Since the CDR3 is encoded in the D- and J-minigene segments, no particular canonical residues are defined for this CDR.

All the members of the VH1 family defined above contained the CDR1 conformation H1-1, but differed in their CDR2 conformation: the H2-2 conformation was found in 6 germline genes, whereas the conformation H2-3 was found in 8 germline genes. Since the two types of CDR2 conformations are defined by different types of amino acid at the framework position 72, the VH1 family was divided into two subfamilies: VH1A with CDR2 conformation H2-2 and VH1B with the conformation H2-3. The members of the VH2 family all had the conformations H1-3 and H2-1 in CDR1 and CDR2, respectively. The CDR1 conformation of the VH3 members was found in all cases to be H1-1, but 4 different types were found in CDR2 (H2-1, H2-3, H2-4 and H2-x). In these CDR2 conformations, the canonical framework residue 71 is always defined by an arginine. Therefore, it was not necessary to divide the VH3 family into subfamilies, since the 4 types of CDR2 conformations were defined solely by the CDR2 itself. The same was true for the VH4 family. Here, all 3 types of CDR1 conformations were found, but since the CDR1 conformation was defined by the CDR itself (the canonical framework residue 26 was found to be glycine in all cases), no subdivisions were necessary. The CDR2 conformation of the VH4 members was found to be H2-1 in all cases. All members of the VH5 family were found to have the conformation H1-1 and H2-2, respectively. The single germline gene of the VH6 family had the conformations H1-3 and H2-5 in CDR1 and CDR2, respectively.

In summary, all possible CDR conformations of the Vκ and Vλ genes were present in the 7 families defined by sequence comparison. From the 12 different CDR conformations found in the used VH germline genes, 7 could be covered by dividing the family VH1 into two subfamilies, thereby creating 7 VH families. The remaining 5 CDR conformations (3 in the VH3 and 2 in the VH4 family) were defined by the CDRs themselves and could be created during the construction of CDR libraries. Therefore, the structural repertoire of the used human V genes could be covered by 49 (7×7) different frameworks.

1.2.3 Computation of Consensus Sequences

The 14 databases of rearranged sequences (4 Vκ, 3 Vλ, and 7 VH) were used to compute the HuCAL consensus sequences of each subgroup (4 HuCAL-Vκ, 3 HuCAL-Vλ, 7 HuCAL-VH, see Table 4, 5 and 6). This was done by counting the number of amino acid residues used at each position (position variability) and subsequently identifying the amino acid residue most frequently used at each position. By using the rearranged sequences instead of the used germline sequences for the calculation of the consensus, the consensus was weighted according to the frequency of usage. Additionally, frequently mutated and highly conserved positions could be identified. The consensus sequences were cross-checked with the consensus of the germline families to see whether the rearranged sequences were biased at certain positions towards amino acid residues which do not occur in the collected germline sequences, but this was found not to be the case. Subsequently, the number of differences of each of the 14 consensus sequences to each of the germline sequences found in each specific family was calculated. The overall deviation from the most homologous germline sequence was found to be 2.4 amino acid residues (s.d.=2.7), ensuring that the “artificial” consensus sequences can still be considered as truly human sequences as far as immunogenicity is concerned.

1.3 Structural Analysis

So far, only sequence information was used to design the consensus sequences. Since it was possible that during the calculation certain artificial combinations of amino acid residues have been created, which are located far away in the sequence but have contacts to each other in the three dimensional structure, leading to destabilized or even misfolded frameworks, the 14 consensus sequences were analyzed according to their structural properties.

It was rationalized that all rearranged sequences present in the database correspond to functional and therefore correctly folded antibody molecules. Hence, the most homologous rearranged sequence was calculated for each consensus sequence. The positions where the consensus differed from the rearranged sequence were identified as potential “artificial residues” and inspected.

The inspection itself was done in two directions. First, the local sequence stretch around each potentially “artificial residue” was compared with the corresponding stretch of all the rearranged sequences. If this stretch was found to be truly artificial, i.e. never occurred in any of the rearranged sequences, the critical residue was converted into the second most common amino acid found at this position and analyzed again. Second, the potentially “artificial residues” were analyzed for their long range interactions. This was done by collecting all available structures of human antibody variable domains from the corresponding PDB files and calculating for every structure the number and type of interactions each amino acid residue established to each side-chain. These “interaction maps” were used to analyze the probable side-chain/side-chain interactions of the potentially “artificial residues”. As a result of this analysis, the following residues were exchanged (given is the name of the gene, the position according to Kabat's numbering scheme, the amino acid found at this position as the most abundant one and the amino acid which was used instead):

VH2: S₆₅T

Vκ1: N₃₄A,

Vλ3: G₉A, D₆₀A, R₇₇S

Vκ3: V₇₈T

1.4 Design of CDR Sequences

The process described above provided the complete consensus sequences derived solely from the databases of rearranged sequences. It was rationalized that the CDR1 and CDR2 regions should be taken from the databases of used germline sequences, since the CDRs of rearranged and mutated sequences are biased towards their particular antigens. Moreover, the germline CDR sequences are known to allow binding to a variety of antigens in the primary immune response, where only CDR3 is varied. Therefore, the consensus CDRs obtained from the calculations described above were replaced by germline CDRs in the case of VH and Vκ. In the case of Vλ, a few amino acid exchanges were introduced in some of the chosen germline CDRs in order to avoid possible protease cleavage sites as well as possible structural constraints.

The CDRs of following germline genes have been chosen:

HuCAL gene CDR1 CDR2 HuCAL-VH1A VH1-12-1 VH1-12-1 HuCAL-VH1B VH1-13-16 VH1-13-6, -7, -8, -9 HuCAL-VH2 VH2-31-10, -11, -12, -13 VH2-31-3, -4 HuCAL-VH3 VH3-13-8, -9, -10 VH3-13-8, -9, -10 HuCAL-VH4 VH4-11-7 to -14 VH4-11-8, -9, -11, -12, -14, -16 VH4-31-17, -18, -19, -20 HuCAL-VH5 VH5-12-1, -2 VH5-12-1, -2 HuCAL-VH6 VH6-35-1 VH6-35-1 HuCAL-Vκ1 Vκ1-14, -15 Vκ1-2, -3, -4, -5, -7, -8, -12, -13, -18, -19 HuCAL-Vκ2 Vκ2-6 Vκ2-6 HuCAL-Vκ3 Vκ3-1, -4 Vκ3-4 HuCAL-Vκ4 Vκ4-1 Vκ4-1 HuCAL-Vλ1 HUMLV117, DPL5 DPL5 HuCAL-Vλ2 DPL11, DPL12 DPL12 HuCAL-Vλ3 DPL23 HUMLV318

In the case of the CDR3s, any sequence could be chosen since these CDRs were planned to be the first to be replaced by oligonucleotide libraries. In order to study the expression and folding behavior of the consensus sequences in E. coli, it would be useful to have all sequences with the same CDR3, since the influence of the CDR3s on the folding behavior would then be identical in all cases. The dummy sequences QQHYTTPP (see, for instance, positions 89–96 of SEQ ID NO: 28 and positions 88–95 of SEQ ID NO: 34) and ARWGGDGFYAMDY (positions 97–109 of SEQ ID NOS 35 & 36) were selected for the VL chains (kappa and lambda) and for the VH chains, respectively. These sequences are known to be compatible with antibody folding in E. coli (Carter et al., 1992).

1.5 Gene Design

The final outcome of the process described above was a collection of 14 HuCAL amino acid sequences, which represent the frequently used structural antibody repertoire of the human immune system (see FIG. 2). These sequences were back-translated into DNA sequences. In a first step, the back-translation was done using only codons which are known to be frequently used in E. coli. These gene sequences were then used for creating a database of all possible restriction endonuclease sites, which could be introduced without changing the corresponding amino acid sequences. Using this database, cleavage sites were selected which were located at the flanking regions of all sub-elements of the genes (CDRs and framework regions) and which could be introduced in all HuCAL VH, Vκ or Vλ genes simultaneously at the same position. In a few cases it was not possible to find cleavage sites for all genes of a subgroup. When this happened, the amino acid sequence was changed, if this was possible according to the available sequence and structural information. This exchange was then analyzed again as described above. In total, the following 6 amino acid residues were exchanged during this design (given is the name of the gene, the position according to Kabat's numbering scheme, the amino acid found at this position as the most abundant one and the amino acid which was used instead):

VH2: T₃Q

VH6: S₄₂G

Vκ3: E₁D, I₅₈V

Vκ4: K₂₄R

Vλ3: T₂₂S

In one case (5′-end of VH framework 3) it was not possible to identify a single cleavage site for all 7 VH genes. Two different type of cleavage sites were used instead: BstEII for HuCAL VH1A, VH1B, VH4 and VH5, and NspV for HuCAL VH2, VH3, VH4 and VH6.

Several restriction endonuclease sites were identified, which were not located at the flanking regions of the sub-elements but which could be introduced in every gene of a given group without changing the amino acid sequence. These cleavage sites were also introduced in order to make the system more flexible for further improvements. Finally, all but one remaining restriction endonuclease sites were removed in every gene sequence. The single cleavage site, which was not removed was different in all genes of a subgroup and could be therefore used as a “fingerprint” site to ease the identification of the different genes by restriction digest. The designed genes, together with the corresponding amino acid sequences and the group-specific restriction endonuclease sites are shown in FIGS. 3, 4 and 5, respectively.

1.6 Gene Synthesis and Cloning

The consensus genes were synthesized using the method described by Prodromou & Pearl, 1992, using the oligonucleotides shown in FIG. 6. Gene segments encoding the human constant domains Cκ, Cλ and CH1 were also synthesized, based on sequence information given by Kabat et al., 1991 (see FIG. 6 and FIG. 7). Since for both the CDR3 and the framework 4 gene segments identical sequences were chosen in all HuCAL Vκ, Vλ and VH genes, respectively, this part was constructed only once, together with the corresponding gene segments encoding the constant domains. The PCR products were cloned into pCR-Script KS(+) (Stratagene, Inc.) or pZErO-1 (Invitrogen, Inc.) and verified by sequencing.

Example 2 Cloning and Testing of a HuCAL-Based Antibody Library

A combination of two of the synthetic consensus genes was chosen after construction to test whether binding antibody fragments can be isolated from a library based on these two consensus frameworks. The two genes were cloned as a single-chain Fv (scFv) fragment, and a VH-CDR3 library was inserted. In order to test the library for the presence of functional antibody molecules, a selection procedure was carried out using the small hapten fluorescein bound to BSA (FITC-BSA) as antigen.

2.1 Cloning of the HuCAL VH3-Vk2 scFv Fragment

In order to test the design of the consensus genes, one randomly chosen combination of synthetic light and heavy gene (HuCAL-Vκ2 and HuCAL-VH3) was used for the construction of a single-chain antibody (scFv) fragment. Briefly, the gene segments encoding the VH3 consensus gene and the CH1 gene segment including the CDR3-framework 4 region, as well as the Vκ2 consensus gene and the Cκ gene segment including the CDR3-framework 4 region were assembled yielding the gene for the VH3-CH1 Fd fragment and the gene encoding the Vκ2-Cκ light chain, respectively. The CH1 gene segment was then replaced by an oligonucleotide (SEQ ID NOS 2 & 3, respectively) cassette encoding a 20-mer peptide linker (SEQ ID NO: 1) with the sequence AGGGSGGGGSGGGGSGGGGS. The two oligonucleotides encoding this linker were 5′-TCAGCGGGTGGCGGTTCTGGCGGCGGTGGGAGCGGTG GCGGTGGTTCTGGCGGTGGTGGTTCCGATATCGGTCCACGTACGG-3′ and 5′-AATTCCGTACGTGGACCGATATCGGAACCACCACCGCCAGA ACCACCGCCACCGCTCCCACCGCCGCCAGAACCGCCACCCGC-3′, respectively. Finally, the HuCAL-Vκ2 gene was inserted via EcoRV and BsiWI into the plasmid encoding the HuCAL-VH3-linker fusion, leading to the final gene HuCAL-VH3-Vκ2, which encoded the two consensus sequences in the single-chain format VH-linker-VL. The complete coding sequence is shown in FIG. 8.

2.2 Construction of a Monovalent Phage-Display Phagemid Vector pIG10.3

Phagemid pIG10.3 (FIG. 9) was constructed in order to create a phage-display system (Winter et al., 1994) for the H3κ2 scFv gene. Briefly, the EcoRI/HindIII restriction fragment in the phagemid vector pIG10 (Ge et al., 1995) was replaced by the c-myc followed by an amber codon (which encodes an glutamate in the amber-suppresser strain XL1 Blue and a stop codon in the non-suppresser strain JM83) and a truncated version of the gene III (fusion junction at codon 249, see Lowman et al., 1991) through PCR mutagenesis.

2.3 Construction of H-CDR3 Libraries

Heavy chain CDR3 libraries of two lengths (10 and 15 amino acids) were constructed using trinucleotide codon containing oligonucleotides (Virnekas et al., 1994) as templates and the oligonucleotides complementing the flanking regions as primers. To concentrate only on the CDR3 structures that appear most often in functional antibodies, we kept the salt-bridge of R_(H94) and D_(H101) in the CDR3 loop. For the 15-mer library, both phenylalanine and methionine were introduced at position 100 since these two residues were found to occur quite often in human CDR3s of this length (not shown). For the same reason, valine and tyrosine were introduced at position 102. All other randomized positions contained codons for all amino acids except cystein, which was not used in the trinucleotide mixture.

The CDR3 libraries of lengths 10 and 15 were generated from the PCR fragments using oligonucleotide templates (SEQ ID NOS 4 & 5, respectively) O3HCDR103T (5′-GATACGGCCGTGTATTATTGCGCGCGT (TRI)₆ GATTATTGGGGCCAAGGCACCCTG-3′) and O3HCDR153T (5′-GATACGGCCGTGTATTATTGCGCGCGT(TRI)₆ (TTT/ATG)GAT(GTT/TAT)TGGGGCCAAGGCACCCTG-3′), and primers (SEQ ID NOS 6 & 7, respectively) O3HCDR35 (5′-GATACGGCCGTGTATTATTGC-3′) and O3HCDR33 (5′-CAGGGTGCCTTGGCCCC-3′), where TRI are trinucleotide mixtures representing all amino acids without cystein, (TTT/ATG) and (GTT/TAT) are trinucleotide mixtures encoding the amino acids phenylalanine/methionine and valine/tyrosine, respectively. The potential diversity of these libraries was 4.7×10⁷ and 3.4×10¹⁰ for 10-mer and 15-mer library, respectively. The library cassettes were first synthesized from PCR amplification of the oligo templates in the presence of both primers: 25 pmol of the oligo template O3HCDR103T or O3HCDR153T, 50 pmol each of the primers O3HCDR35 and O3HCDR33, 20 nmol of dNTP, 10× buffer and 2.5 units of Pfu DNA polymerase (Stratagene) in a total volume of 100 ml for 30 cycles (1 minute at 92° C., 1 minute at 62° C. and 1 minute at 72° C.). A hot-start procedure was used. The resulting mixtures were phenol-extracted, ethanol-precipitated and digested overnight with EagI and Styl. The vector pIG10.3-sCH3κ2cat, where the EagI-Styl fragment in the vector pIG10.3-sCH3κ2 encoding the H-CDR3 was replaced by the chloramphenicol acetyltransferase gene (cat) flanked with these two sites, was similarly digested. The digested vector (35 μg) was gel-purified and ligated with 100 μg of the library cassette overnight at 16° C. The ligation mixtures were isopropanol precipitated, air-dried and the pellets were redissolved in 100 ml of ddH2O. The ligation was mixed with 1 ml of freshly prepared electrocompetent XL 1 Blue on ice. 20 rounds of electroporation were performed and the transformants were diluted in SOC medium, shaken at 37° C. for 30 minutes and plated out on large LB plates (Amp/Tet/Glucose) at 37° C. for 6–9 hrs. The number of transformants (library size) was 3.2×10⁷ and 2.3×10⁷ for the 10-mer and the 15-mer library, respectively. The colonies were suspended in 2xYT medium (Amp/Tet/Glucose) and stored as glycerol culture. In order to test the quality of the initial library, phagemids from 24 independent colonies (12 from the 10-mer and 12 from the 15-mer library, respectively) were isolated and analyzed by restriction digestion and sequencing. The restriction analysis of the 24 phagemids indicated the presence of intact vector in all cases. Sequence analysis of these clones (see FIG. 10) indicated that 22 out of 24 contained a functional sequence in their heavy chain CDR3 regions. 1 out of 12 clones of the 10-mer library had a CDR3 of length 9 instead of 10, and 2 out of 12 clones of the 15-mer library had no open reading frame, thereby leading to a non-functional scFv; one of these two clones contained two consecutive inserts, but out of frame (data not shown). All codons introduced were presented in an even distribution.

Expression levels of individual library members were also measured. Briefly, 9 clones from each library were grown in 2xYT medium containing Amp/Tet/0.5% glucose at 37° C. overnight. Next day, the cultures were diluted into fresh medium with Amp/Tet. At an OD_(600nm) of 0.4, the cultures were induced with 1 mM of IPTG and shaken at RT overnight. Then the cell pellets were suspended in 1 ml of PBS buffer+1 mM of EDTA. The suspensions were sonicated and the supernatants were separated on an SDS-PAGE under reducing conditions, blotted on nylon membrane and detected with anti-FLAG M1 antibody (see FIG. 11). From the nine clones of the 10-mer library, all express the scFv fragments. Moreover, the gene III scFv fusion proteins were present in all cases. Among the nine clones from the 15-mer library analyzed, 6/9 (67%) led to the expression of both scFv and the gene III/scFv fusion proteins. More importantly, all clones expressing the scFvs and gene III/scFv fusions gave rise to about the same level of expression.

2.4 Biopanning

Phages displaying the antibody libraries were prepared using standard protocols. Phages derived from the 10-mer library were mixed with phages from the 15-mer library in a ratio of 20:1 (1×10¹⁰ cfu/well of the 10-mer and 5×10⁸ cfu/well of the 15-mer phages, respectively). Subsequently, the phage solution was used for panning in ELISA plates (Maxisorp, Nunc) coated with FITC-BSA (Sigma) at concentration of 100 μg/ml in PBS at 4° C. overnight. The antigen-coated wells were blocked with 3% powder milk in PBS and the phage solutions in 1% powder milk were added to each well and the plate was shaken at RT for 1 hr. The wells were then washed with PBST and PBS (4 times each with shaking at RT for 5 minutes). The bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes. The eluted phage solutions were immediately neutralized with ½ the volume of 1 M Tris.Cl, pH 7.6. Eluted phage solutions (ca. 450 μl) were used to infect 5 ml of XL1 Blue cells at 37° C. for 30 min. The infected cultures were then plated out on large LB plates (Amp/Tet/Glucose) and allowed to grow at 37° C. until the colonies were visible. The colonies were suspended in 2xYT medium and the glycerol cultures were made as above described. This panning round was repeated twice, and in the third round elution was carried out with addition of fluorescein in a concentration of 100 μg/ml in PBS. The enrichment of specific phage antibodies was monitored by panning the initial as well as the subsequent fluorescein-specific sub-libraries against the blocking buffer (FIG. 12). Antibodies with specificity against fluorescein were isolated after 3 rounds of panning.

2.5 ELISA Measurements

One of the criteria for the successful biopanning is the isolation of individual phage clones that bind to the targeted antigen or hapten. We undertook the isolation of anti-FITC phage antibody clones and characterized them first in a phage ELISA format. After the 3rd round of biopanning (see above), 24 phagemid containing clones were used to inoculate 100 μl of 2xYT medium (Amp/Tet/Glucose) in an ELISA plate (Nunc), which was subsequently shaken at 37° C. for 5 hrs. 100 μl of 2xYT medium (Amp/Tet/1 mM IPTG) were added and shaking was continued for 30 minutes. A further 100 μl of 2xYT medium (Amp/Tet) containing the helper phage (1×10⁹ cfu/well) was added and shaking was done at RT for 3 hrs. After addition of kanamycin to select for successful helper phage infection, the shaking was continued overnight. The plates were then centrifuged and the supernatants were pipetted directly into ELISA wells coated with 100 μl FITC-BSA (100 μg/ml) and blocked with milk powder. Washing was performed similarly as during the panning procedure and the bound phages were detected with anti-M13 antibody-POD conjugate (Pharmacia) using soluble POD substrate (Boehringer-Mannheim). Of the 24 clones screened against FITC-BSA, 22 were active in the ELISA (FIG. 13). The initial libraries of similar titer gave rise to no detectable signal.

Specificity for fluorescein was measured in a competitive ELISA. Periplasmic fractions of five FITC specific scFvs were prepared as described above. Western blotting indicated that all clones expressed about the same amount of scFv fragment (data not shown). ELISA was performed as described above, but additionally, the periplasmic fractions were incubated 30 min at RT either with buffer (no inhibition), with 10 mg/ml BSA (inhibition with BSA) or with 10 mg/ml fluorescein (inhibition with fluorescein) before adding to the well. Binding scFv fragment was detected using the anti-FLAG antibody M1. The ELISA signal could only be inhibited, when soluble fluorescein was added, indicating binding of the scFvs was specific for fluorescein (FIG. 14).

2.6 Sequence Analysis

The heavy chain CDR3 region of 20 clones were sequenced in order to estimate the sequence diversity of fluorescein binding antibodies in the library (FIG. 15). In total, 16 of 20 sequences (80%) were different, showing that the constructed library contained a highly diverse repertoire of fluorescein binders. The CDR3s showed no particular sequence homology, but contained on average 4 arginine residues. This bias towards arginine in fluorescein binding antibodies had already been described by Barbas et al., 1992.

2.7 Production

E. coli JM83 was transformed with phagemid DNA of 3 selected clones and cultured in 0.5 L 2xYT medium. Induction was carried out with 1 mM IPTG at OD_(600nm)=0.4 and growth was continued with vigorous shaking at RT overnight. The cells were harvested and pellets were suspended in PBS buffer and sonicated. The supernatants were separated from the cell debris via centrifugation and purified via the BioLogic system (Bio-Rad) by with a POROS®MC 20 column (IMAC, PerSeptive Biosystems, Inc.) coupled with an ion-exchange chromatography column. The ion-exchange column was one of the POROS®HS, CM or HQ or PI 20 (PerSeptive Biosystems, Inc.) depended on the theoretical pI of the scFv being purified. The pH of all the buffers was adjusted to one unit lower or higher than the pI of the scFv being purified throughout. The sample was loaded onto the first IMAC column, washed with 7 column volumes of 20 mM sodium phosphate, 1 M NaCl and 10 mM imidazole. This washing was followed by 7 column volumes of 20 mM sodium phosphate and 10 mM imidazole. Then 3 column volumes of an imidazole gradient (10 to 250 mM) were applied and the eluent was connected directly to the ion-exchanger. Nine column volumes of isocratic washing with 250 mM imidazole was followed by 15 column volumes of 250 mM to 100 mM and 7 column volumes of an imidazole/NaCl gradient (100 to 10 mM imidazole, 0 to 1 M NaCl). The flow rate was 5 ml/min. The purity of scFv fragments was checked by SDS-PAGE Coomassie staining (FIG. 16). The concentration of the fragments was determined from the absorbance at 280 nm using the theoretically determined extinction coefficient (Gill & von Hippel, 1989). The scFv fragments could be purified to homogeneity (see FIG. 16). The yield of purified fragments ranged from 5 to 10 mg/L/OD.

Example 3 HuCAL H3κ2 Library Against a Collection of Antigens

In order to test the library used in Example 2 further, a new selection procedure was carried out using a variety of antigens comprising β-estradiol, testosterone, Lewis-Y epitope (LeY), interleukin-2 (IL-2), lymphotoxin-β(LT-β), E-selectin ligand-1 (ESL-1), and BSA.

3.1 Biopanning

The library and all procedures were identical to those described in Example 2. The ELISA plates were coated with β-estradiol-BSA (100 μg/ml), testosterone-BSA (100 μg/ml), LeY-BSA (20 μg/ml) IL-2 (20 μg/ml), ESL-1 (20 μg/ml) and BSA (100 μg/ml), LT-β (denatured protein, 20 μg/ml). In the first two rounds, bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes. In the case of BSA, elution after three rounds of panning was carried out with addition of BSA in a concentration of 100 μg/ml in PBS. In the case of the other antigens, third round elution was done with 0.1 M triethylamine. In all cases except LeY, enrichment of binding phages could be seen (FIG. 17). Moreover, a repetition of the biopanning experiment using only the 15-mer library resulted in the enrichment of LeY-binding phages as well (data not shown).

3.2. ELISA Measurements

Clones binding to β-estradiol, testosterone, LeY, LT-β, ESL-1 and BSA were further analyzed and characterized as described in Example 2 for FITC. ELISA data for anti-β-estradiol and anti-ESL-1 antibodies are shown in FIG. 18. In one experiment, selectivity and cross-reactivity of binding scFv fragments were tested. For this purpose, an ELISA plate was coated with FITC, testosterone, β-estradiol, BSA, and ESL-1, with 5 wells for each antigen arranged in 5 rows, and 5 antibodies, one against each of the antigens, were screened against each of the antigens. FIG. 19 shows the specific binding of the antibodies to the antigen it was selected for, and the low cross-reactivity with the other four antigens.

3.3 Sequence Analysis

The sequencing data of several clones against β-estradiol (34 clones), testosterone (12 clones), LT-β (23 clones), ESL-1 (34 clones), and BSA (10 clones) are given in FIGS. 20 to 24.

Example 4 Vector Construction

To be able to take advantage of the modularity of the consensus gene repertoire, a vector system had to be constructed which could be used in phage display screening of HuCAL libraries and subsequent optimization procedures. Therefore, all necessary vector elements such as origins of single-stranded or double-stranded replication, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, or detection tags had to be made compatible with the restriction site pattern of the modular consensus genes. FIG. 25 shows a schematic representation of the pCAL vector system and the arrangement of vector modules and restriction sites therein. FIG. 25 a shows a list of all restriction sites which are already incorporated into the consensus genes or the vector elements as part of the modular system or which are not yet present in the whole system. The latter could be used in a later stage for the introduction of or within new modules.

4.1 Vector Modules

A series of vector modules was constructed where the restriction sites flanking the gene sub-elements of the HuCAL genes were removed, the vector modules themselves being flanked by unique restriction sites. These modules were constructed either by gene synthesis or by mutagenesis of templates. Mutagenesis was done by add-on PCR, by site-directed mutagenesis (Kunkel et al., 1991) or multisite oligonucleotide-mediated mutagenesis (Sutherland et al., 1995; Perlak, 1990) using a PCR-based assembly method.

FIG. 26 contains a list of the modules constructed. Instead of the terminator module M9 (HindIII-Ipp-PacI), a larger cassette M9II was prepared to introduce FseI as additional restriction site. M9II can be cloned via HindIII/BsrGI.

All vector modules were characterized by restriction analysis and sequencing. In the case of module M11-II, sequencing of the module revealed a two-base difference in positions 164/65 compared to the sequence database of the template. These two different bases (CA→GC) created an additional BanII site. Since the same two-base difference occurs in the f1 origin of other bacteriophages, it can be assumed that the two-base difference was present in the template and not created by mutagenesis during cloning. This BanII site was removed by site-directed mutagenesis, leading to module M11-III. The BssSI site of module M14 could initially not be removed without impact on the function of the ColE1 origin, therefore M14-Ext2 was used for cloning of the first pCAL vector series. FIGS. 29 to 34 are showing the functional maps and sequences of the modules used for assembly of the modular vector pCAL4 (see below). The functional maps and sequences of additional modules can be found in FIGS. 35A-9 to 35A-75. FIGS. 35A-76 to 35A-80 contain lists of oligonucleotides and primers used for the synthesis of the modules.

4.2 Cloning Vector pMCS

To be able to assemble the individual vector modules, a cloning vector pMCS containing a specific multi-cloning site (MCS) was constructed. First, an MCS cassette (FIG. 27) was made by gene synthesis. This cassette contains all those restriction sites in the order necessary for the sequential introduction of all vector modules and can be cloned via the 5′-HindIII site and a four base overhang at the 3′-end compatible with an AatII site. The vector pMCS (FIG. 28) was constructed by digesting pUC19 with AatII and HindIII, isolating the 2174 base pair fragment containing the bla gene and the ColE1 origin, and ligating the MCS cassette.

4.3 Cloning of Modular Vector pCAL4

This was cloned step by step by restriction digest of pMCS and subsequent ligation of the modules M1 (via AatII/XbaI), M7III (via EcoRI/HindIII), and M9II (via HindIII/BsrGI), and M11-II (via BsrGI/NheI). Finally, the bla gene was replaced by the cat gene module M17 (via AatII/BgIII), and the wild type ColE1 origin by module M14-Ext2 (via BgIII/NheI). FIG. 35 is showing the functional map and the sequence of pCAL4.

4.4 Cloning of Low-Copy Number Plasmid Vectors pCALO

A series of low-copy number plasmid vectors was constructed in a similar way using the p15A module M12 instead of the ColE1 module M14-Ext2. FIGS. 35A-9 to 35A-75 show the functional maps and sequences of the vectors pCALO1 to pCALO3.

Example 5 Construction of a HuCAL scFv Library

5.1. Cloning of All 49 HuCAL scFv Fragments

All 49 combinations of the 7 HuCAL-VH and 7 HuCAL-VL consensus genes were assembled as described for the HuCAL VH3-Vκ2 scFv in Example 2 and inserted into the vector pBS12, a modified version of the pLisc series of antibody expression vectors (Skerra et al., 1991).

5.2 Construction of a CDR Cloning Cassette

For replacement of CDRs, a universal β-lactamase cloning cassette was constructed having a multi-cloning site at the 5′-end as well as at the 3′-end. The 5′-multi-cloning site comprises all restriction sites adjacent to the 5′-end of the HuCAL VH and VL CDRs, the 3′-multi-cloning site comprises all restriction sites adjacent to the 3′ end of the HuCAL VH and VL CDRs. Both 5′- and 3′-multi-cloning site were prepared as cassettes via add-on PCR using synthetic oligonucleotides as 5′- and 3′-primers using wild type β-lactamase gene as template. FIG. 36 shows the functional map and the sequence of the cassette bla-MCS.

5.3. Preparation of VL-CDR3 Library Cassettes

The VL-CDR3 libraries comprising 7 random positions were generated from the PCR fragments using oligonucleotide templates Vκ1&Vκ3, Vκ2 and Vκ4 and primers O_K3L_(—)5 and O_K3L_(—)3 (FIG. 37) for the Vκ genes, and Vλ and primers (SEQ ID NO: 8) O_L3L_(—)5 (5′-GCAGAAGGCGAACGTCC-3′) and O_L3LA_(—)3 (FIG. 38) for the Vλ genes. Construction of the cassettes was performed as described in Example 2.3.

5.4 Cloning of HuCAL scFv Genes with VL-CDR3 Libraries

Each of the 49 single-chains was subcloned into pCAL4 via XbaI/EcoRI and the VL-CDR3 replaced by the β-lactamase cloning cassette via BbsI/MscI, which was then replaced by the corresponding VL-CDR3 library cassette synthesized as described above. This CDR replacement is described in detail in Example 2.3 where the cat gene was used.

5.5 Preparation of VH-CDR3 Library Cassette

The VH-CDR3 libraries were designed and synthesized as described in Example 2.3.

5.6 Cloning of HuCAL scFv Genes with VL- and VH-CDR3 Libraries

Each of the 49 single-chain VL-CDR3 libraries was digested with BssHII/StyI to replace VH-CDR3. The “dummy” cassette digested with BssHII/Styl was inserted, and was then replaced by a corresponding VH-CDR3 library cassette synthesized as described above.

Example 6 Expression Tests

Expression and toxicity studies were performed using the scFv format VH-linker-VL. All 49 combinations of the 7 HuCAL-VH and 7 HuCAL-VL consensus genes assembled as described in Example 5 were inserted into the vector pBS13, a modified version of the pLisc series of antibody expression vectors (Skerra et al., 1991). A map of this vector is shown in FIG. 39.

E. coli JM83 was transformed 49 times with each of the vectors and stored as glycerol stock. Between 4 and 6 clones were tested simultaneously, always including the clone H3κ2, which was used as internal control throughout. As additional control, the McPC603 scFv fragment (Knappik & Plückthun, 1995) in pBS13 was expressed under identical conditions. Two days before the expression test was performed, the clones were cultivated on LB plates containing 30 μg/ml chloramphenicol and 60 mM glucose. Using this plates an 3 ml culture (LB medium containing 90 μg chloramphenicol and 60 mM glucose) was inoculated overnight at 37° C. Next day the overnight culture was used to inoculate 30 ml LB medium containing chloramphenicol (30 μg/ml). The starting OD_(600nm) was adjusted to 0.2 and a growth temperature of 30.degree. C. was used. The physiology of the cells was monitored by measuring every 30 minutes for 8 to 9 hours the optical density at 600 nm. After the culture reached an OD_(600nm) of 0.5, antibody expression was induced by adding IPTG to a final concentration of 1 mM. A 5 ml aliquot of the culture was removed after 2 h of induction in order to analyze the antibody expression. The cells were lysed and the soluble and insoluble fractions of the crude extract were separated as described in Knappik & Pluckthun, 1995. The fractions were assayed by reducing SDS-PAGE with the samples normalized to identical optical densities. After blotting and immunostaining using the α-FLAG antibody M1 as the first antibody (see Ge et al., 1994) and an Fc-specific anti-mouse antiserum conjugated to alkaline phosphatase as the second antibody, the lanes were scanned and the intensities of the bands of the expected size (appr. 30 kDa) were quantified densitometrically and tabulated relative to the control antibody (see FIG. 40).

Example 7 Optimization of Fluorescein Binders

7.1. Construction of L-CDR3 and H-CDR2 Library Cassettes

A L-CDR3 library cassette was prepared from the oligonucleotide (SEQ ID NO: 9) template CDR3L (5′-TGGAAGCTGAAGACGTGGGCGTGTATTATT GCCAGCAG(TR5)(TRI)₄CCG(TRI)TTTGGCCAGGGTACGAAAGTT-3′) and primer (SEQ ID NO: 10) 5′-AATTTCGTACCCTGGCC-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (TR5) comprised a trinucleotide mixture representing the 5 codons for Ala, Arg, His, Ser, and Tyr.

A H-CDR2 library cassette was prepared from the oligonucleotide template CDRsH (SEQ ID NOS 11 & 12, respectively) (5′-AGGGTCTCG AGTGGGTGAGC(TRI)ATT(TRI)₂₋₃(6)₂(TRI)ACC(TRI)TATGCG GATAGCGTGAAAGGCCGTTTTACCATTTCACGTGATAATTCGAAAAA CACCA-3′), and primer (SEQ ID NO: 13) 5′-TGGTGTTTTTCGAATTATCA-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (6) comprised the incorporation of (A/G) (A/C/G) T, resulting in the formation of 6 codons for Ala, Asn, Asp, Gly, Ser, and Thr, and the length distribution being obtained by performing one substoichiometric coupling of the (TRI) mixture during synthesis, omitting the capping step normally used in DNA synthesis.

DNA synthesis was performed on a 40 nmole scale, oligos were dissovled in TE buffer, purified via gel filtration using spin columns (S-200), and the DNA concentration determined by OD measurement at 260 nm (OD 1.0=40 μg/ml). 10 nmole of the oligonucleotide templates and 12 nmole of the corresponding primers were mixed and annealed at 80° C. for 1 min, and slowly cooled down to 37° C. within 20 to 30 min. The fill-in reaction was performed for 2 h at 37° C. using Klenow polymerase (2.0 μl) and 250 nmole of each dNTP. The excess of dNTPs was removed by gel filtration using Nick-Spin columns (Pharmacia), and the double-stranded DNA digested with BbsI/MscI (L-CDR3), or XhoI/SfuI (H-CDR2) over night at 37° C. The cassettes were purified via Nick-Spin columns (Pharmacia), the concentration determined by OD measurement, and the cassettes aliquoted (15 pmole) for being stored at −80° C.

7.2 Library Cloning:

DNA was prepared from the collection of FITC binding clones obtained in Example 2 (approx. 10⁴ to clones). The collection of scFv fragments was isolated via XbaI/EcoRI digest. The vector pCAL4 (100 fmole, 10 μg) described in Example 4.3 was similarly digested with XbaI/EcoRI, gel-purified and ligated with 300 fmole of the scFv fragment collection over night at 16° C. The ligation mixture was isopropanol precipitated, air-dried, and the pellets were redissolved in 100 μl of dd H₂O. The ligation mixture was mixed with 1 ml of freshly prepared electrocompetent SCS 101 cells (for optimization of L-CDR3), or XL1 Blue cells (for optimization of H-CDR2) on ice. One round of electroporation was performed and the transformants were eluted in SOC medium, shaken at 37° C. for 30 minutes, and an aliquot plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6–9 hrs. The number of transformants was 5×10⁴.

Vector DNA (100 μg) was isolated and digested (sequence and restriction map of sCH3κ2 see FIG. 8) with BbsI/MscI for optimization of L-CDR3, or XhoI/NspV for optimization of H-CDR2. 10 μg of purified vector fragments (5 pmole) were ligated with 15 pmole of the L-CDR3 or H-CDR2 library cassettes over night at 16° C. The ligation mixtures were isopropanol precipitated, air-dried, and the pellets were redissolved in 100 μl of dd H₂O. The ligation mixtures were mixed with 1 ml of freshly prepared electrocompetent XL1 Blue cells on ice. Electroporation was performed and the transformants were eluted in SOC medium and shaken at 37° C. for 30 minutes. An aliquot was plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6–9 hrs. The number of transformants (library size) was greater than 10⁸ for both libraries. The libraries were stored as glycerol cultures.

7.3. Biopanning

This was performed as described for the initial H3κ2H-CDR3 library in Example 2.1. Optimized scFvs binding to FITC could be characterized and analyzed as described in Example 2.2 and 2.3, and further rounds of optimization could be made if necessary.

REFERENCES

-   Barbas III, C. F., Bain, J. D., Hoekstra, D. M. & Lerner, R. A.,     PNAS 89, 4457–4461 (1992). -   Better, M., Chang, P., Robinson, R. & Horwitz, A. H., Science 240,     1041–1043 (1988). -   Blake, M. S., Johnston, K. H., Russel-Jones, G. J. & Gotschlich, E.     C., Anal. Biochem. 136, 175–179 (1984). -   Carter, P., Kelly, R. F., Rodrigues, M. L., Snedecor, B.,     Covrrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M.,     Kotts, C. E., Carver, M. E., Yang, M., Bourell, J. H.,     Shepard, H. M. & Henner, D., Bio/Technology 10, 163–167 (1992). -   Chothia, C. & Lesk, A. M., J. Biol. Chem. 196, 910–917 (1987). -   Chothia, C., Lesk, A. M., Gherardi, E., Tomlinson, I. A., Walter,     G., Marks, J. D., Llewelyn, M. B. & Winter, G., J. Mol. Biol. 227,     799–817 (1992). -   Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S.     J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R.,     Colman, P. M., Spinelli, S., Alzari, P. M. & Poljak, R. J., Nature     342, 877–883 (1989). -   Chuchana, P., Blancher, A., Brockly, F., Alexandre, D., Lefranc, G.     & Lefranc, M.-P., Eur. J. Immunol. 20, 1317–1325 (1990). -   Cox, J. P. L., Tomlinson, I. M. & Winter, G., Eur. J. Immunol.     24,827–836 (1994). -   Ge, L., Knappik, A., Pack, P., Freund, C. & Plückthun, A., In:     Antibody Engineering. Borrebaeck, C. A. K. (Ed.). p. 229–266 (1995),     Oxford University Press, New York, Oxford.) -   Ghi, S. C. & von Hippel, P. H., Anal. Biochem. 182, 319.326 (1989).

Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. & Stüber, D., Bio/Technology 6, 1321–1325 (1988).

-   Hopp, T. P., Prickett, K. S., Price, V. L., Libby, R. T., March, C.     J., Cerretti, D. P., Urdal, D. L. & Conlon, P. J. Bio/Technology 6,     1204–1210 (1988). -   Kabat, E. A., Wu, T. T., Perry, H. M., Gottesmann, K. S. & Foeller,     C., Sequences of proteins of immunological interest, NIH publication     91–3242 (1991). -   Knappik, A. & Plückthun, A., Biotechniques 17, 754–761 (1994). -   Knappik, A. & Plückthun, A., Protein Engineering 8, 81–89 (1995). -   Kunkel, T. A., Bebenek, K. & McClary, J., Methods in Enzymol     204,125–39 (1991). -   Lindner, P., Guth, B., Wülfing, C., Krebber, C., Steipe, B.,     Müller, F. & Plückthun, A., Methods: A Companion to Methods Enzymol.     4, 41–56 (1992). -   Lowman, H. B., Bass, S. H., Simpson, N. and Wells, J. A.,     Biochemistry 30, 10832–10838 (1991). -   Pack, P. & Plückthun, A., Biochemistry 31, 1579–1584 (1992). -   Pack, P., Kujau, M., Schroeckh, V., Knüpfer, U., Wenderoth, R.,     Riesenberg D. & Plückthun, A., Bio/Technology 11, 1271–1277 (1993). -   Pack, P., Ph.D. thesis, Ludwig-Maximilians-Universität München     (1994). -   Perlak, F. J., Nuc. Acids Res. 18, 7457–7458 (1990). -   Plückthun, A., Krebber, A., Krebber, C., Horn, U., Knüpfer, U.,     Wenderoth, R., Nieba, L., Proba, K. & Riesenberg, D., A practical     approach. Antibody Engineering (Ed. J. McCafferty). IRL Press,     Oxford, pp. 203–252 (1996). -   Prodromou, C. & Pearl, L. H., Protein Engineering 5, 827–829 (1992). -   Rosenberg, S. A. & Lotze, M. T., Ann. Rev. Immunol. 4,681–709     (1986). -   Skerra, A. & Plückthun, A., Science 240, 1038–1041 (1988). -   Skerra, A., Pfitzinger, I. & Plückthun, A., Bio/Technology 9,     273–278 (1991). -   Sutherland, L., Davidson, J., Glass, L. L., & Jacobs, H. T.,     BioTechniques 18, 458–464, 1995. -   Tomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B. &     Winter, G., J. Mol. Biol. 227, 776–798 (1992). -   Ullrich, H. D., Patten, P. A., Yang, P. L., Romesberg, F. E. &     Schultz, P. G., Proc. Natl. Acad. Sci. USA 92, 11907–11911 (1995). -   Van Dijk, K. W., Mortari, F., Kirkham, P. M., Schroeder Jr., H. W. &     Milner, E. C. B., Eur. J. Immunol. 23, 832–839 (1993). -   Virnekäs, B., Ge, L., Plückthun, A., Schneider, K. C.,     Wellnhofer, G. & Moroney, S. E., Nucleic Acids Research 22,     5600–5607 (1994). -   Vitetta, E. S., Thorpe, P. E. & Uhr, J., Immunol. Today 14, 253–259     (1993). -   Williams, S. C. & Winter, G., Eur. J. Immunol. 23, 1456–1461 (1993). -   Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R.,     Ann. Rev. Immunol. 12, 433–455 (1994).

TABLE 1A Human kappa germline gene segments Used Ref- Name¹ erence² Family³ Germline genes⁴ Vk1-1 9 1 O8; O18; DPK1 Vk1-2 1 1 L14; DPK2 Vk1-3 2 1 L15(1); HK101; HK146; HK189 Vk1-4 9 1 L11 Vk1-5 2 1 A30 Vk1-6 1 1 LFVK5 Vk1-7 1 1 LFVK431 Vk1-8 1 1 L1; HK137 Vk1-9 1 1 A20; DPK4 Vk1-10 1 1 L18; Va″ Vk1-11 1 1 L4; L18; Va′; V4a Vk1-12 2 1 L5; L19(1); Vb; Vb4; DPK5; L19(2); Vb″; DPK6 Vk1-13 2 1 L15(2); HK134; HK166; DPK7 Vk1-14 8 1 L8; Vd; DPK8 Vk1-15 8 1 L9; Ve Vk1-16 1 1 L12(1); HK102; V1 Vk1-17 2 1 L12(2) Vk1-18 1 1 O12a(V3b) Vk1-19 6 1 O2; O12; DPK9 Vk1-20 2 1 L24; Ve″; V13; DPK10 Vk1-21 1 1 O4; O14 Vk1-22 2 1 L22 Vk1-23 2 1 L23 Vk2-1 1 2 A2; DPK12 Vk2-2 6 2 O1; O11(1); DPK13 Vk2-3 6 2 O12(2); V3a Vk2-4 2 2 L13 Vk2-5 1 2 DPK14 Vk2-6 4 2 A3; A19; DPK15 Vk2-7 4 2 A29; DPK27 Vk2-8 4 2 A13 Vk2-9 1 2 A23 Vk2-10 4 2 A7; DPK17 Vk2-11 4 2 A17; DPK18 Vk2-12 4 2 A1; DPK19 Vk3-1 11 3 A11; humkv305; DPK20 Vk3-2 1 3 L20; Vg″ Vk3-3 2 3 L2; L16; humkv328; humkv328h2; humkv328h5; DPK21 Vk3-4 11 3 A27; humkv325; VkRF; DPK22 Vk3-5 2 3 L25; DPK23 Vk3-6 2 3 L10(1) Vk3-7 7 3 L10(2) Vk3-8 7 3 L6; Vg Vk4-1 3 4 B3; VkIV; DPK24 Vk5-1 10 5 B2; EV15 Vk6-1 12 6 A14; DPK25 Vk6-2 12 6 A10; A26; DPK26 Vk7-1 5 7 B1

TABLE 1B Human lambda germline gene segments Used Name¹ Reference² Family³ Germilne genes⁴ DPL1 1 1 DPL2 1 1 HUMLV1L1 DPL3 1 1 HUMLV122 DPL4 1 1 VLAMBDA 1.1 HUMLV117 2 1 DPL5 1 1 HUMLV117D DPL6 1 1 DPL7 1 1 IGLVIS2 DPL8 1 1 HUMLV1042 DPL9 1 1 HUMLV101 DPL10 1 2 VLAMBDA 2.1 3 2 DPL11 1 2 DPL12 1 2 DPL13 1 2 DPL14 1 2 DPL16 1 3 Humlv418; IGLV3S1 DPL23 1 3 VI III.1 Humlv318 4 3 DPL18 1 7 4A; HUMIGLVA DPL19 1 DPL21 1 8 VL8.1 HUMLV801 5 8 DPL22 1 9 DPL24 1 unassigned VLAMBDA N.2 gVLX-4.4 6 10 

TABLE 1C Human heavy chain germline gene segments Ref- Used Name¹ erence² Family³ Germline genes⁴ VH1-12-1 19 1 DP10; DA-2; DA-6 VH1-12-8 22 1 RR.VH1.2 VH1-12-2 6 1 hv1263 VH1-12-9 7 1 YAC-7; RR.VH1.1; 1-69 VH1-12-3 19 1 DP3 VH1-12-4 19 1 DP21; 4d275a; VH7a VH1-12-5 18 1 1-4.1b; V1-4.1b VH1-12-6 21 1 1D37; VH7b; 7-81; YAC-10 VH1-12-7 19 1 DP14; VH1GRR; V1-18 VH1-13-1 10 1 71-5; DP2 VH1-13-2 10 1 E3-10 VH1-13-3 19 1 DP1 VH1-13-4 12 1 V35 VH1-13-5 8 1 V1-2b VH1-13-6 18 1 1-2; DP75 VH1-13-7 21 1 V1-2 VH1-13-8 19 1 DP8 VH1-13-9 3 1 1-1 VH1-13-10 19 1 DP12 VH1-13-11 15 1 V13C VH1-13-12 18 1 1-3b; DP25; V1-3b VH1-13-13 3 1 1-92 VH1-13-14 18 1 1-3; V1-3 VH1-13-15 19 1 DP15; V1-8 VH1-13-16 3 1 21-2; 3-1; DP7; V1-46 VH1-13-17 16 1 HG3 VH1-13-18 19 1 DP4; 7-2; V1-45 VH1-13-19 27 1 COS 5 VH1-1X-1 19 1 DP5; 1-24P VH2-21-1 18 2 II-5b VH2-31-1 2 2 VH2S12-1 VH2-31-2 2 2 VH2S12-7 VH2-31-3 2 2 VH2S12-9; DP27 VH2-31-4 2 2 VH2S12-10 VH2-31-5 14 2 V2-26; DP26; 2-26 VH2-31-6 15 2 VF2-26 VH2-31-7 19 2 DP28; DA-7 VH2-31-14 7 2 YAC-3; 2-70 VH2-31-8 2 2 VH2S12-5 VH2-31-9 2 2 VH2S12-12 VH2-31-10 18 2 II-5; V2-5 VH2-31-11 2 2 VH2S12-2; VH2S12-8 VH2-31-12 2 2 VH2S12-4; VH2S12-6 VH2-31-13 2 2 VH2S12-14 VH3-11-1 13 3 v65-2; DP44 VH3-11-2 19 3 DP45 VH3-11-3 3 3 13-2; DP48 VH3-11-4 19 3 DP52 VH3-11-5 14 3 v3-13 VH3-11-6 19 3 DP42 VH3-11-7 3 3 8-1B; YAC-5; 3-66 VH3-11-8 14 3 V3-53 VH3-13-1 3 3 22-28; DP35; V3-11 VH3-13-5 19 3 DP59; VH19; V3-35 VH3-13-6 25 3 f1-p1; DP61 VH3-13-7 19 3 DP46; GL-SJ2; COS 8; hv3005; hv3005f3; 3d21b; 56p1 VH3-13-8 24 3 VH26 VH3-13-9 5 3 vh26c VH3-13-10 19 3 DP47; VH26; 3-23 VH3-13-11 3 3 1-91 VH3-13-12 19 3 DP58 VH3-13-13 3 3 1-9III; DP49; 3-30; 3d28.1 VH3-13-14 24 3 3019B9; DP50, 3-33; 3d277 VH3-13-15 27 3 COS 3 VH3-13-16 19 3 DP51 VH3-13-17 16 3 H11 VH3-13-18 19 3 DP53; COS 6; 3-74; DA-8 VH3-13-19 19 3 DP54; VH3-11; V3-7 VH3-13-20 14 3 V3-64; YAC-6 VH3-13-21 14 3 V3-48 VH3-13-22 14 3 V3-43; DP33 VH3-13-23 14 3 V3-33 VH3-13-24 14 3 V3-21; DP77 VH3-13-25 14 3 V3-20; DP32 VH3-13-26 14 3 V3-9; DP31 VH3-14-1 3 3 12-2; DP29; 3-72; DA-3 VH3-14-4 7 3 YAC-9; 3-73; MTGL VH3-14-2 4 3 VHD26 VH3-14-3 19 3 DP30 VH3-1X-1 1 3 LSG8.1; LSG9.1; LSG10.1; HUM12IGVH; HUM13IGVH VH3-1X-2 1 3 LSG11.1; HUM4IGVH VH3-1X-3 3 3 9-1; DP38; LSG7.1; RCG1.1; LSG1.1; LSG3.1; LSG5.1; HUM15IGVH; HUM2IGVH; HUM9IGVH VH3-1X-4 1 3 LSG4.1 VH3-1X-5 1 3 LSG2.1 VH3-1X-6 1 3 LSG6.1; HUM10IGVH VH3-1X-7 18 3 3-15; V3-15 VH3-1X-8 1 3 LSG12.1; HUM5IGVH VH3-1X-9 14 3 V3-49 VH4-11-1 22 4 Tou-VH4.21 VH4-11-2 17 4 VH4.21; DPG3; VH5; 4d76; V4-34 VH4-11-3 23 4 4.44 VH4-11-4 23 4 4.44.3 VH4-11-5 23 4 4.36 VH4-11-6 23 4 4.37 VH4-11-7 18 4 IV-4; 4.35; V4-4 VH4-11-8 17 4 VH4.11; 3d197d; DP71; 58p2 VH4-11-9 20 4 H7 VH4-11-10 20 4 H8 VH4-11-11 20 4 H9 VH4-11-12 17 4 VH4.16 VH4-11-13 23 4 4.38 VH4-11-14 17 4 VH4.15 VH4-11-15 11 4 58 VH4-11-16 10 4 71-4; V4-59 VH4-21-1 11 4 11 VH4-21-2 17 4 VH4.17; VH4.23; 4d255; 4.40; DP69 VH4-21-3 17 4 VH4.19; 79; V4-4b VH4-21-4 19 4 DP70; 4d68; 4.41 VH4-21-5 19 4 DP67; VH4-4B VH4-21-6 17 4 VH4.22; VHSP; VH-JA VH4-21-7 17 4 VH4.13; 1-9II; 12G-1; 3d28d; 4.42; DP68; 4-28 VH4-21-8 26 4 hv4005; 3d24d VH4-21-9 17 4 VH4.14 VH4-31-1 23 4 4.34; 3d230d; DP78 VH4-31-2 23 4 4.34.2 VH4-31-3 19 4 DP64; 3d216d VH4-31-4 19 4 DP65; 4-31; 3d277d VH4-31-5 23 4 4.33; 3d75d VH4-31-6 20 4 H10 VH4-31-7 20 4 H11 VH4-31-8 23 4 4.31 VH4-31-9 23 4 4.32 VH4-31-10 20 4 3d277d VH4-31-11 20 4 3d216d VH4-31-12 20 4 3d279d VH4-31-13 17 4 VH4.18; 4d154; DP79 VH4-31-14 8 4 V4-39 VH4-31-15 11 4 2-1; DP79 VH4-31-16 23 4 4.30 VH4-31-17 17 4 VH4.12 VH4-31-18 10 4 71-2; DP66 VH4-31-19 23 4 4.39 VH4-31-20 8 4 V4-61 VH5-12-1 9 5 VH251; DP73; VHVCW; 51-R1; VHVLB; VHVCH; VHVTT; VHVAU; VHVBLK; VhAU; V5-51 VH5-12-2 17 5 VHVJB VH5-12-3 3 5 1-v; DP80; 5-78 VH5-12-4 9 5 VH32; VHVRG; VHVMW; 5-2R1 VH6-35- 1 4 6 VHVI; VH6; VHVIIS; VHVITE; VHVUB; VHVICH; VHVICW; VHVIBLK; VHVIMW; DP74; 6-1G1; V6-1

TABLE 2A rearranged human kappa sequences Computed Germline Diff. to % diff. to Name¹ aa² family³ gene⁴ germline⁵ germline⁶ Reference⁷ III-3R 108 1 O8 1 1.1% 70 No.86 109 1 O8 3 3.2% 80 AU 108 1 O8 6 6.3% 103 ROY 108 1 O8 6 6.3% 43 IC4 108 1 O8 6 6.3% 70 HIV-B26 106 1 O8 3 3.2% 8 GRI 108 1 O8 8 8.4% 30 AG 106 1 O8 8 8.6% 116 REI 108 1 O8 9 9.5% 86 CLL PATIENT 16 88 1 O8 2 2.3% 122 CLL PATIENT 14 87 1 O8 2 2.3% 122 CLL PATIENT 15 88 1 O8 2 2.3% 122 GM4672 108 1 O8 11 11.6% 24 HUM.YFC51.1 108 1 O8 12 12.6% 110 LAY 108 1 O8 12 12.6% 48 HIV-b13 106 1 O8 9 9.7% 8 MAL-NaCl 108 1 O8 13 13.7% 102 STRAb SA-1A 108 1 O2 0 0.0% 120 HuVHCAMP 108 1 O8 13 13.7% 100 CRO 108 1 O2 10 10.5% 30 Am107 108 1 O2 12 12.6% 108 WALKER 107 1 O2 4 4.2% 57 III-2R 109 1 A20 0 0.0% 70 FOG1-A4 107 1 A20 4 4.2% 41 HK137 95 1 L1 0 0.0% 10 CEA4-8A 107 1 O2 7 7.4% 41 Va′ 95 1 L4 0 0.0% 90 TR1.21 108 1 O2 4 4.2% 92 HAU 108 1 O2 6 6.3% 123 HK102 95 1 L12(1) 0 0.0% 9 H20C3K 108 1 L12(2) 3 3.2% 125 CHEB 108 1 O2 7 7.4% 5 HK134 95 1 L15(2) 0 0.0% 10 TEL9 108 1 O2 9 9.5% 73 TR1.32 103 1 O2 3 3.2% 92 RF-KES1 97 1 A20 4 4.2% 121 WES 108 1 L5 10 10.5% 61 DILp1 95 1 O4 1 1.1% 70 SA-4B 107 1 L12(2) 8 8.4% 120 HK101 95 1 L15(1) 0 0.0% 9 TR1.23 108 1 O2 5 5.3% 92 HF2-1/17 108 1 A30 0 0.0% 4 2E7 108 1 A30 1 1.1% 62 33.C9 107 1 L12(2) 7 7.4% 126 3D6 105 1 L12(2) 2 2.1% 34 I-2a 108 1 L8 8 8.4% 70 RF-KL1 97 1 L8 4 4.2% 121 TNF-E7 108 1 A30 9 9.5% 41 TR1.22 108 1 O2 7 7.4% 92 HIV-B35 106 1 O2 2 2.2% 8 HIV-b22 106 1 O2 2 2.2% 8 HIV-b27 106 1 O2 2 2.2% 8 HIV-B8 107 1 O2 10 10.8% 8 HIV-b8 107 1 O2 10 10.8% 8 RF-SJ5 95 1 A30 5 5.3% 113 GAL(1) 108 1 A30 6 6.3% 64 R3.5H5G 108 1 O2 6 6.3% 70 HIV-b14 106 1 A20 2 2.2% 8 TNF-E1 105 1 L5 8 8.4% 41 WEA 108 1 A30 8 8.4% 37 EU 108 1 L12(2) 5 5.3% 40 FOG1-G8 108 1 L8 11 11.6% 41 1X7RG1 108 1 L1 8 8.4% 70 BLI 108 1 L8 3 3.2% 72 KUE 108 1 L12(2) 11 11.6% 32 LUNm01 108 1 L12(2) 10 10.5% 6 HIV-b1 106 1 A20 4 4.3% 8 HIV-s4 103 1 O2 2 2.2% 8 CAR 107 1 L12(2) 11 11.7% 79 BR 107 1 L12(2) 11 11.6% 50 CLL PATIENT 10 88 1 O2 0 0.0% 122 CLL PATIENT 12 88 1 O2 0 0.0% 122 KING 108 1 L12(2) 12 12.6% 30 V13 95 1 L24 0 0.0% 46 CLL PATIENT 11 87 1 O2 0 0.0% 122 CLL PATIENT 13 87 1 O2 0 0.0% 122 CLL PATIENT 9 88 1 O12 1 1.1% 122 HIV-B2 106 1 A20 9 9.7% 8 HIV-b2 106 1 A20 9 9.7% 8 CLL PATIENT 5 88 1 A20 1 1.1% 122 CLL PATIENT 1 88 1 L8 2 2.3% 122 CLL PATIENT 2 88 1 L8 0 0.0% 122 CLL PATIENT 7 88 1 L5 0 0.0% 122 CLL PATIENT 8 88 1 L5 0 0.0% 122 HIV-b5 105 1 L5 11 12.0% 8 CLL PATIENT 3 87 1 L8 1 1.1% 122 CLL PATIENT 4 88 1 L9 0 0.0% 122 CLL PATIENT 18 85 1 L9 6 7.1% 122 CLL PATIENT 17 86 1 L12(2) 7 8.1% 122 HIV-b20 107 3 A27 11 11.7% 8 2C12 108 1 L12(2) 20 21.1% 68 1B11 108 1 L12(2) 20 21.1% 68 1H1 108 1 L12(2) 21 22.1% 68 2A12 108 1 L12(2) 21 22.1% 68 CUR 109 3 A27 0 0.0% 66 GLO 109 3 A27 0 0.0% 16 RF-TS1 96 3 A27 0 0.0% 121 GAR′ 109 3 A27 0 0.0% 67 FLO 109 3 A27 0 0.0% 66 PIE 109 3 A27 0 0.0% 91 HAH 14.1 109 3 A27 1 1.0% 51 HAH 14.2 109 3 A27 1 1.0% 51 HAH 16.1 109 3 A27 1 1.0% 51 NOV 109 3 A27 1 1.0% 52 33.F12 108 3 A27 1 1.0% 126 8E10 110 3 A27 1 1.0% 25 TH3 109 3 A27 1 1.0% 25 HIC(R) 108 3 A27 0 0.0% 51 SON 110 3 A27 1 1.0% 67 PAY 109 3 A27 1 1.0% 66 GOT 109 3 A27 1 1.0% 67 mAbA6H4C5 109 3 A27 1 1.0% 12 BOR′ 109 3 A27 2 2.1% 84 RF-SJ3 96 3 A27 2 2.1% 121 SIE 109 3 A27 2 2.1% 15 ESC 109 3 A27 2 2.1% 98 HEW′ 110 3 A27 2 2.1% 98 YES8c 109 3 A27 3 3.1% 33 TI 109 3 A27 3 3.1% 114 mAb113 109 3 A27 3 3.1% 71 HEW 107 3 A27 0 0.0% 94 BRO 106 3 A27 0 0.0% 94 ROB 106 3 A27 0 0.0% 94 NG9 96 3 A27 4 4.2% 11 NEU 109 3 A27 4 4.2% 66 WOL 109 3 A27 4 4.2% 2 35G6 109 3 A27 4 4.2% 59 RF-SJ4 109 3 A11 0 0.0% 88 KAS 109 3 A27 4 4.2% 84 BRA 106 3 A27 1 1.1% 94 HAH 106 3 A27 1 1.1% 94 HIC 105 3 A27 0 0.0% 94 FS-2 109 3 A27 6 6.3% 87 JH′ 107 3 A27 6 6.3% 38 EV1-15 109 3 A27 6 6.3% 83 SCA 108 3 A27 6 6.3% 65 mAb112 109 3 A27 6 6.3% 71 SIC 103 3 A27 3 3.3% 94 SA-4A 109 3 A27 6 6.3% 120 SER 108 3 A27 6 6.3% 98 GOL′ 109 3 A27 7 7.3% 82 BSG10K 105 3 A27 9 9.7% 125 HG2B10K 110 3 A27 9 9.4% 125 Taykv322 105 3 A27 5 5.4% 52 CLL PATIENT 24 89 3 A27 1 1.1% 122 HIV-b24 107 3 A27 7 7.4% 8 HIV-b6 107 3 A27 7 7.4% 8 Taykv310 99 3 A27 1 1.1% 52 KA3D1 108 3 L6 0 0.0% 85 19.E7 107 3 L6 0 0.0% 126 rsv61 109 3 A27 12 12.5% 7 Taykv320 98 3 A27 1 1.2% 52 Vh 96 3 L10(2) 0 0.0% 89 LS8 108 3 L6 1 1.1% 109 LS1 108 3 L6 1 1.1% 109 LS2S3-3 107 3 L6 2 2.1% 99 LS2 108 3 L6 1 1.1% 109 LS7 108 3 L6 1 1.1% 109 LS2S3-4d 107 3 L6 2 2.1% 99 LS2S3-4a 107 3 L6 2 2.1% 99 LS4 108 3 L6 1 1.1% 109 LS6 108 3 L6 1 1.1% 109 LS2S3-10a 107 3 L6 2 2.1% 99 LS2S3-8c 107 3 L6 2 2.1% 99 LS5 108 3 L6 1 1.1% 109 LS2S3-5 107 3 L6 3 3.2% 99 LUNm03 109 3 A27 13 13.5% 6 IARC/BL41 108 3 A27 13 13.7% 55 slkv22 99 3 A27 3 3.5% 13 POP 108 3 L6 4 4.2% 111 LS2S3-10b 107 3 L6 3 3.2% 99 LS2S3-8f 107 3 L6 3 3.2% 99 LS2S3-12 107 3 L6 3 3.2% 99 HIV-B30 107 3 A27 11 11.7% 8 HIV-B20 107 3 A27 11 11.7% 8 HIV-b3 108 3 A27 11 11.7% 8 HIV-s6 104 3 A27 9 9.9% 8 YSE 107 3 L2/L16 1 1.1% 72 POM 109 3 L2/L16 9 9.4% 53 Humkv328 95 3 L2/L16 1 1.1% 19 CLL 109 3 L2/L16 3 3.2% 47 LES 96 3 L2/L16 3 3.2% 38 HIV-s5 104 3 A27 11 12.1% 8 HIV-s7 104 3 A27 11 12.1% 8 slkv1 99 3 A27 7 8.1% 13 Humka31es 95 3 L2/L16 4 4.2% 18 slkv12 101 3 A27 8 9.2% 13 RF-TS2 95 3 L2/L16 3 3.2% 121 II-1 109 3 L2/L16 4 4.2% 70 HIV-s3 105 3 A27 13 14.3% 8 RF-TMC1 96 3 L6 10 10.5% 121 GER 109 3 L2/L16 7 7.4% 75 GF4/1.1 109 3 L2/L16 8 8.4% 36 mAb114 109 3 L2/L16 6 6.3% 71 HIV-loop13 109 3 L2/L16 7 7.4% 8 bkv16 86 3 L6 1 1.2% 13 CLL PATIENT 29 86 3 L6 1 1.2% 122 slkv9 98 3 L6 3 3.5% 13 bkv17 99 3 L6 1 1.2% 13 slkv14 99 3 L6 1 1.2% 13 slkv16 101 3 L6 2 2.3% 13 bkv33 101 3 L6 4 4.7% 13 slkv15 99 3 L6 2 2.3% 13 bkv6 100 3 L6 3 3.5% 13 R6B8K 108 3 L2/L16 12 12.6% 125 AL 700 107 3 L2/L16 9 9.5% 117 slkv11 100 3 L2/L16 3 3.5% 13 slkv4 97 3 L6 4 4.8% 13 CLL PATIENT 26 87 3 L2/L16 1 1.1% 122 AL Se124 103 3 L2/L16 9 9.5% 117 slkv13 100 3 L2/116 6 7.0% 13 bkv7 100 3 L2/L16 5 5.8% 13 bkv22 100 3 L2/L16 6 7.0% 13 CLL PATIENT 27 84 3 L2/L16 0 0.0% 122 bkv35 100 3 L6 8 9.3% 13 CLL PATIENT 25 87 3 L2/L16 4 4.6% 122 slkv3 86 3 L2/L16 7 8.1% 13 slkv7 99 1 O2 7 8.1% 13 HuFd79 111 3 L2/L16 24 24.2% 21 RAD 99 3 A27 9 10.3% 78 CLL PATIENT 28 83 3 L2/L16 4 4.8% 122 REE 104 3 L2/L16 25 27.2% 95 FR4 99 3 A27 8 9.2% 77 MD3.3 92 3 L6 1 1.3% 54 MD3.1 92 3 L6 0 0.0% 54 GA3.6 92 3 L6 2 2.6% 54 M3.5N 92 3 L6 3 3.8% 54 WEI′ 82 3 A27 0 0.0% 65 MD3.4 92 3 L2/L16 1 1.3% 54 MD3.2 91 3 L6 3 3.8% 54 VER 97 3 A27 19 22.4% 20 CLL PATIENT 30 78 3 L6 3 3.8% 122 M3.1N 92 3 L2/L16 1 1.3% 54 MD3.6 91 3 L2/L16 0 0.0% 54 MD3.8 91 3 L2/L16 0 0.0% 54 GA3.4 92 3 L6 7 9.0% 54 M3.6N 92 3 A27 0 0.0% 54 MD3.10 92 3 A27 0 0.0% 54 MD3.13 91 3 A27 0 0.0% 54 MD3.7 93 3 A27 0 0.0% 54 MD3.9 93 3 A27 0 0.0% 54 GA3.1 93 3 A27 6 7.6% 54 bkv32 101 3 A27 5 5.7% 13 GA3.5 93 3 A27 5 6.3% 54 GA3.7 92 3 A27 7 8.9% 54 MD3.12 92 3 A27 2 2.5% 54 M3.2N 90 3 L6 6 7.8% 54 MD3.5 92 3 A27 1 1.3% 54 M3.4N 91 3 L2/L16 8 10.3% 54 M3.8N 91 3 L2/116 7 9.0% 54 M3.7N 92 3 A27 3 3.8% 54 GA3.2 92 3 A27 9 11.4% 54 GA3.8 93 3 A27 4 5.1% 54 GA3.3 92 3 A27 8 10.1% 54 M3.3N 92 3 A27 5 6.3% 54 B6 83 3 A27 8 11.3% 78 E29.1 KAPPA 78 3 L2/L16 0 0.0% 22 SCW 108 1 O8 12 12.6% 31 REI-based CAMPATH-9 107 1 O8 14 14.7% 39 RZ 107 1 O8 14 14.7% 50 B1 108 1 O8 14 14.7% 14 AND 107 1 O2 13 13.7% 69 2A4 109 1 O2 12 12.6% 23 KA 108 1 O8 19 20.0% 107 MEV 109 1 O2 14 14.7% 29 DEE 106 1 O2 13 14.0% 76 OU(IOC) 108 1 O2 18 18.9% 60 HuRSV19VK 111 1 O8 21 21.0% 115 SP2 108 1 O2 17 17.9% 93 BJ26 99 1 O8 21 24.1% 1 N1 112 1 O8 24 24.2% 106 BMA O310EUC|V2 106 1 L12(1) 21 22.3% 105 CLL PATIENT 6 71 1 A20 0 0.0% 122 BJ19 85 1 O8 16 21.9% 1 GM 607 113 2 A3 0 0.0% 58 R5A3K 114 2 A3 1 1.0% 125 R1C8K 114 2 A3 1 1.0% 125 VK2.R149 113 2 A3 2 2.0% 118 TR1.6 109 2 A3 4 4.0% 92 TR1.37 104 2 A3 5 5.0% 92 FS-1 113 2 A3 6 6.0% 87 TR1.8 110 2 A3 6 6.0% 92 NIM 113 2 A3 8 8.0% 28 Inc 112 2 A3 11 11.0% 35 TEW 107 2 A3 6 6.4% 96 CUM 114 2 O1 7 6.9% 44 HRF1 71 2 A3 4 5.6% 124 CLL PATIENT 19 87 2 A3 0 0.0% 122 CLL PATIENT 20 87 2 A3 0 0.0% 122 Mu 112 2 A3 16 16.2% 26 FR 113 2 A3 20 20.0% 101 MAL-Urine 83 1 O2 6 8.6% 102 Taykv306 73 3 A27 1 1.6% 52 Taykv312 75 3 A27 1 1.6% 52 HIV-b29 93 3 A27 14 17.5% 8 1-185-37 110 3 A27 0 0.0% 119 1-187-29 110 3 A27 0 0.0% 119 TT117 110 3 A27 9 9.4% 63 HIV-loop8 108 3 A27 16 16.8% 8 rsv23L 108 3 A27 16 16.8% 7 HIV-b7 107 3 A27 14 14.9% 8 HIV-b11 107 3 A27 15 16.0% 8 HIV-LC1 107 3 A27 19 20.2% 8 HIV-LC7 107 3 A27 20 21.3% 8 HIV-LC22 107 3 A27 21 22.3% 8 HIV-LC13 107 3 A27 21 22.3% 8 HIV-LC3 107 3 A27 21 22.3% 8 HIV-LC5 107 3 A27 21 22.3% 8 HIV-LC28 107 3 A27 21 22.3% 8 HIV-b4 107 3 A27 22 23.4% 8 CLL PATIENT 31 87 3 A27 15 17.2% 122 HIV-loop2 108 3 L2/L16 17 17.9% 8 HIV-loop35 108 3 L2/116 17 17.9% 8 HIV-LC11 107 3 A27 23 24.5% 8 HIV-LC24 107 3 A27 23 24.5% 8 HIV-b12 107 3 A27 24 25.5% 8 HIV-LC25 107 3 A27 24 25.5% 8 HIV-b21 107 3 A27 24 25.5% 8 HIV-LC26 107 3 A27 26 27.7% 8 G3D10k 108 1 L12(2) 12 12.6% 125 TT125 108 1 L5 8 8.4% 63 HIV-s2 103 3 A27 28 31.1% 8 265-695 108 1 L5 7 7.4% 3 2-115-19 108 1 A30 2 2.1% 119 rsv13L 107 1 O2 20 21.1% 7 HIV-b18 106 1 O2 14 15.1% 8 RF-KL5 98 3 L6 36 36.7% 97 ZM1-1 113 2 A17 7 7.0% 3 HIV-s8 103 1 O8 16 17.8% 8 K-EV15 95 5 B2 0 0.0% 112 RF-TS3 100 2 A23 0 0.0% 121 HF-21/28 111 2 A17 1 1.0% 17 RPMI6410 113 2 A17 1 1.0% 42 JC11 113 2 A17 1 1.0% 49 O-81 114 2 A17 5 5.0% 45 FK-001 113 4 B3 0 0.0% 81 CD5+.28 101 4 B3 1 1.0% 27 LEN 114 4 B3 1 1.0% 104 UC 114 4 B3 1 1.0% 111 CD5+.5 101 4 B3 1 1.0% 27 CD5+.26 101 4 B3 1 1.0% 27 CD5+.12 101 4 B3 2 2.0% 27 CD5+.23 101 4 B3 2 2.0% 27 CD5+.7 101 4 B3 2 2.0% 27 VJI 113 4 B3 3 3.0% 56 LOC 113 4 B3 3 3.0% 72 MAL 113 4 B3 3 3.0% 72 CD5+.6 101 4 B3 3 3.0% 27 H2F 113 4 B3 3 3.0% 70 PB17IV 114 4 B3 4 4.0% 74 CD5+.27 101 4 B3 4 4.0% 27 CD5+.9 101 4 B3 4 4.0% 27 CD5−.28 101 4 B3 5 5.0% 27 CD5−.26 101 4 B3 6 5.9% 27 CD5+.24 101 4 B3 6 5.9% 27 CD5+.10 101 4 B3 6 5.9% 27 CD5−.19 101 4 B3 6 5.9% 27 CD5−.18 101 4 B3 7 6.9% 27 CD5−.16 101 4 B3 8 7.9% 27 CD5−.24 101 4 B3 8 7.9% 27 CD5−.17 101 4 B3 10 9.9% 27 MD4.1 92 4 B3 0 0.0% 54 MD4.4 92 4 B3 0 0.0% 54 MD4.5 92 4 B3 0 0.0% 54 MD4.6 92 4 B3 0 0.0% 54 MD4.7 92 4 B3 0 0.0% 54 MD4.2 92 4 B3 1 1.3% 54 MD4.3 92 4 B3 5 6.3% 54 CLL PATIENT 22 87 2 A17 2 2.3% 122 CLL PATIENT 23 84 2 A17 2 2.4% 122

TABLE 2B rearranged human lambda sequences Computed Germline Diff. to % diff. to Name¹ aa² family³ gene⁴ germline⁵ germline⁶ Reference⁷ WAH 110 1 DPL3 7  7% 68 1B9/F2 112 1 DPL3 7  7% 9 DIA 112 1 DPL2 7  7% 36 mAb67 89 1 DPL3 0  0% 29 HiH2 110 1 DPL3 12 11% 3 NIG-77 112 1 DPL2 9  9% 72 OKA 112 1 DPL2 7  7% 84 KOL 112 1 DPL2 12 11% 40 T2:C5 111 1 DPL5 0  0% 6 T2:C14 110 1 DPL5 0  0% 6 PR-TS1 110 1 DPL5 0  0% 55 4G12 111 1 DPL5 1  1% 35 KIM46L 112 1 HUMLV117 0  0% 8 Fog-B 111 1 DPL5 3  3% 31 9F2L 111 1 DPL5 3  3% 79 mAb111 110 1 DPL5 3  3% 48 PHOX15 111 1 DPL5 4  4% 49 BL2 111 1 DPL5 4  4% 74 NIG-64 111 1 DPL5 4  4% 72 RF-SJ2 100 1 DPL5 6  6% 78 AL EZI 112 1 DPL5 7  7% 41 ZIM 112 1 HUMLV117 7  7% 18 RF-SJ1 100 1 DPL5 9  9% 78 IGLV1.1 98 1 DPL4 0  0% 1 NEW 112 1 HUMLV117 11 10% 42 CB-201 87 1 DPL2 1  1% 62 MEM 109 1 DPL2 6  6% 50 H210 111 2 DPL10 4  4% 45 NOV 110 2 DPL10 8  8% 25 NEI 111 2 DPL10 8  8% 24 ALMC 110 2 DPL11 6  6% 28 MES 112 2 DPL11 8  8% 84 FOG1-A3 111 2 DPL11 9  9% 27 AL NOV 112 2 DPL11 7  7% 28 HMST-1 110 2 DPL11 4  4% 82 HBW4-1 108 2 DPL12 9  9% 52 WH 110 2 DPL11 11 11% 34 11-50 110 2 DPL11 7  7% 82 HBp2 110 2 DPL12 8  8% 3 NIG-84 113 2 DPL11 12 11% 73 VIL 112 2 DPL11 9  9% 58 TRO 111 2 DPL12 10 10% 61 ES492 108 2 DPL11 15 15% 76 mAb216 89 2 DPL12 1  1% 7 BSA3 109 3 DPL16 0  0% 49 THY-29 110 3 DPL16 0  0% 27 PR-TS2 108 3 DPL16 0  0% 55 E29.1 LAMBDA 107 3 DPL16 1  1% 13 mAb63 109 3 DPL16 2  2% 29 TEL14 110 3 DPL16 6  6% 49 6H-3C4 108 3 DPL16 7  7% 39 SH 109 3 DPL16 7  7% 70 AL GIL 109 3 DPL16 8  8% 23 H6-3C4 108 3 DPL16 8  8% 83 V-lambda-2.DS 111 2 DPL11 3  3% 15 8.12 ID 110 2 DPL11 3  3% 81 DSC 111 2 DPL11 3  3% 56 PV11 110 2 DPL11 1  1% 56 33.H11 110 2 DPL11 4  4% 81 AS17 111 2 DPL11 7  7% 56 SD6 110 2 DPL11 7  7% 56 KS3 110 2 DPL11 9  9% 56 PV6 110 2 DPL12 5  5% 56 NGD9 110 2 DPL11 7  7% 56 MUC1-1 111 2 DPL11 11 10% 27 A30c 111 2 DPL10 6  6% 56 KS6 110 2 DPL12 6  6% 56 TEL13 111 2 DPL11 11 10% 49 AS7 110 2 DPL12 6  6% 56 MCG 112 2 DPL12 12 11% 20 U266L 110 2 DPL12 13 12% 77 PR-SJ2 110 2 DPL12 14 13% 55 BOH 112 2 DPL12 11 10% 37 TOG 111 2 DPL11 19 18% 53 TEL16 111 2 DPL11 19 18% 49 No.13 110 2 DPL10 14 13% 52 BO 112 2 DPL12 18 17% 80 WIN 112 2 DPL12 17 16% 11 BUR 104 2 DPL12 15 15% 46 NIG-58 110 2 DPL12 20 19% 69 WEIR 112 2 DPL11 26 25% 21 THY-32 111 1 DPL8 8  8% 27 TNF-H9G1 111 1 DPL8 9  9% 27 mAb61 111 1 DPL3 1  1% 29 LV1L1 98 1 DPL2 0  0% 54 HA 113 1 DPL3 14 13% 63 LA1L1 111 1 DPL2 3  3% 54 RHE 112 1 DPL1 17 16% 22 K1B12L 113 1 DPL8 17 16% 79 LOC 113 1 DPL2 15 14% 84 NIG-51 112 1 DPL2 12 11% 67 NEWM 104 1 DPL8 23 22% 10 MD3-4 106 3 DPL23 14 13% 4 COX 112 1 DPL2 13 12% 84 HiH10 106 3 DPL23 13 12% 3 VOR 112 1 DPL2 16 15% 16 AL POL 113 1 DPL2 16 15% 57 CD4-74 111 1 DPL2 19 18% 27 AMYLOID MOL 102 3 DPL23 15 15% 30 OST577 108 3 Humlv318 10 10% 4 NIG-48 113 1 DPL3 42 40% 66 CARR 108 3 DPL23 18 17% 19 mAb60 108 3 DPL23 14 13% 29 NIG-68 99 3 DPL23 25 26% 32 KERN 107 3 DPL23 26 25% 59 ANT 106 3 DPL23 17 16% 19 LEE 110 3 DPL23 18 17% 85 CLE 94 3 DPL23 17 17% 19 VL8 98 8 DPL21 0  0% 81 MOT 110 3 Humlv318 23 22% 38 GAR 108 3 DPL23 26 25% 33 32.B9 98 8 DPL21 5  5% 81 PUG 108 3 Humlv318 24 23% 19 T1 115 8 HUMLV801 52 50% 6 RF-TS7 96 7 DPL18 4  4% 60 YM-1 116 8 HUMLV801 51 49% 75 K6H6 112 8 HUMLV801 20 19% 44 K5C7 112 8 HUMLV801 20 19% 44 K5B8 112 8 HUMLV801 20 19% 44 K5G5 112 8 HUMLV801 20 19% 44 K4B8 112 8 HUMLV801 19 18% 44 K6F5 112 8 HUMLV801 17 16% 44 HIL 108 3 DPL23 22 21% 47 KIR 109 3 DPL23 20 19% 19 CAP 109 3 DPL23 19 18% 84 1B8 110 3 DPL23 22 21% 43 SHO 108 3 DPL23 19 18% 19 HAN 108 3 DPL23 20 19% 19 cML23 96 3 DPL2J 3  3% 12 PR-SJ1 96 3 DPL23 7  7% 55 BAU 107 3 DPL23 9  9% 5 TEX 99 3 DPL23 8  8% 19 X(PET) 107 3 DPL23 9  9% 51 DOY 106 3 DPL23 9  9% 19 COT 106 3 DPL23 13 12% 19 Pag-1 111 3 Humlv318 5  5% 31 DIS 107 3 Humlv318 2  2% 19 WIT 108 3 Humlv318 7  7% 19 I.RH 108 3 Humlv318 12 11% 19 S1-1 108 3 Humlv318 12 11% 52 DEL 108 3 Humlv318 14 13% 17 TYR 108 3 Humlv318 11 10% 19 J.RH 109 3 Humlv318 13 12% 19 THO 112 2 DPL13 38 36% 26 LBV 113 1 DPL3 38 36% 2 WLT 112 1 DPL3 33 31% 14 SUT 112 2 DPL12 37 35% 65

TABLE 2C rearranged human heavy chain sequences Diff. % diff. Com- to to Ref- puted Germline germ- germ- er- Name¹ aa² family³ gene⁴ line⁵ line⁶ ence⁷ 21/28 119 1 VH1-13-12 0 0.0% 31 8E10 123 1 VH1-13-12 0 0.0% 31 MUC1-1 118 1 VH1-13-6 4 4.1% 42 gF1 98 1 VH1-13-12 10 10.2% 75 VHGL 1.2 98 1 VH1-13-6 2 2.0% 26 HV1L1 98 1 VH1-13-6 0 0.0% 81 RF-TS7 104 1 VH1-13-6 3 3.1% 96 E55 1.A15 106 1 VH1-13-15 1 1.0% 26 HA1L1 126 1 VH1-13-6 7 7.1% 81 UC 123 1 VH1-13-6 5 5.1% 115 WIL2 123 1 VH1-13-6 6 6.1% 55 R3.5H5G 122 1 VH1-13-6 10 10.2% 70 N89P2 123 1 VH1-13-16 11 11.2% 77 mAb113 126 1 VH1-13-6 10 10.2% 71 LS2S3-3 125 1 VH1-12-7 5 5.1% 98 LS2S3-12a 125 1 VH1-12-7 5 5.1% 98 LS2S3-5 125 1 VH1-12-7 5 5.1% 98 L52S3-12e 125 1 VH1-12-7 5 5.1% 98 LS2S3-4 125 1 VH1-12-7 5 5.1% 98 LS2S3-10 125 1 VH1-12-7 5 5.1% 98 LS2S3-12d 125 1 VH1-12-7 6 6.1% 98 LS2S3-8 125 1 VH1-12-7 5 5.1% 98 LS2 125 1 VH1-12-7 6 6.1% 113 LS4 105 1 VH1-12-7 6 6.1% 113 LS5 125 1 VH1-12-7 6 6.1% 113 LS1 125 1 VH1-12-7 6 6.1% 113 LS6 125 1 VH1-12-7 6 6.1% 113 LS8 125 1 VH1-12-7 7 7.1% 113 THY-29 122 1 VH1-12-7 0 0.0% 42 1B9/F2 122 1 VH1-12-7 10 10.2% 21 51P1 122 1 VH1-12-1 0 0.0% 105 NEI 127 1 VH1-12-1 0 0.0% 55 AND 127 1 VH1-12-1 0 0.0% 55 L7 127 1 VH1-12-1 0 0.0% 54 L22 124 1 VH1-12-1 0 0.0% 54 L24 127 1 VH1-12-1 0 0.0% 54 L26 116 1 VH1-12-1 0 0.0% 54 L33 119 1 VH1-12-1 0 0.0% 54 L34 117 1 VH1-12-1 0 0.0% 54 L36 118 1 VH1-12-1 0 0.0% 54 L39 120 1 VH1-12-1 0 0.0% 54 L41 120 1 VH1-12-1 0 0.0% 54 L42 125 1 VH1-12-1 0 0.0% 54 VHGL 1.8 101 1 VH1-12-1 0 0.0% 26 783c 127 1 VH1-12-1 0 0.0% 22 X17115 127 1 VH1-12-1 0 0.0% 37 L25 124 1 VH1-12-1 0 0.0% 54 L17 120 1 VH1-12-1 1 1.0% 54 L30 127 1 VH1-12-1 1 1.0% 54 L37 120 1 VH1-12-1 1 1.0% 54 TNF-E7 116 1 VH1-12-1 2 2.0% 42 mAb111 122 1 VH1-12-1 7 7.1% 71 III-2R 122 1 VH1-12-9 3 3.1% 70 KAS 121 1 VH1-12-1 7 7.1% 79 YES8c 122 1 VH1-12-1 8 8.2% 34 RF-TS1 123 1 VH1-12-1 8 8.2% 82 BOR 121 1 VH1-12-8 7 7.1% 79 VHGL 1.9 101 1 VH1-12-1 8 8.2% 26 mAb410.30F305 117 1 VH1-12-9 5 5.1% 52 EV1-15 127 1 VH1-12-8 10 10.2% 78 mAb112 122 1 VH1-12-1 11 11.2% 71 EU 117 1 VH1-12-1 11 11.2% 28 H210 127 1 VH1-12-1 12 12.2% 66 TRANSGENE 104 1 VH1-12-1 0 0.0% 111 CLL2-1 93 1 VH1-12-1 0 0.0% 30 CLL10 13-3 97 1 VH1-12-1 0 0.0% 29 LS7 99 1 VH1-12-7 4 4.1% 113 ALL7-1 87 1 VH1-12-7 0 0.0% 30 CLL3-1 91 1 VH1-12-7 1 1.0% 30 ALL56-1 85 1 VH1-13-8 0 0.0% 30 ALL1-1 87 1 VH1-13-6 1 1.0% 30 ALL4-1 94 1 VH1-13-8 0 0.0% 30 ALL56 15-4 85 1 VH1-13-8 5 5.1% 29 CLL4-1 88 1 VH1-13-1 1 1.0% 30 Au92.1 98 1 VH1-12-5 0 0.0% 49 RF-TS3 120 1 VH1-12-5 1 1.0% 82 Au4.1 98 1 VH1-12-5 1 1.0% 49 HP1 121 1 VH1-13-6 13 13.3% 110 BLI 127 1 VH1-13-15 5 5.1% 72 No.13 127 1 VH1-12-2 19 19.4% 76 TR1.23 122 1 VH1-13-2 23 23.5% 88 S1-1 125 1 VH1-12-2 18 18.4% 76 TR1.10 119 1 VH1-13-12 14 14.3% 88 E55 1.A2 102 1 VH1-13-15 3 3.1% 26 SP2 119 1 VH1-13-6 15 15.3% 89 TNF-H9G1 111 1 VH1-13-18 2 2.0% 42 G3D10H 127 1 VH1-13-16 19 19.4% 127 TR1.9 118 1 VH1-13-12 14 14.3% 88 TR1.8 121 1 VH1-12-1 24 24.5% 88 LUNm01 127 1 VH1-13-6 22 22.4% 9 K1B12H 127 1 VH1-12-7 23 23.5% 127 L3B2 99 1 VH1-13-6 2 2.0% 46 ss2 100 1 VH1-13-6 2 2.0% 46 No.86 124 1 VHI-12-1 20 20.4% 76 TR1.6 124 1 VH1-12-1 19 19.4% 88 ss7 99 1 VH1-12-7 3 3.1% 46 s5B7 102 1 VH1-12-1 0 0.0% 46 s6A3 97 1 VH1-12-1 0 0.0% 46 ss6 99 1 VH1-12-1 0 0.0% 46 L2H7 103 1 VH1-13-12 0 0.0% 46 s6BG8 93 1 VH1-13-12 0 0.0% 46 s6C9 107 1 VH1-13-12 0 0.0% 46 HIV-b4 124 1 VH1-13-12 21 21.4% 12 HIV-b12 124 1 VH1-13-12 21 21.4% 12 L3G5 98 1 VH1-13-6 1 1.0% 46 22 115 1 VH1-13-6 11 11.2% 118 L2A12 99 1 VH1-13-15 3 3.1% 46 PHOX15 124 1 VH1-12-7 20 20.4% 73 LUNm03 127 1 VH1-1X-1 18 18.4% 9 CEA4-8A 129 1 VH1-12-7 1 1.0% 42 M60 121 2 VH2-31-3 3 3.0% 103 HiH10 127 2 VH2-31-5 9 9.0% 4 COR 119 2 VH2-31-2 11 11.0% 91 2-115-19 124 2 VH2-31-11 8 8.1% 124 OU 125 2 VH2-31-14 20 25.6% 92 HE 120 2 VH2-31-13 19 19.0% 27 CLL33 40-1 78 2 VH2-31-5 2 2.0% 29 E55 3.9 88 3 VH3-11-5 7 7.2% 26 MTFC3 125 3 VH3-14-4 21 21.0% 131 MTFC11 125 3 VH3-14-4 21 21.0% 131 MTFJ1 114 3 VH3-14-4 21 21.0% 131 MTFJ2 114 3 VH3-14-4 21 21.0% 131 MTFUJ4 100 3 VH3-14-4 21 21.0% 131 MTFUJ5 100 3 VH3-14-4 21 21.0% 131 MTFUJ2 100 3 VH3-14-4 22 22.0% 131 MTFC8 125 3 VH3-14-4 23 23.0% 131 TD e Vq 113 3 VH3-14-4 0 0.0% 16 rMTF 114 3 VH3-14-4 5 5.0% 131 MTFUJ6 100 3 VH3-14-4 10 10.0% 131 RF-KES 107 3 VH3-14-4 9 9.0% 85 N51P8 126 3 VH3-14-1 9 9.0% 77 TEI 119 3 VH3-13-8 21 21.4% 20 33.H11 115 3 VH3-13-19 10 10.2% 129 SB1/D8 101 3 VH3-1X-8 14 14.0% 2 38P1 119 3 VH3-11-3 0 0.0% 104 BRO′IGM 119 3 VH3-11-3 13 13.4% 19 NIE 119 3 VH3-13-7 15 15.3% 87 3D6 126 3 VH3-13-26 5 5.1% 35 ZM1-1 112 3 VH3-11-3 8 8.2% 5 E55 3.15 110 3 VH3-13-26 0 0.0% 26 gF9 108 3 VH3-13-8 15 15.3% 75 THY-32 120 3 VH3-13-26 3 3.1% 42 RF-KL5 100 3 VH3-13-26 5 5.1% 96 OST577 122 3 VH3-13-13 6 6.1% 5 BO 113 3 VH3-13-19 15 15.3% 10 TT125 121 3 VH3-13-10 15 15.3% 64 2-115-58 127 3 VH3-13-10 11 11.2% 124 KOL 126 3 VH3-13-14 16 16.3% 102 mAb60 118 3 VH3-13-17 14 14.3% 45 RF-AN 106 3 VH3-13-26 8 8.2% 85 BUT 115 3 VH3-11-6 13 13.4% 119 KOL-based 118 3 VH3-13-13 16 16.3% 41 CAMPATH-9 B1 119 3 VH3-13-19 13 13.3% 53 N98P1 127 3 VH3-13-1 13 13.3% 77 TT117 107 3 VH3-13-10 12 12.2% 64 WEA 114 3 VH3-13-12 15 15.3% 40 HIL 120 3 VH3-13-14 14 14.3% 23 s5A10 97 3 VH3-13-14 0 0.0% 46 s5D11 98 3 VH3-13-7 0 0.0% 46 s6C8 100 3 VH3-13-7 0 0.0% 46 s6H12 98 3 VH3-13-7 0 0.0% 46 VH10.7 119 3 VH3-13-14 16 16.3% 128 HIV-loop2 126 3 VH3-13-7 16 16.3% 12 HIV-loop35 126 3 VH3-13-7 16 16.3% 12 TRO 122 3 VH3-13-1 13 13.3% 61 SA-4B 123 3 VH3-13-1 15 15.3% 125 L2B5 98 3 VH3-13-13 0 0.0% 46 s6E11 95 3 VH3-13-13 0 0.0% 46 s6H7 100 3 VH3-13-13 0 0.0% 46 ss1 102 3 VH3-13-13 0 0.0% 46 ss8 94 3 VH3-13-13 0 0.0% 46 DOB 120 3 VH3-13-26 21 21.4% 116 THY-33 115 3 VH3-13-15 20 20.4% 42 NOV 118 3 VH3-13-19 14 14.3% 38 rsv13H 120 3 VH3-13-24 20 20.4% 11 L3G11 98 3 VH3-13-20 2 2.0% 46 L2E8 99 3 VH3-13-19 0 0.0% 46 L2D10 101 3 VH3-13-10 1 1.0% 46 L2E7 98 3 VH3-13-10 1 1.0% 46 L3A10 100 3 VH3-13-24 0 0.0% 46 L2E5 97 3 VH3-13-2 1 1.0% 46 BUR 119 3 VH3-13-7 21 21.4% 67 s4D5 107 3 VH3-11-3 1 1.0% 46 19 116 3 VH3-13-16 4 4.1% 118 s5D4 99 3 VH3-13-1 0 0.0% 46 s6A8 100 3 VH3-13-1 0 0.0% 46 HIV-loop13 123 3 VH3-13-12 17 17.3% 12 TR1.32 112 3 VH3-11-8 18 18.6% 88 L2B10 97 3 VH3-11-3 1 1.0% 46 TR1.5 114 3 VH3-11-8 21 21.6% 88 s6H9 101 3 VH3-13-25 0 0.0% 46 8 112 3 VH3-13-1 6 6.1% 118 23 115 3 VH3-13-1 6 6.1% 118 7 115 3 VH3-13-1 4 4.1% 118 TR1.3 120 3 VH3-11-8 20 20.6% 88 18/2 125 3 VH3-13-10 0 0.0% 32 18/9 125 3 VH3-13-10 0 0.0% 31 30P1 119 3 VH3-13-10 0 0.0% 106 HF2-1/17 125 3 VH3-13-10 0 0.0% 8 A77 109 3 VH3-13-10 0 0.0% 44 B19.7 108 3 VH3-13-10 0 0.0% 44 M43 119 3 VH3-13-10 0 0.0% 103 1/17 125 3 VH3-13-10 0 0.0% 31 18/17 125 3 VH3-13-10 0 0.0% 31 E54 3.4 109 3 VH3-13-10 0 0.0% 26 LAMBDA-VH26 98 3 VH3-13-10 1 1.0% 95 E54 3.8 111 3 VH3-13-10 1 1.0% 26 GL16 106 3 VH3-13-10 1 1.0% 44 4G12 125 3 VH3-13-10 1 1.0% 56 A73 106 3 VH3-13-10 2 2.0% 44 AL1.3 111 3 VH3-13-10 3 3.1% 117 3.A290 118 3 VH3-13-10 2 2.0% 108 Ab18 127 3 VH3-13-8 2 2.0% 100 E54 3.3 105 3 VH3-13-10 3 3.1% 26 35G6 121 3 VH3-13-10 3 3.1% 57 A95 107 3 VH3-13-10 5 5.1% 44 Ab25 128 3 VH3-13-10 5 5.1% 100 N87 126 3 VH3-13-10 4 4.1% 77 ED8.4 99 3 VH3-13-10 6 6.1% 2 RF-KL1 122 3 VH3-13-10 6 6.1% 82 AL1.1 112 3 VH3-13-10 2 2.0% 117 AL3.11 102 3 VH3-13-10 1 1.0% 117 32.B9 127 3 VH3-13-8 6 6.1% 129 TK1 109 3 VH3-13-10 2 2.0% 117 POP 123 3 VH3-13-10 8 8.2% 115 9F2H 127 3 VH3-13-10 9 9.2% 127 VD 115 3 VH3-13-10 9 9.2% 10 Vh38Cl.10 121 3 VH3-13-10 8 8.2% 74 Vh38Cl.9 121 3 VH3-13-10 8 8.2% 74 Vh38Cl.8 121 3 VH3-13-10 8 8.2% 74 63P1 120 3 VH3-11-8 0 0.0% 104 60P2 117 3 VH3-11-8 0 0.0% 104 AL3.5 90 3 VH3-13-10 2 2.0% 117 GF4/1.1 123 3 VH3-13-10 10 10.2% 39 Ab21 126 3 VH3-13-10 12 12.2% 100 TD d Vp 118 3 VH3-13-17 2 2.0% 16 Vh38Cl.4 119 3 VH3-13-10 8 8.2% 74 Vh38Cl.5 119 3 VH3-13-10 8 8.2% 74 AL3.4 104 3 VH3-13-10 1 1.0% 117 FOG1-A3 115 3 VH3-13-19 2 2.0% 42 HA3D1 117 3 VH3-13-21 1 1.0% 81 E54 3.2 112 3 VH3-13-24 0 0.0% 26 mAb52 128 3 VH3-13-12 2 2.0% 51 mAb53 128 3 VH3-13-12 2 2.0% 51 mAb56 128 3 VH3-13-12 2 2.0% 51 mAb57 128 3 VH3-13-12 2 2.0% 51 mAb58 128 3 VH3-13-12 2 2.0% 51 mAb59 128 3 VH3-13-12 2 2.0% 51 mAb105 128 3 VH3-13-12 2 2.0% 51 mAb107 128 3 VH3-13-12 2 2.0% 51 E55 3.14 110 3 VH3-13-19 0 0.0% 26 F13-28 106 3 VH3-13-19 1 1.0% 94 mAb55 127 3 VH3-13-18 4 4.1% 51 YSE 117 3 VH3-13-24 6 6.1% 72 E55 3.23 106 3 VH3-13-19 2 2.0% 26 RF-TS5 101 3 VH3-13-1 3 3.1% 85 N42P5 124 3 VH3-13-2 7 7.1% 77 FOG1-H6 110 3 VH3-13-16 7 7.1% 42 O-81 115 3 VH3-13-19 11 11.2% 47 HIV-s8 122 3 VH3-13-12 11 11.2% 12 mAb114 125 3 VH3-13-19 12 12.2% 71 33.F12 116 3 VH3-13-2 4 4.1% 129 4B4 119 3 VH3-1X-3 0 0.0% 101 M26 123 3 VH3-1X-3 0 0.0% 103 VHGL 3.1 100 3 VH3-1X-3 0 0.0% 26 E55 3.13 113 3 VH3-1X-3 1 1.0% 26 SB5/D6 101 3 VH3-1X-6 3 3.0% 2 RAY4 101 3 VH3-1X-6 3 3.0% 2 82-D V-D 106 3 VH3-1X-3 5 5.0% 112 MAL 129 3 VH3-1X-3 5 5.0% 72 LOC 123 3 VH3-1X-6 5 5.0% 72 LSF2 101 3 VH3-1X-6 11 11.0% 2 HIB RC3 100 3 VH3-1X-6 11 11.0% 1 56P1 119 3 VH3-13-7 0 0.0% 104 M72 122 3 VH3-13-7 0 0.0% 103 M74 121 3 VH3-13-7 0 0.0% 103 E54 3.5 105 3 VH3-13-7 0 0.0% 26 2E7 123 3 VH3-13-7 0 0.0% 63 2P1 117 3 VH3-13-7 0 0.0% 104 RF-SJ2 127 3 VH3-13-7 1 1.0% 83 PR-TS1 114 3 VH3-13-7 1 1.0% 85 KIM46H 127 3 VH3-13-13 0 0.0% 18 E55 3.6 108 3 VH3-13-7 2 2.0% 26 E55 3.10 107 3 VH3-13-13 1 1.0% 26 3.B6 114 3 VH3-13-13 1 1.0% 108 E54 3.6 110 3 VH3-13-13 1 1.0% 26 FL2-2 114 3 VH3-13-13 1 1.0% 80 RF-SJ3 112 3 VH3-13-7 2 2.0% 85 E55 3.5 105 3 VH3-13-14 1 1.0% 26 BSA3 121 3 VH3-13-13 1 1.0% 73 HMST-1 119 3 VH3-13-7 3 3.1% 130 RF-TS2 126 3 VH3-13-13 4 4.1% 82 E55 3.12 109 3 VH3-13-15 0 0.0% 26 19.E7 126 3 VH3-13-14 3 3.1% 129 11-50 119 3 VH3-13-13 6 6.1% 130 E29.1 120 3 VH3-13-15 2 2.0% 25 E55 3.16 108 3 VH3-13-7 6 6.1% 26 TNF-E1 117 3 VH3-13-7 7 7.1% 42 AF-SJ1 127 3 VH3-13-13 6 6.1% 83 FOG1-A4 116 3 VH3-13-7 8 8.2% 42 TNF-A1 117 3 VH3-13-15 4 4.1% 42 PR-SJ2 107 3 VH3-13-14 8 8.2% 85 HN.14 124 3 VH3-13-13 10 10.2% 33 CAM′ 121 3 VH3-13-7 12 12.2% 65 HIV-B8 125 3 VH3-13-7 9 9.2% 12 HIV-b27 125 3 VH3-13-7 9 9.2% 12 HIV-b8 125 3 VH3-13-7 9 9.2% 12 HIV-s4 125 3 VH3-13-7 9 9.2% 12 HIV-B26 125 3 VH3-13-7 9 9.2% 12 HIV-B35 125 3 VH3-13-7 10 10.2% 12 HIV-b18 125 3 VH3-13-7 10 10.2% 12 HIV-b22 125 3 VH3-13-7 11 11.2% 12 HIV-b13 125 3 VH3-13-7 12 12.2% 12 333 117 3 VH3-14-4 24 24.0% 24 1H1 120 3 VH3-14-4 24 24.0% 24 1B11 120 3 VH3-14-4 23 23.0% 24 CLL30 2-3 86 3 VH3-13-19 1 1.0% 29 GA 110 3 VH3-13-7 19 19.4% 36 JeB 99 3 VH3-13-14 3 3.1% 7 GAL 110 3 VH3-13-19 10 10.2% 126 K6H6 119 3 VH3-1X-6 18 18.0% 60 K4B8 119 3 VH3-1X-6 18 18.0% 60 K5B8 119 3 VH3-1X-6 18 18.0% 60 K5C7 119 3 VH3-1X-6 19 19.0% 60 K5G5 119 3 VH3-1X-6 19 19.0% 60 K6F5 119 3 VH3-1X-6 19 19.0% 60 AL3.16 98 3 VH3-13-10 1 1.0% 117 N86P2 98 3 VH3-13-10 3 3.1% 77 N54P6 95 3 VH3-13-16 7 7.1% 77 LAMBDA 126 4 VH4-11-2 0 0.0% 3 HT112-1 HY18 121 4 VH4-11-2 0 0.0% 43 mAb63 126 4 VH4-11-2 0 0.0% 45 FS-3 105 4 VH4-11-2 0 0.0% 86 FS-5 111 4 VH4-11-2 0 0.0% 86 FS-7 107 4 VH4-11-2 0 0.0% 86 FS-8 110 4 VH4-11-2 0 0.0% 86 PR-TS2 105 4 VH4-11-2 0 0.0% 85 RF-TMC 102 4 VH4-11-2 0 0.0% 85 mAb216 122 4 VH4-11-2 1 1.0% 15 mAb410.7.F91 122 4 VH4-11-2 1 1.0% 52 mAbA6H4C5 124 4 VH4-11-2 1 1.0% 15 Ab44 127 4 VH4-11-2 2 2.1% 100 6H-3C4 124 4 VH4-11-2 3 3.1% 59 FS-6 108 4 VH4-11-2 6 6.2% 86 FS-2 114 4 VH4-11-2 6 6.2% 84 H1G1 126 4 VH4-11-2 7 7.2% 62 FS-4 105 4 VH4-11-2 8 8.2% 86 SA-4A 123 4 VH4-11-2 9 9.3% 125 LES-C 119 4 VH4-11-2 10 10.3% 99 DI 78 4 VH4-11-9 16 16.5% 58 Ab26 126 4 VH4-31-4 8 8.1% 100 TS2 124 4 VH4-31-12 15 15.2% 110 265-695 115 4 VH4-11-7 16 16.5% 5 WAH 129 4 VH4-31-13 19 19.2% 93 268-D 122 4 VH4-11-8 22 22.7% 6 58P2 118 4 VH4-11-8 0 0.0% 104 mAb67 128 4 VH4-21-4 1 1.0% 45 4.L39 115 4 VH4-11-8 2 2.1% 108 mF7 111 4 VH4-31-13 3 3.0% 75 33.C9 122 4 VH4-21-5 7 7.1% 129 Pag-1 124 4 VH4-11-16 5 5.2% 50 B3 123 4 VH4-21-3 8 8.2% 53 IC4 120 4 VH4-11-8 6 6.2% 70 C6B2 127 4 VH4-31-12 4 4.0% 48 N78 118 4 VH4-11-9 11 11.3% 77 B2 109 4 VH4-11-8 12 12.4% 53 WRD2 123 4 VH4-11-12 6 6.2% 90 mAb426.4.2F20 126 4 VH4-11-8 2 2.1% 52 E54 4.58 115 4 VH4-11-8 1 1.0% 26 WRD6 123 4 VH4-11-12 10 10.3% 90 mAb426.12.3F1.4 122 4 VH4-11-9 4 4.1% 52 E54 4.2 108 4 VH4-21-6 2 2.0% 26 WIL 127 4 VH4-31-13 0 0.0% 90 COF 126 4 VH4-31-13 0 0.0% 90 LAR 122 4 VH4-31-13 2 2.0% 90 WAT 125 4 VH4-31-13 4 4.0% 90 mAb61 123 4 VH4-31-13 5 5.1% 45 WAG 127 4 VH4-31-4 0 0.0% 90 RF-SJ4 108 4 VH4-31-12 2 2.0% 85 E54 4.4 110 4 VH4-11-7 0 0.0% 26 E55 4.A1 108 4 VH4-11-7 0 0.0% 26 PR-SJ1 103 4 VH4-11-7 1 1.0% 85 E54 4.23 111 4 VH4-11-7 1 1.0% 26 CLL7 7-2 97 4 VH4-11-12 0 0.0% 29 37P1 95 4 VH4-11-12 0 0.0% 104 ALL52 30-2 91 4 VH4-31-12 4 4.0% 29 EBV-21 98 5 VH5-12-1 0 0.0% 13 CB-4 98 5 VH5-12-1 0 0.0% 13 CLL-12 98 5 VH5-12-1 0 0.0% 13 L3-4 98 5 VH5-12-1 0 0.0% 13 CLL11 98 5 VH5-12-1 0 0.0% 17 CORD3 98 5 VH5-12-1 0 0.0% 17 CORD4 98 5 VH5-12-1 0 0.0% 17 CORD8 98 5 VH5-12-1 0 0.0% 17 CORD9 98 5 VH5-12-1 0 0.0% 17 CD + 1 98 5 VH5-12-1 0 0.0% 17 CD + 3 98 5 VH5-12-1 0 0.0% 17 CD + 4 98 5 VH5-12-1 0 0.0% 17 CD − 1 98 5 VH5-12-1 0 0.0% 17 CD − 5 98 5 VH5-12-1 0 0.0% 17 VERG14 98 5 VH5-12-1 0 0.0% 17 PBL1 98 5 VH5-12-1 0 0.0% 17 PBL10 98 5 VH5-12-1 0 0.0% 17 STRAb SA-1A 127 5 VH5-12-1 0 0.0% 125 DOB′ 122 5 VH5-12-1 0 0.0% 97 VERG5 98 5 VH5-12-1 0 0.0% 17 PBL2 98 5 VH5-12-1 1 1.0% 17 Tu16 119 5 VH5-12-1 1 1.0% 49 PBL12 98 5 VH5-12-1 1 1.0% 17 CD + 2 98 5 VH5-12-1 1 1.0% 17 CORD10 98 5 VH5-12-1 1 1.0% 17 PBL9 98 5 VH5-12-1 1 1.0% 17 CORD2 98 5 VH5-12-1 2 2.0% 17 PBL6 98 5 VH5-12-1 2 2.0% 17 CORD5 98 5 VH5-12-1 2 2.0% 17 CD − 2 98 5 VH5-12-1 2 2.0% 17 CORD1 98 5 VH5-12-1 2 2.0% 17 CD − 3 98 5 VH5-12-1 3 3.1% 17 VERG4 98 5 VH5-12-1 3 3.1% 17 PBL13 98 5 VH5-12-1 3 3.1% 17 PBL7 98 5 VH5-12-1 3 3.1% 17 HAN 119 5 VH5-12-1 3 3.1% 97 VERG3 98 5 VH5-12-1 3 3.1% 17 PBL3 98 5 VH5-12-1 3 3.1% 17 VERG7 98 5 VH5-12-1 3 3.1% 17 PBL5 94 5 VH5-12-1 0 0.0% 17 CD − 4 98 5 VH5-12-1 4 4.1% 17 CLL10 98 5 VH5-12-1 4 4.1% 17 PBL11 98 5 VH5-12-1 4 4.1% 17 CORD6 98 5 VH5-12-1 4 4.1% 17 VERG2 98 5 VH5-12-1 5 5.1% 17 83P2 119 5 VH5-12-1 0 0.0% 103 VERG9 98 5 VH5-12-1 6 6.1% 17 CLL6 98 5 VH5-12-1 6 6.1% 17 PBL8 98 5 VH5-12-1 7 7.1% 17 Ab2022 120 5 VH5-12-1 3 3.1% 100 CAV 127 5 VH5-12-4 0 0.0% 97 HOW′ 120 5 VH5-12-4 0 0.0% 97 PET 127 5 VH5-12-4 0 0.0% 97 ANG 121 5 VH5-12-4 0 0.0% 97 KER 121 5 VH5-12-4 0 0.0% 97 5.M13 118 5 VH5-12-4 0 0.0% 107 Au2.1 118 5 VH5-12-4 1 1.0% 49 WS1 126 5 VH5-12-1 9 9.2% 110 TD Vn 98 5 VH5-12-4 1 1.0% 16 TEL13 116 5 VH5-12-1 9 9.2% 73 E55 5.237 112 5 VH5-12-4 2 2.0% 26 VERG1 98 5 VH5-12-1 10 10.2% 17 CD4-74 117 5 VH5-12-1 10 10.2% 42 257-D 125 5 VH5-12-1 11 11.2% 6 CLL4 98 5 VH5-12-1 11 11.2% 17 CLL8 98 5 VH5-12-1 11 11.2% 17 Ab2 124 5 VH5-12-1 12 12.2% 120 Vh3B3ex 98 5 VH5-12-1 12 12.2% 120 CLL3 98 5 VH5-12-2 11 11.2% 17 Au59.1 122 5 VH5-12-1 12 12.2% 49 TEL16 117 5 VH5-12-1 12 12.2% 73 M61 104 5 VH5-12-1 0 0.0% 103 TuO 99 5 VH5-12-1 5 5.1% 49 P2-51 122 5 VH5-12-1 13 13.3% 121 P2-54 122 5 VH5-12-1 11 11.2% 121 P1-56 119 5 VH5-12-1 9 9.2% 121 P2-53 122 5 VH5-12-1 10 10.2% 121 P1-51 123 5 VH5-12-1 19 19.4% 121 P1-54 123 5 VH5-12-1 3 3.1% 121 P3-69 127 5 VH5-12-1 4 4.1% 121 P3-9 119 5 VH5-12-1 4 4.1% 121 1-185-37 125 5 VH5-12-4 0 0.0% 124 1-187-29 125 5 VH5-12-4 0 0.0% 124 P1-58 128 5 VH5-12-4 10 10.2% 121 P2-57 118 5 VH5-12-4 3 3.1% 121 P2-55 123 5 VH5-12-1 5 5.1% 121 P2-56 123 5 VH5-12-1 20 20.4% 121 P2-52 122 5 VH5-12-1 11 11.2% 121 P3-60 122 5 VH5-12-1 8 8.2% 121 P1-57 123 5 VH5-12-1 4 4.1% 121 P1-55 122 5 VH5-12-1 14 14.3% 121 MD3-4 128 5 VH5-12-4 12 12.2% 5 P1-52 121 5 VH5-12-1 11 11.2% 121 CLL5 98 5 VH5-12-1 13 13.3% 17 CLL7 98 5 VH5-12-1 14 14.3% 17 L2F10 100 5 VH5-12-1 1 1.0% 46 L386 98 5 VH5-12-1 1 1.0% 46 VH6.A12 119 6 VH6-35-1 13 12.9% 122 s5A9 102 6 VH6-35-1 1 1.0% 46 s6G4 99 6 VH6-35-1 1 1.0% 46 ss3 99 6 VH6-35-1 1 1.0% 46 6-1G1 101 6 VH6-35-1 0 0.0% 14 F19L16 107 6 VH6-35-1 0 0.0% 68 L16 120 6 VH6-35-1 0 0.0% 69 M71 121 6 VH6-35-1 0 0.0% 103 ML1 120 6 VH6-35-1 0 0.0% 69 F19ML1 107 6 VH6-35-1 0 0.0% 68 15P1 127 6 VH6-35-1 0 0.0% 104 VH6.N1 121 6 VH6-35-1 0 0.0% 122 VH6.N11 123 6 VH6-35-1 0 0.0% 122 VH6.N12 123 6 VH6-35-1 0 0.0% 122 VH6.N2 125 6 VH6-35-1 0 0.0% 122 VH6.N5 125 6 VH6-35-1 0 0.0% 122 VH6.N6 127 6 VH6-35-1 0 0.0% 122 VH6.N7 126 6 VH6-35-1 0 0.0% 122 VH6.N8 123 6 VH6-35-1 0 0.0% 122 VH6.N9 123 6 VH6-35-1 0 0.0% 122 VH6.N10 123 6 VH6-35-1 0 0.0% 122 VH6.A3 123 6 VH6-35-1 0 0.0% 122 VH6.A1 124 6 VH6-35-1 0 0.0% 122 VH6.A4 120 6 VH6-35-1 0 0.0% 122 E55 6.16 116 6 VH6-35-1 0 0.0% 26 E55 6.17 120 6 VH6-35-1 0 0.0% 26 E55 6.6 120 6 VH6-35-1 0 0.0% 26 VHGL 6.3 102 6 VH6-35-1 0 0.0% 26 CB-201 118 6 VH6-35-1 0 0.0% 109 VH6.N4 122 6 VH6-35-1 0 0.0% 122 E54 6.4 109 6 VH6-35-1 1 1.0% 26 VH6.A6 126 6 VH6-35-1 1 1.0% 122 E55 6.14 120 6 VH6-35-1 1 1.0% 26 E54 6.6 107 6 VH6-35-1 1 1.0% 26 E55 6.10 112 6 VH6-35-1 1 1.0% 26 E54 6.1 107 6 VH6-35-1 2 2.0% 26 E55 6.13 120 6 VH6-35-1 2 2.0% 26 E55 6.3 120 6 VH6-35-1 2 2.0% 26 E55 6.7 116 6 VH6-35-1 2 2.0% 26 E55 6.2 120 6 VH6-35-1 2 2.0% 26 E55 6.X 111 6 VH6-35-1 2 2.0% 26 E55 6.11 111 6 VH6-35-1 3 3.0% 26 VH6.A11 118 6 VH6-35-1 3 3.0% 122 A10 107 6 VH6-35-1 3 3.0% 68 E55 6.1 120 6 VH6-35-1 4 4.0% 26 FK-001 124 6 VH6-35-1 4 4.0% 65 VH6.A5 121 6 VH6-35-1 4 4.0% 122 VH6.A7 123 6 VH6-35-1 4 4.0% 122 HBp2 119 6 VH6-35-1 4 4.0% 4 Au46.2 123 6 VH6-35-1 5 5.0% 49 A431 106 6 VH6-35-1 5 5.0% 68 VH6.A2 120 6 VH6-35-1 5 5.0% 122 VH6.A9 125 6 VH6-35-1 8 7.9% 122 VH6.A8 118 6 VH6-35-1 10 9.9% 122 VH6-FF3 118 6 VH6-35-1 2 2.0% 123 VH6.A10 126 6 VH6-35-1 12 11.9% 122 VH6-EB10 117 6 VH6-35-1 3 3.0% 123 VH6-E6 119 6 VH6-35-1 6 5.9% 123 VH6-FE2 121 6 VH6-35-1 6 5.9% 123 VH6-EE6 116 6 VH6-35-1 6 5.9% 123 VH6-FD10 118 6 VH6-35-i 6 5.9% 123 VH6-EX8 113 6 VH6-35-1 6 5.9% 123 VH6-FG9 121 6 VH6-35-1 8 7.9% 123 VH6-E5 116 6 VH6-35-1 9 8.9% 123 VH6-EC8 122 6 VH6-35-1 9 8.9% 123 VH6-E10 120 6 VH6-35-1 10 9.9% 123 VH6-FF11 122 6 VH6-35-1 11 10.9% 123 VH6-FD2 115 6 VH6-35-1 11 10.9% 123 CLL10 17-2 88 6 VH6-35-1 4 4.0% 29 VH6-BB11 94 6 VH6-35-1 4 4.0% 123 VH6-B4I 93 6 VH6-35-1 7 6.9% 123 JU17 102 6 VH6-35-1 3 3.0% 114 VH6-BD9 96 6 VH6-35-1 11 10.9% 123 VH6-BB9 94 6 VH6-35-1 12 11.9% 123

TABLE 3A assignment of rearranged V kappa sequences to their germline counterparts Family¹ Name Rearranged² Sum 1 Vk1-1 28 1 Vk1-2 0 1 Vk1-3 1 1 Vk1-4 0 1 Vk1-5 7 1 Vk1-6 0 1 Vk1-7 0 1 Vk1-8 2 1 Vk1-9 9 1 Vk1-10 0 1 Vk1-11 1 1 Vk1-12 7 1 Vk1-13 1 1 Vk1-14 7 1 Vk1-15 2 1 Vk1-16 2 1 Vk1-17 16 1 Vk1-18 1 1 Vk1-19 33 1 Vk1-20 1 1 Vk1-21 1 1 Vk1-22 0 1 Vk1-23 0 119 entries 2 Vk2-1 0 2 Vk2-2 1 2 Vk2-3 0 2 Vk2-4 0 2 Vk2-5 0 2 Vk2-6 16 2 Vk2-7 0 2 Vk2-8 0 2 Vk2-9 1 2 Vk2-10 0 2 Vk2-11 7 2 Vk2-12 0 25 entries 3 Vk3-1 1 3 Vk3-2 0 3 Vk3-3 35 3 Vk3-4 115 3 Vk3-5 0 3 Vk3-6 0 3 Vk3-7 1 3 Vk3-8 40 192 entries 4 Vk4-1 33 33 entries 5 Vk5-1 1 1 entry 6 Vk6-1 0 6 Vk6-2 0 0 entries 7 Vk7-1 0 0 entries

TABLE 3B assignment of rearranged V lambda sequences to their germline counterparts Family¹ Name Rearranged² Sum 1 DPL1 1 1 DPL2 14 1 DPL3 6 1 DPL4 1 1 HUMLV117 4 1 DPL5 13 1 DPL6 0 1 DPL7 0 1 DPL8 3 1 DPL9 0 42 entries  2 DPL10 5 2 VLAMBDA 2.1 0 2 DPL11 23 2 DPL12 15 2 DPL13 0 2 DPL14 0 43 entries  3 DPL16 10 3 DPL23 19 3 Humlv318 9 38 entries  7 DPL18 1 7 DPL19 0 1 entries 8 DPL21 2 8 HUMLV801 6 8 entries 9 DPL22 0 0 entries unassigned DPL24 0 0 entries 10  gVLX-4.4 0 0 entries

TABLE 3C assignment of rearranged V heavy chain sequences to their germline counterparts Family¹ Name Rearranged² Sum 1 VH1-12-1 38 1 VH1-12-8 2 1 VH1-12-2 2 1 VH1-12-9 2 1 VH1-12-3 0 1 VH1-12-4 0 1 VH1-12-5 3 1 VH1-12-6 0 1 VH1-12-7 23 1 VH1-13-1 1 1 VH1-13-2 1 1 VH1-13-3 0 1 VH1-13-4 0 1 VH1-13-5 0 1 VH1-13-6 17 1 VH1-13-7 0 1 VH1-13-8 3 1 VH1-13-9 0 1 VH1-13-10 0 1 VH1-13-11 0 1 VH1-13-12 10 1 VH1-13-13 0 1 VH1-13-14 0 1 VH1-13-15 4 1 VH1-13-16 2 1 VH1-13-17 0 1 VH1-13-18 1 1 VH1-13-19 0 1 VH1-1X-1 1 110 entries 2 VH2-21-1 0 2 VH2-31-1 0 2 VH2-31-2 1 2 VH2-31-3 1 2 VH2-31-4 0 2 VH2-31-5 2 2 VH2-31-6 0 2 VH2-31-7 0 2 VH2-31-14 1 2 VH2-31-8 0 2 VH2-31-9 0 2 VH2-31-10 0 2 VH2-31-11 1 2 VH2-31-12 0 2 VH2-31-13 1  7 entries 3 VH3-11-1 0 3 VH3-11-2 0 3 VH3-11-3 5 3 VH3-11-4 0 3 VH3-11-5 1 3 VH3-11-6 1 3 VH3-11-7 0 3 VH3-11-8 5 3 VH3-13-1 9 3 VH3-13-2 3 3 VH3-13-3 0 3 VH3-13-4 0 3 VH3-13-5 0 3 VH3-13-6 0 3 VH3-13-7 32 3 VH3-13-8 4 3 VH3-13-9 0 3 VH3-13-10 46 3 VH3-13-11 0 3 VH3-13-12 11 3 VH3-13-13 17 3 VH3-13-14 8 3 VH3-13-15 4 3 VH3-13-16 3 3 VH3-13-17 2 3 VH3-13-18 1 3 VH3-13-19 13 3 VH3-13-20 1 3 VH3-13-21 1 3 VH3-13-22 0 3 VH3-13-23 0 3 VH3-13-24 4 3 VH3-13-25 1 3 VH3-13-26 6 3 VH3-14-1 1 3 VH3-14-4 15 3 VH3-14-2 0 3 VH3-14-3 0 3 VH3-1X-1 0 3 VH3-1X-2 0 3 VH3-1X-3 6 3 VH3-1X-4 0 3 VH3-1X-5 0 3 VH3-1X-6 11 3 VH3-1X-7 0 3 VH3-1X-8 1 3 VH3-1X-9 0 212 entries 4 VH4-11-1 0 4 VH4-11-2 20 4 VH4-11-3 0 4 VH4-11-4 0 4 VH4-11-5 0 4 VH4-11-6 0 4 VH4-11-7 5 4 VH4-11-8 7 4 VH4-11-9 3 4 VH4-11-10 0 4 VH4-11-11 0 4 VH4-11-12 4 4 VH4-11-13 0 4 VH4-11-14 0 4 VH4-11-15 0 4 VH4-11-16 1 4 VH4-21-1 0 4 VH4-21-2 0 4 VH4-21-3 1 4 VH4-21-4 1 4 VH4-21-5 1 4 VH4-21-6 1 4 VH4-21-7 0 4 VH4-21-8 0 4 VH4-21-9 0 4 VH4-31-1 0 4 VH4-31-2 0 4 VH4-31-3 0 4 VH4-31-4 2 4 VH4-31-5 0 4 VH4-31-6 0 4 VH4-31-7 0 4 VH4-31-8 0 4 VH4-31-9 0 4 VH4-31-10 0 4 VH4-31-11 0 4 VH4-31-12 4 4 VH4-31-13 7 4 VH4-31-14 0 4 VH4-31-15 0 4 VH4-31-16 0 4 VH4-31-17 0 4 VH4-31-18 0 4 VH4-31-19 0 4 VH4-31-20 0  57 entries 5 VH5-12-1 82 5 VH5-12-2 1 5 VH5-12-3 0 5 VH5-12-4 14  97 entries 6 VH6-35-1 74  74 entries

TABLE 4A Analysis of V kappa subgroup 1 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 A 1 1 102 1 B 1 1 C 1 D 64 E 8 14 1 F 1 6 1 G 105 H I 65 4 K 1 L 6 21 96 1 M 1 66 N P 103 1 2 1 Q 62 88 1 R S 89 102 80 103 103 T 1 88 18 V 1 9 8 2 98 W X 1 Y — unknown (?) not sequenced 31 31 18 18 17 16 16 2 1 sum of seq² 74 74 87 87 88 89 89 103 104 105 105 105 105 105 105 105 oomcaa³ 64 65 62 66 88 88 89 103 102 80 96 103 102 103 98 105 mcaa⁴ D I Q M T Q S P S S L S A S V G rel. oomcaa⁵ 86% 88% 71% 76% 100% 99% 100% 100% 98% 76% 91% 98% 97% 98% 93% 100% pos occupied⁶ 4 5 5 2 1 2 1 1 3 4 3 2 3 3 5 1 Framework I CDRI amino acid¹ 17 18 19 20 21 22 23 24 25 26 27 A B C D A 1 1 1 103 B 1 C 105 D 101 E 2 1 1 2 F 2 G 1 H 1 I 6 4 101 1 K 2 1 L 1 M N 1 P Q 20 100 R 94 81 S 5 1 102 T 6 99 103 1 1 V 98 2 W X 1 Y 1 — 105 105 105 105 unknown (?) not sequenced sum of seq² 105 105 105 105 105 105 105 105 105 105 105 105 105 105 105 oomcaa³ 101 94 98 99 101 103 105 81 103 102 100 105 105 105 105 mcaa⁴ D R V T I T C R A S Q — — — — rel. oomcaa⁵ 96% 90% 93% 94% 96% 98% 100% 77% 98% 97% 95% 100% 100% 100% 100% pos occupied⁶ 4 3 3 4 3 3 1 5 3 4 5 1 1 1 1 CDRI Framework II amino acid¹ E F 28 29 30 31 32 33 34 35 36 37 38 39 40 A 1 1 1 42 B 1 1 C 1 D 25 1 5 7 1 E 1 2 F 1 1 7 6 G 25 7 3 4 H 1 2 2 1 2 I 98 1 4 1 K 7 95 L 2 1 101 M N 6 16 42 50 P 102 Q 98 103 2 R 16 3 2 3 1 S 41 2 57 32 3 1 1 1 T 7 4 4 1 V 1 4 1 1 W 21 104 X 1 Y 1 60 98 — 105 105 unknown (?) 3 not sequenced 1 1 1 1 1 1 1 1 1 1 sum of seq² 105 105 105 105 105 104 104 104 104 104 104 104 104 104 104 oomcaa³ 105 105 41 98 57 42 60 101 50 104 98 98 103 95 102 mcaa⁴ — — S I S N Y L N W Y Q Q K P rel. oomcaa⁵ 100% 100% 39% 93% 54% 40% 58% 97% 48% 100% 94% 94% 99% 91% 98% pos occupied⁶ 1 1 6 4 12 11 9 4 8 1 2 5 2 4 3 Framework II CDR II amino acid¹ 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 A 94 50 95 3 B C D 21 1 1 1 1 E 1 3 1 1 1 1 33 F 1 3 1 G 100 1 9 2 2 H 2 1 I 1 1 100 1 3 K 95 86 16 2 5 1 L 1 89 103 101 M 2 N 10 2 1 25 6 P 104 1 1 1 Q 1 1 62 R 3 3 1 1 2 1 S 1 5 1 1 99 41 2 68 T 3 1 1 4 1 31 19 V 9 9 1 1 W X 1 1 Y 92 1 — unknown (?) 3 not sequenced 1 1 1 1 1 1 2 3 3 2 1 1 1 1 1 sum of seq² 104 104 104 104 104 104 103 102 102 103 104 104 104 104 104 105 oomcaa³ 100 95 94 104 86 89 103 100 92 50 95 99 41 101 62 68 mcaa⁴ G K A P K L L I Y A A S S L Q S rel. oomcaa⁵ 96% 91% 90% 100% 83% 86% 100% 98% 90% 49% 91% 95% 39% 97% 60% 65% pos occupied⁶ 2 6 3 1 8 6 1 2 4 10 6 6 9 3 6 10 Framework III amino acid¹ 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 A 2 1 1 1 3 B 1 C D 67 E 1 30 F 1 103 3 102 1 G 105 105 4 101 102 H 3 I 4 1 3 K 1 1 L 1 M 1 N P 101 2 Q 1 R 103 1 1 1 2 S 2 103 98 96 100 2 T 1 1 2 3 101 98 V 99 1 1 1 W X 1 1 1 2 Y 1 1 1 — unknown (?) not sequenced 1 1 sum of seq² 105 105 105 105 105 105 105 105 105 105 105 105 105 105 104 104 oomcaa³ 105 99 101 103 103 103 98 105 96 101 100 102 101 67 102 98 mcaa⁴ G V P S R F S G S G S G T D F T rel. oomcaa⁵ 100% 94% 96% 98% 98% 98% 93% 100% 91% 96% 95% 97% 96% 64% 98% 94% pos occupied⁶ 1 4 4 2 3 3 5 1 5 4 4 4 4 7 3 4 Framework III amino acid¹ 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 A 1 2 101 1 B 1 3 2 C 102 D 1 16 101 E 83 F 21 73 7 G 4 1 2 H 1 I 99 5 17 K 1 L 81 103 1 1 M 1 N 7 4 1 P 97 1 Q 97 R 2 1 2 S 1 86 94 4 1 1 T 102 2 1 97 V 2 4 1 11 1 W X 1 1 2 Y 101 93 — unknown (?) 1 not sequenced 1 1 1 1 1 1 2 2 2 2 2 2 3 2 3 3 sum of seq² 104 104 104 104 104 104 103 103 103 103 103 103 102 103 102 102 oomcaa³ 81 102 99 86 94 103 97 97 83 101 73 101 97 101 93 102 mcaa⁴ L T I S S L Q P E D F A T Y Y C rel. oomcaa⁵ 78% 98% 95% 83% 90% 99% 94% 94% 81% 98% 71% 98% 95% 98% 91% 100% pos occupied⁶ 3 3 3 7 5 2 4 3 5 2 5 2 6 3 3 1 CDR III amino acid¹ 89 90 91 92 93 94 95 A B C D E F 96 97 A 1 7 1 5 1 1 B 2 3 C D 23 5 1 1 E 1 1 1 1 F 3 13 6 G 1 1 2 1 1 H 4 6 7 3 1 2 1 I 4 1 2 1 5 K 7 1 1 1 L 7 6 2 18 2 18 1 M 1 N 6 31 19 1 1 P 1 82 6 6 Q 90 86 1 2 1 R 1 2 2 6 S 27 3 58 5 10 2 2 T 3 1 15 25 2 82 V 5 2 W 1 15 X Y 42 32 1 23 16 — 3 82 88 89 89 89 89 4 1 unknown (?) not sequenced 2 2 1 1 1 1 4 16 16 16 16 16 16 16 16 sum of seq² 103 103 104 104 104 104 101 89 89 89 89 89 89 89 89 oomcaa³ 90 86 42 32 58 25 82 82 88 89 89 89 89 18 82 mcaa⁴ Q Q Y Y S T P — — — — — — L T rel. oomcaa⁵ 87% 83% 40% 31% 56% 24% 81% 92% 99% 100% 100% 100% 100% 20% 92% pos occupied⁶ 4 5 11 12 10 14 8 3 2 1 1 1 1 17 1 Framework IV amino acid¹ 98 99 100 101 102 103 104 105 106 A 107 108 sum A 627 B 1 1 19 C 209 D 15 459 E 2 65 258 F 86 2 451 G 87 29 87 2 894 H 40 I 1 72 606 K 77 79 480 L 1 22 4 2 793 M 5 77 N 1 2 232 P 7 1 620 Q 48 1 865 R 6 2 70 413 S 1636 T 87 3 2 1021 V 1 63 3 440 W 141 X 14 Y 564 — 85 1 1250 unknown (?) 7 not sequenced 18 18 18 18 18 18 19 19 20 20 20 31 589 sum of seq² 87 87 87 87 87 87 86 86 85 85 85 74 oomcaa³ 86 87 48 87 87 77 63 65 72 85 79 70 mcaa⁴ F G G G T K V E I — K R rel. oomcaa⁵ 99% 100% 55% 100% 100% 89% 73% 76% 85% 100% 93% 95% pos occupied⁶ 2 1 5 1 1 4 3 5 6 1 4 4

TABLE 4B Analysis of V kappa subgroup 2 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 A B C D 14 E  3 F  1  1 G H I  8 K L  3  1 17 18  6 M 15 N P 18 18 15 Q 18 R S 18 17 T 17 21 V  6 17  1 18 W X Y — unknown (?)  1 not sequenced  5  5  5  5  4  4  4  4  4  4  4  4  4  1  1 sum of seq² 17 17 17 17 18 18 18 18 18 18 18 18 18 21 21 oomcaa³ 14 8 17 15 17 18 18 18 17 17 18 18 18 21 15 mcaa⁴ D I V M T Q S P L S L P V T P rel. oomcaa⁵ 82% 47% 100% 88% 94% 100% 100% 100% 94% 94% 100% 100% 100% 100% 71% pos occupied⁶  2  3  1  3  1  1  1  1  2  2  1  1  1  1  2 Framework I CDRI amino acid¹ 16 17 18 19 20 21 22 23 24 25 26 27 A B C D A 22 B C 22 D  1 E 15 F G 22 H 16 I 22 K  1 L  1 22 13 M  1 N P 22 Q  7  1 21 R 21 S 22 21 22 22 22 T V  8 W  1 X Y  4 — unknown (?) not sequenced sum of seq² 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 oomcaa³ 22 15 22 22 22 22 21 22 21 22 22 21 22 22 13 16 mcaa⁴ G E P A S I S C R S S Q S L L H rel. oomcaa⁵ 100% 68% 100% 100% 100% 100% 95% 100% 95% 100% 100% 95% 100% 100% 59% 73% pos occupied⁶  1  2  1  1  1  1  2  1  2  1  1  2  1  1  3  4 CDRI Framework II amino acid¹ E F 28 29 30 31 32 33 34 35 36 37 38 39 40 A B C D  9  1  1 11 E F  2  7 G  1 22 H  1  1 I K  1 15 L 22 16 M N 10  7 12  9 P 22 Q  6 22 R  2  7 S 19  1 T  8 V W 22 X  1  1  1 Y  1 11 21 15 — 22 unknown (?) not sequenced sum of seq² 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 oomcaa³ 19 22 10 22 11 12 21 22 11 22 15 16 22 15 22 mcaa⁴ S — N G Y N Y L D W Y L Q K P rel. oomcaa⁵ 86% 100% 45% 100% 50% 55% 95% 100% 50% 100% 68% 73% 100% 68% 100% pos occupied⁶  3  1  5  1  5  4  2  1  4  1  2  2  1  2  1 Framework II CDR II amino acid¹ 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 A 14 B C D  7 E  1 F G 22 12  1 H I  1 22 K  5 L 14 21 14  1 M N 18 P 21 Q 22 12  1 R  8  7  1 22 S 21  2 22  2 22 T  1 V  1  6 W X Y 21  1 — unknown (?) not sequenced  1  1  1  1  1  1 sum of seq² 22 22 21 21 21 22 22 22 21 21 21 22 22 22 22 22 oomcaa³ 22 22 21 21 12 14 21 22 21 14 12 22 18 22 14 22 mcaa⁴ G Q S P Q L L I Y L G S N R A S rel. oomcaa⁵ 100% 100% 100% 100% 57% 64% 95% 100% 100% 67% 57% 100% 82% 100% 64% 100% pos occupied⁶  1  1  1  1  3  3  2  1  1  4  4  1  4  1  3  1 Framework III amino acid¹ 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 A B C D 22  1  1 22 E F 21 22 G 22 21 22 21 H I K L M N P 22 Q R 20  1 S  1 22 21 22 T  1 22 21 V 22 1 W X Y — unknown (?)  1 not sequenced sum of seq² 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 oomcaa³ 22 22 22 22 20 21 22 21 21 22 22 21 22 22 22 21 mcaa⁴ G V P D R F S G S G S G T D F T rel. oomcaa⁵ 100% 100% 100% 100% 91% 95% 100% 95% 95% 100% 100% 95% 100% 100% 100% 95% pos occupied⁶  1  1  1  1  3  2  1  2  2  1  1  2  1  1  1  1 Framework III amino acid¹ 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 A 20 B C 21 D  1 21 E 19 20 F G  1 21 H I  1 21  1 K 19 L 21  1  1 M N P  1 Q  1 R 20 S 20  1 T  1 V 21 21 19 W X Y 21 21 — unknown (?) not sequenced  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1 sum of seq² 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 21 oomcaa³ 21 19 21 20 20 21 19 20 20 21 21 21 19 21 21 21 mcaa⁴ L K I S R V E A E D V G V Y Y C rel. oomcaa⁵ 100% 90% 100% 95% 95% 100% 90% 95% 95% 100% 100% 100% 90% 100% 100% 100% pos occupied⁶  1  3  1  2  2  1  3  2  2  1  1  1  3  1  1  1 CDR III amino acid¹ 89 90 91 92 93 94 95 A B C D E F 96 97 A 14  1 B  1  1 C D E F  1 G  6  1  2 H  1  7 I  1  3 K L 12  2  2 M N P  2 16  1  1 Q 20 13  1 R  1 S  3  2 T  8  7 17 V W  6  2 X Y  7 — 14 17 17 17 17 17 unknown (?) not sequenced  1  1  1  1  1  1  2  5  5  5  5  5  5  5  5 sum of seq² 21 21 21 21 21 21 20 17 17 17 17 17 17 17 17 oomcaa³ 21 20 14 12 13  7 16 14 17 17 17 17 17  7 17 mcaa⁴ M Q A L Q T P — — — — — — Y T rel. oomcaa⁵ 100% 95% 67% 57% 62% 33% 80% 82% 100% 100% 100% 100% 100% 41% 100% pos occupied⁶  1  2  3  3  3  7  3  3  1  1  1  1  1  7  1 Framework IV amino acid¹ 98 99 100 101 102 103 104 105 106 A 107 108 sum A 71 B  1 3 C 43 D 112 E 13 71 F 17 72 G 17  2 16  1 233 H 26 I 14 94 K 12 13 66 L 11 219 M 37 N 56 P 159 Q 14 159 R  4 12 126 S 325 T 16 140 V  5 146 W 31 X 3 Y 123 — 13 134 unknown (?) 2 not sequenced  5  5  6  6  6  6  6  7  8  9  9 10 211 sum of seq² 17 17 16 16 16 16 16 15 14 13 13 12 oomcaa³ 17 17 14 16 16 12 11 13 14 13 13 12 mcaa⁴ F G Q G T K L E I — K R rel. oomcaa⁵ 100% 100% 88% 100% 100% 75% 69% 87% 100% 100% 100% 100% pos occupied⁶  1  1  2  1  1  2  2  3  1  1  1  1

TABLE 4C Analysis of V kappa subgroup 3 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 A 5 2 27 1 B 1 C 2 D 2 14 E 76 27 F 1 1 G 1 82 1 H 1 I 75 K 3 L 4 1 104 1 150 129 1 M 5 13 N 5 P 124 147 Q 123 R 1 S 119 3 1 150 1 141 T 2 117 147 5 1 V 1 89 1 1 1 22 1 W X Y — unknown (?) not sequenced sum of seq² 88 88 117 118 118 123 123 124 126 149 151 152 152 152 152 oomcaa³ 76 75 89 104 117 123 119 124 82 147 150 150 129 141 147 mcaa⁴ E I V L T Q S P G T L S L S P rel. oomcaa⁵ 86% 85% 76% 88% 99% 100% 97% 100% 65% 99% 99% 99% 85% 93% 97% pos occupied⁶ 6 6 3 3 2 1 4 1 4 3 2 2 3 4 6 Framework I CDRI amino acid¹ 16 17 18 19 20 21 22 23 24 25 26 27 A B C A 178 2 166 1 B C 181 1 D 6 E 146 1 1 F 7 1 G 152 1 1 1 1 1 H 17 I 1 5 2 K 1 5 L 173 1 1 M N 9 P Q 159 R 175 176 1 1 10 S 180 7 175 87 T 1 174 7 2 1 V 1 4 1 1 1 W 1 X Y 1 1 — 72 182 182 unknown (?) 1 not sequenced sum of seq² 152 153 181 182 182 182 182 181 182 182 181 181 182 182 182 oomcaa³ 152 146 175 178 174 173 180 181 176 166 175 159 87 182 182 mcaa⁴ G E R A T L S C R A S Q S — — rel. oomcaa⁵ 100% 95% 97% 98% 96% 95% 99% 100% 97% 91% 97% 88% 48% 100% 100% pos occupied⁶ 1 3 7 2 4 3 3 1 3 5 6 6 8 1 1 CDRI Framework II amino acid¹ D E F 28 29 30 31 32 33 34 35 36 37 38 39 40 A 1 1 181 B C D 1 1 2 1 E 1 1 F 1 7 1 G 2 7 3 1 2 1 H 1 2 1 12 1 1 I 24 4 1 1 K 1 1 153 L 8 1 1 176 3 M N 3 12 25 32 P 1 170 Q 1 1 183 167 1 R 10 3 18 16 1 1 27 5 S 72 86 151 118 4 5 T 1 1 3 8 1 1 V 76 68 1 7 3 2 W 5 185 X Y 1 1 115 183 — 182 182 182 unknown (?) 1 not sequenced sum of seq² 182 182 182 182 182 181 181 182 183 184 185 185 185 185 184 184 oomcaa³ 182 182 182 76 86 151 118 115 176 181 185 183 183 167 153 170 mcaa⁴ — — — V S S S Y L A W Y Q Q K P rel. oomcaa⁵ 100% 100% 100% 42% 47% 83% 65% 63% 96% 98% 100% 99% 99% 90% 83% 92% pos occupied⁶ 1 1 1 6 11 10 13 12 2 3 1 3 2 4 6 6 Framework II CDR II amino acid¹ 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 A 176 4 147 176 1 B C 1 D 43 2 E 1 F 1 1 4 G 184 125 2 10 H 9 1 I 178 1 K 1 7 1 L 2 1 179 174 1 M 3 1 N 1 1 53 2 P 5 184 2 2 2 Q 181 1 R 182 1 4 180 S 3 6 4 179 74 1 5 T 3 11 2 44 164 V 3 9 3 19 3 W 1 1 X Y 165 — unknown (?) 1 not sequenced sum of seq² 184 184 184 185 185 183 183 183 183 183 183 183 183 183 185 185 oomcaa³ 184 181 176 184 182 179 174 178 165 125 147 179 74 180 176 164 mcaa⁴ G Q A P R L L I Y G A S S R A T rel. oomcaa⁵ 100% 98% 96% 99% 98% 98% 95% 97% 90% 68% 80% 98% 40% 98% 95% 89% pos occupied⁶ 1 3 3 2 3 3 2 4 6 7 6 3 6 4 5 7 Framework III amino acid¹ 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 A 68 3 5 3 1 3 B C D 4 112 1 152 E 1 1 30 F 183 183 G 179 184 3 178 177 H 1 I 168 1 1 K 1 L 1 M 1 N 1 1 P 177 Q 1 R 182 2 1 2 S 7 180 179 185 3 7 T 2 1 2 3 2 177 172 V 15 3 1 1 W 1 X Y 2 1 — unknown (?) 1 not sequenced sum of seq² 185 185 185 185 185 185 185 185 185 185 185 185 185 184 184 184 oomcaa³ 179 168 177 112 182 183 180 184 179 178 185 177 177 152 183 172 mcaa⁴ G I P D R F S G S G S G T D F T rel. oomcaa⁵ 97% 91% 96% 61% 98% 99% 97% 99% 97% 96% 100% 96% 96% 83% 99% 93% pos occupied⁶ 3 3 3 5 3 3 3 2 4 5 1 5 4 4 2 5 Framework III amino acid¹ 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 A 3 174 B 1 C 2 1 182 D 1 3 182 E 149 175 F 2 1 178 2 1 4 G 3 1 2 H 1 I 3 178 1 1 9 K 1 L 182 178 1 1 7 1 M 1 5 N 1 5 P 149 Q 34 1 R 1 111 3 S 2 169 65 34 1 2 T 179 8 4 1 V 4 6 1 3 159 W X Y 1 1 183 176 — unknown (?) not sequenced sum of seq² 184 184 184 184 184 184 184 184 182 184 184 184 184 184 184 183 oomcaa³ 182 179 178 169 111 178 149 149 175 182 178 174 159 183 176 182 mcaa⁴ L T I S R L E P E D F A V Y Y C rel. oomcaa⁵ 99% 97% 97% 92% 60% 97% 81% 81% 96% 99% 97% 95% 86% 99% 96% 99% pos occupied⁶ 2 3 4 5 5 2 3 3 4 3 6 6 7 2 5 2 CDR III amino acid¹ 89 90 91 92 93 94 95 A B C D E F 96 97 A 1 8 3 3 B C 2 1 2 D 8 5 1 E 2 2 1 F 5 2 7 G 1 104 15 1 1 2 1 H 1 7 4 1 2 I 1 1 4 K 2 1 1 L 1 2 7 5 42 M 1 1 2 N 28 71 1 P 1 139 24 7 2 Q 181 155 1 1 3 1 3 R 1 34 2 3 2 2 19 S 2 33 58 102 15 2 1 8 T 8 2 13 1 1 2 1 154 V 7 3 1 2 W 69 24 X Y 1 2 134 1 1 43 — 3 3 7 127 167 169 169 169 169 8 1 unknown (?) not sequenced 14 14 14 14 14 14 14 17 sum of seq² 183 183 183 183 183 182 182 169 169 169 169 169 169 169 166 oomcaa³ 181 155 134 104 71 102 139 127 167 169 169 169 169 43 154 mcaa⁴ Q Q Y G N S P — — — — — — Y T rel. oomcaa⁵ 99% 85% 73% 57% 39% 56% 76% 75% 99% 100% 100% 100% 100% 25% 93% pos occupied⁶ 3 8 8 11 13 8 11 12 2 1 1 1 1 18 5 Framework IV amino acid¹ 98 99 100 101 102 103 014 105 106 A 107 108 sum A 1 1345 B 2 C 375 D 23 564 E 3 141 759 F 166 6 765 G 166 41 166 1 1804 H 1 64 I 143 803 K 1 152 157 489 L 54 1 2 1596 M 3 36 N 1 3 255 P 9 1 1 1147 Q 114 1 1 1314 R 9 2 4 134 1326 S 2 2629 T 162 1 1 1593 V 111 11 646 W 287 X Y 1 1014 — 1 1 1 1 1 1 1 1 1 166 1 1 2151 unknown (?) 4 not sequenced 16 16 16 16 16 15 16 16 16 17 17 45 337 sum of seq² 167 167 167 167 167 168 167 167 167 166 166 138 oomcaa³ 166 166 114 166 162 152 111 141 143 166 157 134 mcaa⁴ F G Q G T K V E I — K R rel. oomcaa⁵ 99% 99% 68% 99% 97% 90% 66% 84% 86% 100% 95% 97% pos occupied⁶ 2 2 6 2 5 7 4 5 7 1 5 4

TABLE 4D Analysis of V kappa subgroup 4 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 24  1 26 B C  1  1 D 25 26 E 25 F G  1 24 H I 26 K  1 L  1 26 26 M 24 N  1 P 26  1 Q  1 25 R 26 S 26 25 26  1 T 26 V 25  1 26 W X Y — unknown (?) not  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7 sequenced sum of seq² 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 oomcaa³ 25 26 25 24 26 25 26 26 26 25 26 24 26 26 26 24 25 26 26 mcaa⁴ D I V M T Q S P D S L A V S L G E R A rel. oomcaa⁵ 96% 100% 96% 92% 100% 96% 100% 100% 100% 96% 100% 92% 100% 100% 100% 92% 96% 100% 100% pos  2  1  2  3  1  2  1  1 1  2  1  3  1 1  1  3  2  1  1 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 31 A  1  1 B C 33 D  1  1  1 E F G H I 26  1 K 33  2 30 L  2 31 M N 26 30 31  1 33 P  1  1 Q 32  1 R  1  1  1 S 31 33 33 32 32  1 T 26  1 V 28  2 W X Y 32 unknown (?) not sequenced  7  7  7 sum of seq² 26 26 26 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 26 26 26 33 33 31 33 32 33 28 31 32 32 32 30 31 30 33 mcaa⁴ T I N C K S S Q S V L Y S S N N K N rel. oomcaa⁵ 100% 100% 100% 100% 100% 94% 100% 97% 100% 85% 94% 97% 97% 97% 91% 94% 91% 100% pos occupied⁶  1  1  1  1  1  3  1  2  1  5  2  2  2  2  3  3  4  1 CDRI Framework II amino acid¹ 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 A 32  2 B C D E  1 F G 32 H  2 I 32 K 33 32 L 33 29 33 M  1 N P 31 31 33 Q 32 33 32 R  1  1  1 S  2 T  1 V  4 W 33 X Y 33 31 33 unknown (?) not sequenced sum of seq² 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 33 33 32 33 31 32 33 33 31 32 32 31 33 32 29 33 32 33 mcaa⁴ Y L A W Y Q Q K P G Q P P K L L I Y rel. oomcaa⁵ 100% 100% 97% 100% 94% 97% 100% 100% 94% 97% 97% 94% 100% 97% 88% 100% 97% 100% pos occupied⁶  1  1  2  1  2  2  1  1  2  2  2  2  1  2  2  1  2  1 CDR II Framework III amino acid¹ 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 A 30 B C D 33 E 32 F 33 G 33  1 33 33 H I  1 K L M N  2 P  1 33  1 Q R 33 32 S  1 31  1 33 32 33 33 T  2  1 29 V  1 33 W 33 X Y — unknown(?) not sequenced sum of seq² 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 33 30 31 29 33 32 33 33 33 33 33 32 33 32 33 33 33 33 mcaa⁴ W A S T R E S G V P D R F S G S G S rel. oomcaa⁵ 100% 91% 94% 88% 100% 97% 100% 100% 100% 100% 100% 97% 100% 97% 100% 100% 100% 100% pos occupied⁶  1  3  3  4  1  2  1  1  1  1  1  2  1  2  1  1  1  1 Framework III amino acid¹ 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 A 33 32 B C D 32 33 E 33 F 32 G 33  1  1 H I 33 K L 33 32 M  1 N  2  1 P Q 32 R  1 S 30 32 T 33 33 33  1 V  1 33 33 W X Y — unknown (?) not sequenced sum of seq² 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 33 33 32 32 33 33 33 33 30 32 32 32 33 33 33 33 32 33 mcaa⁴ G T D F T L T I S S L Q A E D V A V rel. oomcaa⁵ 100% 100% 97% 97% 100% 100% 100% 100% 91% 97% 97% 97% 100% 100% 100% 100% 97% 100% pos occupied⁶  1  1  2  2  1  1  1  1  3  2  2  2  1  1  1  1  2  1 Framework III CDR III amino acid¹ 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 97 A  1 B C 33 D  1  1 E F  1  1 G  2 H  1  3 I  2 K L  1  2  1  3  1 M  1 N  4  4 P  1 29  1  4 Q 30 32  1  1 R  1  1  2 S  2 23  2  1  2 T  2 22 12 V W  2 X Y 33 31 31 29  1 — 13 15 15 15 15 15  3 unknown (?) not sequenced 18 18 18 18 18 18 18 18 sum of seq² 33 33 33 33 33 33 33 33 33 33 15 15 15 15 15 15 15 15 oomcaa³ 33 31 33 30 32 31 29 23 22 29 13 15 15 15 15 15  4 12 mcaa⁴ Y Y C Q Q Y Y S T P — — — — — — P rel. oomcaa⁵ 100% 94% 100% 91% 97% 94% 88% 70% 67% 88% 87% 100% 100% 100% 100% 100% 27% pos occupied⁶  1  3  1  2  2  2  4  6  7  3  3  1  1  1  1  1  8  3 Framework IV amino acid¹ 98 99 100 101 102 103 104 105 106 A 107 108 sum A 183 B C 68 D 154 E 14 105 F 15 82 G 15  4 15 228 H 6 I 14 135 K 14 13 158 L  4 258 M 27 N  1 136 P  1 195 Q 11  1 264 R  1  1  1 11 116 S  1 499 T 14 236 V  9 196 W  1 69 X Y 254 — 15 106 unknown (?) not sequenced 18 18 18 18 18 18 18 18 18 18 18 22 518 sum of seq² 15 15 15 15 15 15 15 15 15 15 15 11 oomcaa³ 15 15 11 15 14 14  9 14 14 15 13 11 mcaa⁴ F G Q G T K V E I — K R rel. oomcaa⁵ 100% 100% 73% 100% 93% 93% 60% 93% 93% 100% 87% 100% pos occupied⁶  1  1  2  1  2  2  4  2  2  1  3  1

TABLE 5A Analysis of V lambda subgroup 1 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 19 18 20 B C D E  1 F G 22 42 H  2 I  1  1 K 14 L  1 41  1 M N P 41 41  1 41 Q 22  1 41 42 R 25 S 39 41 41  1  1 T 41 19  1 V  1 38 20  1  1 42 W X Y Z 16 — 41 unknown (?) not  2  2  1  1  1  1  1  1  1  1  1  1  1  1 sequenced sum of seq² 40 40 41 41 41 41 41 41 41 41 41 41 41 41 42 42 42 42 42 oomcaa³ 22 39 38 41 41 41 41 41 41 41 20 41 22 20 41 42 42 25 42 mcaa⁴ Q S V L T Q P P S — V S G A P G Q R V rel. oomcaa⁵ 55% 98% 93% 100% 100% 100% 100% 100% 100% 100% 49% 100% 54% 49% 98% 100% 100% 60% 100% pos  3  2  4  1  1  1  1  1  1  1  4  1  3  4  2  1  1  5  1 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 D E 28 29 30 31 A 32 33 34 A  2  1  2  2  1 B C 42 D  3  3  1  3  1 E  1 F  1  1  1  1 G 42  3  1  2 39  4  2 H  2  2  2 I  1 41  1 37  1 K  1  1 L  1  1 M  1 N  2  1 37 13 31  2  1  9 P  1 Q  1 R  1  1  5 S  1 42 38 34 34 38 13  1  1  3 19 T 38  3  4  3  2  1  1  7  2 V  1  2 40 X Y  4  1 20  7 Z — 36 unknown (?) not sequenced  1  1  1  1 sum of seq² 42 42 42 42 42 42 42 42 42 42 42 42 42 42 41 41 41 41 oomcaa³ 38 41 42 42 38 42 34 34 38 37 37 39 13 31 36 20 40 19 mcaa⁴ T I S C S G S S S N I G N N — Y V S rel. oomcaa⁵ 90% 98% 100% 100% 90% 100% 81% 81% 90% 88% 88% 93% 31% 74% 88% 49% 98% 46% pos occupied⁶  4  2  1  1  3  1  4  6  4  4  5  3  8  7  5 10  2  7 Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 A  4 40  1 B C D  1 13 10  8 E  2  5  1 F  1  4  1 G 39  1 H  1  1  6  1  1  1 I 40  1 K  1 35  1  1 18 L  1 31 41 40  1 M  1  1  1 N  1  3 28 30  2 P 42  1 42 Q 39 34 15 R  2  1  1  4  7  2 S  1  9  2  3  1 T 36  1  1 V  1  5  1  2  1 W 42 X Y 40 40  1  1 Z — unknown (?) not sequenced sum of seq² 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 oomcaa³ 42 40 39 34 31 42 39 36 40 42 35 41 40 40 40 13 28 30 18 mcaa⁴ W Y Q Q L P G T A P K L L I Y D N N K rel. oomcaa⁵ 100% 95% 93% 81% 74% 100% 93% 86% 95% 100% 83% 98% 95% 95% 95% 31% 67% 71% 43% pos  1  3  3  4  5  1  4  4  3  1  4  2  2  3  3 10  5  4  9 occupied⁶ CDR II Framework III amino acid¹ 54 55 56 A B C D E 57 58 59 60 61 62 63 64 65 66 A A  1  5 B C D 38 E F 38 G 41  2 36 H  1 I 17  3 K 38 L  1  1  1 M N P 38 38 Q R 40 42  4 S  2 40  2 42 42 T  1 V 24  1 W  1 X Y Z — 41 41 41 41 42 42 unknown (?) not  1  1  1  1  1  1 sequenced sum of seq² 42 41 41 41 41 41 41 42 41 41 41 41 42 42 42 42 42 42 42 oomcaa³ 40 38 40 41 41 41 41 42 41 24 38 38 42 38 42 36 42 38 42 mcaa⁴ R P S — — — — — G V P D R F S G S K — rel. oomcaa⁵ 95% 93% 98% 100% 100% 100% 100% 100% 100% 59% 93% 93% 100% 90% 100% 86% 100% 90% 100% pos  3  3  2  1  1  1  1  1  1  2  3  3  1  3  1  3  1  2  1 occupied⁶ Framework III amino acid¹ B 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A  1  3 41 24  2 38 B C D  1  1 41 E  1 24 42 F G 40 17  1 42 15 H  1 I 41 K L 42 41 M N  1 P  2 Q 31 R  8 S 42  1 42 24 20 20  1 T 38 18 21 17  3 V  1  1  1  1  1 W  1  2 X Y Z — 42 unknown (?) not sequenced sum of seq² 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 oomcaa³ 42 42 40 38 42 41 24 42 24 41 21 42 41 31 20 24 41 42 38 mcaa⁴ — S G T S A S L A I T G L Q S E D E A rel. oomcaa⁵ 100% 100% 95% 90% 100% 98% 57% 100% 57% 98% 50% 100% 98% 74% 48% 57% 98% 100% 90% pos  1  1  3  3  1  2  2  1  3  2  3  1  2  5  5  4  2  1  3 occupied⁶ Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A  1 22 15  1 16  4 B C 42 D 37 39 17  7 E  1  1  1 F  2  1 G 14  1 17  1  5 H  2  1  1 I  1  1 K  1 L  1 37  1 M N  2  2  9  1 P  1  6 Q  3 R  5  1  2  2 S  4 17 35 18  1  1 T 22  1  1  1 V  1  1  1  2  9 W 38  7 X Y 42 39  3  1  3 Z —  2  4 35 39 38 38  1 unknown (?) not sequenced  1  1  1  1  1  1  1  1  1  3  3  3  3  3 sum of seq² 42 42 42 42 41 41 41 41 41 41 41 41 41 39 39 38 38 39 oomcaa³ 37 42 39 42 22 22 38 39 17 35 37 18 17 35 39 38 38  9 mcaa⁴ D Y Y C A T W D D S L S G — — — — V rel. oomcaa⁵ 88% 100% 93% 100% 54% 54% 93% 95% 41% 85% 90% 44% 41% 90% 100% 100% 100% 23% pos occupied⁶  5  1  3  1  5  3  2  2  8  3  5  8  6  5  1  1  1 10 Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A  1 285 B C 84 D 224 E  1 81 F 36 87 G  1 36 31 36 26 559 H 25 I  1 188 K 30 141 L  1 25 34 344 M  1 5 N  1 176 P 1 296 Q  3  1 18 251 R  1  2 156 S  1  2 720 T  3 36  1 36 359 V 34 11 36  1 282 W  1 92 X Y 202 Z 16 — 524 unknown (?) not sequenced  3  4  4  6  6  6  6  6  6  6  6 10 22 141 sum of seq² 39 36 36 36 36 36 36 36 36 36 36 31 19 oomcaa³ 34 36 36 31 36 36 30 25 36 36 34 26 18 mcaa⁴ V F G G G T K L T V L G Q rel. oomcaa⁵ 87% 100% 100% 86% 100% 100% 83% 69% 100% 100% 94% 84% 95% pos occupied⁶  6  1  1  4  1  1  5  2  1  1  3  4  2

TABLE 5B Analysis of V lambda subgroup 2 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 35 30  6  1  1 B C D  1 E F G 42 42 H  2  1 I  1 28 K L 40  3  1 M N P 42  6 40 Q 22  4 41 42 R  6  1 S 41 40 42 42 43 T 42  1 V  1  2 36 14 W X Y Z 16 — 42 unknown (?)  1 not  3  1  1  3  1  1  1  1  1  1  1  1 sequenced sum of seq² 40 42 42 40 42 42 42 42 42 42 42 42 43 43 43 43 43 43 43 oomcaa³ 22 41 35 40 42 41 42 30 40 42 36 42 42 42 40 42 42 43 28 mcaa⁴ Q S A L T Q P A S — V S G S P G Q S I rel. oomcaa⁵ 55% 98% 83% 100% 100% 98% 100% 71% 95% 100% 86% 100% 98% 98% 93% 98% 98% 100% 65% pos  3  2  4  1  1  1  1  3  3  1  2  1  2  2  2  2  2  1  3 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 D E 28 29 30 31 A 32 33 34 A  3  1  1  1 B C 42  1  1 D 39  1  4  5 E  1 F  1  1  4 G 43  1 39 26 H  1  1  1 I 41  1  6 K  4 L  1  4 M N  1  3  4  1  4  3 28 P  1 Q R  1  2 S 42  3  3 35 38  5  1  2  4  1 42 T 43 36 39  3  1  1 V 37 41 W X Y  1  1 37 29 Z —  1 unknown (?)  1 not sequenced  1  1  1  1 sum of seq² 43 43 42 42 43 43 43 43 43 43 43 43 43 43 43 43 42 42 oomcaa³ 43 41 42 42 36 43 39 35 38 39 37 39 26 37 28 29 41 42 mcaa⁴ T I S C T G T S S D V G G Y N Y V S rel. oomcaa⁵ 100% 95% 100% 100% 84% 100% 91% 81% 88% 91% 86% 91% 60% 86% 65% 67% 98% 100% pos occupied⁶  1  3  1  1  4  1  3  7  4  2  2  5  7  5  7  6  2  1 Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 A  1  4 40 B C D  1  2 20  1  2  1 E 20  2 F  2  7  1 G 36  2  2  1 H  2 34  1 I  1  1  9 43  1 K 40 41  1 21 L  1  1 38  6 M 26  1 N  2  1  8 12 P 41 43 Q 41 39  2 R  1  1  2 S  1  2 21  3 T  1  7 V  1  3  4  2 39 W 43 X Y 41  5 34  2 Z — unknown (?)  1  1 not sequenced sum of seq² 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 oomcaa³ 43 41 41 39 34 41 36 40 40 43 41 38 26 43 34 20 39 21 21 mcaa⁴ W Y Q Q H P G K A P K L M I Y D V S K rel. oomcaa⁵ 100% 95% 95% 91% 79% 95% 84% 93% 93% 100% 95% 88% 60% 100% 79% 47% 91% 49% 49% pos  1  2  2  3  5  3  4  4  2  1  2  3  4  1  3  4  4  8  8 occupied⁶ CDR II Framework III amino acid¹ 54 55 56 A B C D E 57 58 59 60 61 62 63 64 65 66 A A  2 B C  1 D 17 E F 42 G 43  1 41 H  2 I  3 K 42 L  1  1 M N 19 P 43 15 Q R 43 43  1 S 43 28  2 43 42 T V 39 W X Y  2 Z — 43 43 43 43 43 43 unknown (?) not sequenced sum of seq² 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 oomcaa³ 43 43 43 43 43 43 43 43 43 39 28 19 43 42 43 41 42 42 43 mcaa⁴ R P S — — — — — G V S N R F S G S K — rel. oomcaa⁵ 100% 100% 100% 100% 100% 100% 100% 100% 100% 91% 65% 44% 100% 98% 100% 95% 98% 98% 100% pos  1  1  1  1  1  1  1  1  1  3  2  6  1  2  1  2  2  2  1 occupied⁶ Framework III amino acid¹ B 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A  3  1 43 36 43 B C D  1  2  3 42 E  1 38 43 F G 39 42  1 H I 35 K  1 L 43 43 M N 38  1  1 P  2 Q 41 R  2 S 42  1 43 42 T  1 41 43  1  2 V  8  3 W X Y Z — 43 unknown (?)  1 not  1 sequenced sum of seq² 43 42 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 oomcaa³ 43 42 39 38 41 43 43 43 43 35 42 42 43 41 36 38 42 43 43 mcaa⁴ — S G N T A S L T I S G L Q A E D E A rel. oomcaa⁵ 100% 100% 91% 88% 95% 100% 100% 100% 100% 81% 98% 98% 100% 95% 84% 88% 98% 100% 100% pos  1  1  3  4  3  1  1  1  1  2  2  2  1  2  4  4  2  1  1 occupied⁶ Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A  2  1 21  1  1 B C 43 11 D 39  3  1  2  1 E  1  1 F  3  3  1  1  5 G  1 21  3  4  1 H  2  1 I  1  1  1  2  1 K  3 L  1  1  6 M  1 N  1  5  7  5  1 P  1  4 Q  1  2 R  2  3  1  5 S  1 30 41 12 23 14  9  1 T 16  4  4  3 21 V  1 11 W  5 X Y 43 39 39  1  6  4 Z —  1  3 36 42 43 43 43 unknown (?)  1  2 not sequenced  1  1 sum of seq² 43 43 43 43 43 42 43 43 43 43 43 42 43 43 43 43 43 43 oomcaa³ 39 43 39 43 30 41 39 21 21 23 14 21 36 42 43 43 43 11 mcaa⁴ D Y Y C S S Y A G S S T — — — — — V rel. oomcaa⁵ 91% 100% 91% 100% 70% 98% 91% 49% 49% 53% 33% 50% 84% 98% 100% 100% 100% 26% pos occupied⁶  3  1  3  1  3  2  3  7  7  8 11  6  5  2  1  1  1 13 Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A  1  1 280 B C 99 D 188 E 107 F 42 113 G 42 33 42 19 567 H 48 I  7  1 184 K 36 189 L  5 28 40 264 M  1 29 N  1 146 P 238 Q  1 14 250 R  1  2  4 121 S  1  2 831 T  7 41 40 398 V 28 14 42  1 327 W 48 X Y  1 285 Z 16 — 555 unknown (?) 8 not sequenced  1  1  1  1  1  2  2  1  1  1  2 15 28 80 sum of seq² 42 42 42 42 42 41 41 42 42 42 41 25 14 oomcaa³ 28 42 42 33 42 41 36 28 40 42 40 19 14 mcaa⁴ V F G G G T K L T V L G Q rel. oomcaa⁵ 67% 100% 100% 79% 100% 100% 88% 67% 95% 100% 98% 76% 100% pos occupied⁶  5  1  1  4  1  1  5  2  3  1  2  3  1

TABLE 5C Analysis of V lambda subgroup 3 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A  1  1  2  7 20  1 27 B C D  5 10 E 20  1  1 F  1  1  1  1 G  1 37 H I K  2 L 37  4  1  9 M N P 26 35  1 27  1 Q 4 4 38 36 R S 13 14  1  1 28 37 18 T 36  1 38 V  8  1  2 34 36 10 W X Y 23 Z — 20 38 unknown (?) not sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 oomcaa³ 20 23 20 37 36 38 26 35 28 38 34 37 36 20 27 37 36 38 27 mcaa⁴ — Y E L T Q P P S — V S V A P G Q T A rel. oomcaa⁵ 53% 61% 53% 97% 95% 100% 68% 92% 74% 100% 89% 97% 95% 53% 71% 97% 95% 100% 71% pos  4  3  5  2  3  1  4  3  4  1  2  2  3  2  4  2  2  1  3 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 D E 28 29 30 31 A 32 33 34 A  1  5  1  1 21  3 B C 38  5 D 30  1 10  3  1 E  2  2  1  3  6 F  1  2 G 9 38  1 23  4 H  1  2  9 I 38  9  1 K  7  2 13 L 28 M 1  1 N  2  4  9  1  2  1  2 P  1  3 Q 10  4 R 25  2 10  1  1 S  9  1 19 10 11  2  8 14 T  3 33  1  1  4 V  1 15 W X Y  1  8 20  1  4 Z — 38 38 37 unknown (?) not  1  1 sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 37 37 37 38 38 oomcaa³ 25 38 33 38 19 38 30 10 38 38 28 23 11 13 37 20 21 14 mcaa⁴ R I T C S G D S — — L G S K — Y A S rel. oomcaa⁵ 66% 100% 87% 100% 50% 100% 79% 26% 100% 100% 74% 61% 29% 35% 100% 54% 55% 37% pos  4  1  5  1  3  1  5  9  1  1  3  5  9  9  1  7  4  7 occupied⁶ Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 A 23  1  1 B C D  9 22  2  8 E  1  5  3  3 F  3  2  1 G 36  9  2 H  1  1  3  1 I  1 28  1 K 32  2  6  1 13 L  2  6 33  1 M  1  1 N  1 19 9 P 36  1 38 Q 37 35  1 36  9  1 R  1  4  2  1  1  1 S  1  2 14 10  1 T  2  4 V  1 31  4 37  9 W 38 X Y 35 35 Z — unknown (?) not sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 oomcaa³ 38 35 37 35 32 36 36 36 23 38 31 33 37 28 35  9 22 19 13 mcaa⁴ W Y Q Q K P G Q A P V L V I Y D D N K rel. oomcaa⁵ 100% 92% 97% 92% 84% 95% 95% 95% 61% 100% 82% 87% 97% 74% 92% 24% 58% 50% 34% pos  1  2  2  3  4 2  2  3  3  1  3  3  2  3  3  7  8  7  9 occupied⁶ CDR II Framework III amino acid¹ 54 55 56 A B C D E 57 58 59 60 61 62 63 64 65 66 A A  1 B C D  9 E 27 F 38 G 38 38 H I 37 K L M N 21 P 37  1 36 Q R 38 38 S  1 36  1 38 38 12 T  5 V W X Y Z — 38 38 38 38 38 38 unknown (?)  1 not  1  1  1 sequenced sum of seq² 38 38 38 38 38 38 38 38 38 37 37 37 38 38 38 38 38 38 38 oomcaa³ 38 37 36 38 38 38 38 38 38 37 36 27 38 38 38 38 38 21 38 mcaa⁴ R P S — — — — — G I P E R F S G S N — rel. oomcaa⁵ 100% 97% 95% 100% 100% 100% 100% 100% 100% 100% 97% 73% 100% 100% 100% 100% 100% 55% 100% pos  1  2  3  1  1  1  1  1  1  1  2  2  1  1  1  1  1  3  1 occupied⁶ Framework III amino acid¹ B 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A  1 36  1  1 11  1 34 38 B C D 38 E 10 14 38 F G 37 28 10 H  1 I  1  1 37  1  1 K  1 L 38  2 M 10 N 28  1 P Q  1 25 R  1 10  1 S 37  2 11 23  1 T  1  6 37 25 36 12 13  2 V  2  1 14  1  1  1 W X Y Z — 38 unknown (?) not sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 oomcaa³ 38 37 37 28 37 36 25 38 36 37 23 28 14 25 34 14 38 38 38 mcaa⁴ — S G N T A T L T I S G V Q A E D E A rel. oomcaa⁵ 100% 97% 97% 74% 97% 95% 66% 100% 95% 97% 61% 74% 37% 66% 89% 37% 100% 100% 100% pos  1  2  2  5  2  2  4  1  3  2  5  2  3  5  4  6  1  1  1 occupied⁶ Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A 13  3  2  1  2  4 B C 38 D 37 32  1  1  6 E  1  1  2  2 F 2  2 G  3 14  3  1  3 H 12  1 I K  1 L  1  1  1  1  1  4 M  1  1 N 10  2  1  2 10  1 P  1  3  1 Q 25  1  1 R 10  1  2  2 S  1 14  1 28 26 13  1  1 T  1  3  7  2 V 11 18 W 23  1 X Y 38 36  1  1  1  3  1  3 Z — 10 15 31 36 37 36 unknown (?) not  1  1  1  1  2  1  1  1  1  1  1 sequenced sum of seq² 38 38 38 38 38 38 38 37 37 37 37 36 37 37 37 37 37 37 oomcaa³ 37 38 36 38 25 14 23 32 28 26 14 10 15 31 36 37 36 18 mcaa⁴ D Y Y C Q S W D S S G N — — — — — V rel. oomcaa⁵ 97% 100% 95% 100% 66% 37% 61% 86% 76% 70% 38% 28% 41% 84% 97% 100% 97% 49% pos  2  1  2  1  5  3  5  4  7  8  6  9  8  5  2  1  2  9 occupied⁶ Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A 265 B C  1 82 D 225 E  2 145 F 35 90 G  1 35 31 35 24 461 H 32 I  4 160 K 30 110 L  2 28 33 233 M  1 17 N 126 P  1 249 Q  7 275 R  2 154 S  2 501 T  4 35 35 347 V 28  7 35 308 W 62 X Y 211 Z —  1 603 unknown (?) 1 not  1  3  3  3  3  3  4  3  3  3  4 11 28 89 sequenced sum of seq² 37 35 35 35 35 35 34 35 35 35 34 27  7 oomcaa³ 28 35 35 31 35 35 30 28 35 35 33 24  7 mcaa⁴ V F G G G T K L T V L G Q rel. oomcaa⁵ 76% 100% 100% 89% 100% 100% 88% 80% 100% 100% 97% 89% 100% pos  6  1  1  2  1  1  3  2  1  1  2  3  1 occupied⁶

TABLE 6A Analysis of V heavy chain subgroup 1A Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A  1 14 60 24  1 B C D E  1  2  1  2 64 F G 58  1 64 H  2 I  2 K  2 57 64 60 L  2 59  3 M  1 N  6 P 63 Q 53 56  2 45 R  1  3 S 60  3  1 40 63 T  1 V  2 55  1 55 61 64 W X Y Z  3 — unknown (?) not 11 10 10 10 10 10 10 10  6  6  6  6  6  6  6  6  6  6  6 sequenced sum of seq² 59 60 60 60 60 60 60 60 64 64 64 64 64 64 64 64 64 64 64 oomcaa³ 53 55 56 59 55 45 60 58 60 64 61 57 64 63 64 40 63 64 60 mcaa⁴ Q V Q L V Q S G A E V K K P G S S V K rel. oomcaa⁵ 90% 92% 93% 98% 92% 75% 100% 97% 94% 100% 95% 89% 100% 98% 100% 63% 98% 100% 94% pos  4  4  3  2  4  3  1  2  3  1  2  3  1  2  1  2  2  1  3 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 35 36 A 62  1 41 B C 63 D  1 E F 69 3 3 G  1 69 41  1 23 H  1  1  1 I  1 61  1 K 63  1  1 L  1  2 M  4 N  2  5  4 P  1 Q R  1  1  1  1 S 63 68  1 40 60  2 60 T  1 2 68 25  3  3  4 V 64  1 W 70 X Y 27 64 Z — 70 70 unknown (?) not  6  6  6  6  5  2  1 sequenced sum of seq² 64 64 64 64 65 68 69 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 64 63 63 63 62 68 69 41 68 69 40 60 70 70 64 41 61 60 70 mcaa⁴ V S C K A S G G T F S S — — Y A I S W rel. oomcaa⁵ 100% 98% 98% 98% 95% 100% 100% 59% 97% 99% 57% 86% 100% 100% 91% 59% 87% 86% 100% pos  1  2  2  2  3  1  1  4  3  2  6  5  1  1  4  6  4  5  1 occupied⁶ Framework II CDR II amino acid¹ 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A B C A 70  1  5 B C D  1 E 69 F  2 G  1 68 69  1 69 39  1 H  1 I  1 65 38 K L  1 68  1  1 M 67  2 N  4 P 68  1 44 Q 69 69 R 70  1  1  1  4 S  1  1  1 22 T  1  2  4 V 69  1  2  2 16 W  1 67 26 X Y  1 Z — 70 70 unknown (?) not sequenced sum of seq² 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 69 70 69 70 68 68 69 69 68 69 67 67 69 39 65 38 44 70 70 mcaa⁴ V R Q A P G Q G L E W M G G I I P — — rel. oomcaa⁵ 99% 100% 99% 100% 97% 97% 99% 99% 97% 99% 96% 96% 99% 56% 93% 54% 63% 100% 100% pos  2  1  2  1  3  3  2  2  3  2  4  4  2  4  4  6  5  1  1 occupied⁶ CDR II Framework III amino acid¹ 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 A  1 34 69 43 B C D 15  1  2 E  1 F  3 39  1 48 3  4 G 68  1  3 67 H  1 I 34  4  1 44 K  1  2  1 47  1  1 L  2  4  1  1 22  2  1  3 M  4 21 N  3 22  9 59 18 P  1  7 Q  1  1  1  1  1 70 64 R  1  2  2  1 69 S  1  1  1  2  1  5 T  1  3 34 26  4  3 66 65 24 V  1  1 65  3 W X Y 20  1 68 Z — unknown (?) not sequenced sum of seq² 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 34 39 68 34 34 59 68 69 70 47 48 64 67 69 65 66 44 65 43 mcaa⁴ I F G T A N Y A Q K F Q G R V T I T A rel. oomcaa⁵ 49% 56% 97% 49% 49% 84% 97% 99% 100% 67% 69% 91% 96% 99% 93% 94% 63% 93% 61% pos 10  6  3 11  6  7  3  2  1  4  2  5  3  2  3  3  4  2  3 occupied⁶ Framework III amino acid¹ 72 73 74 75 76 77 78 79 80 81 82 A B C 83 84 85 86 87 A 64  1  3  1 B C D 70  2 26 70 E 33 64 44 F G  1 H  1  1 I  1  1  3  1  1 K  8  3 L  3 63 70 M 67  1 N  4  1 16 P Q  1  3 R  1  3 23  1 62 S 70 62  1 41 49 67  1 T 27 67  1 69  2  3  2  4 67 V  3  3  4  1 W X Y 68 Z — unknown (?) not sequenced sum of seq² 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 70 33 70 67 62 69 64 68 67 64 63 41 49 70 62 67 44 70 67 mcaa⁴ D E S T S T A Y M E L S S L R S E D T rel. oomcaa⁵ 100% 47% 100% 96% 89% 99% 91% 97% 96% 91% 90% 59% 70% 100% 89% 96% 63% 100% 96% pos  1  5  1  2  4  2  4  3  2  4  3  6  6  1  4  2  2  1  4 occupied⁶ Framework III CDR III amino acid¹ 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F A 70 66  2 16  1  1  1  4  1  2  2  1  1 B C 70  1  1 16  2  1  1  7  2  1 D 16  5  3  3  5  4  3  4  1 E  9  2  1  1 F  1  1  2  1  3  2  3  1  2  2 G  2 14 13 20 10 14  5 20 15 16  3  3  4 H  1  1  1  1 I  2  2  5  2 2  2  2  1  1 K  5  2  1  1 L  2  1  4  4  2  5  2  1  1  4  2  1 M  1  1  2  1  1  1  1 N  2  2  1  2  1  2  2  2  2 P 20  3  1  3  2  2  2  4  2  1 Q  1  1  1  1  1 R 55  1  5  7  8  1  4  2  1 16 S  1  1  5  5  5  5 21  5 11  8  4  3 T  1  3  3  5  4  1  3  4  2  5  2  1 V 64  3  3  2  4  3  3  3  4  2  2  2  1  2 W  1  1  3  1  1  2  3 X Y 69 68  1  2  3 20  5  4  9  1  2 11 20 10 Z —  1  2  2  3  6 11 11 14 23 26 26 unknown (?)  1 not  2  2  2  4  4  4  4  5  5  5  5  5 sequenced sum of seq² 70 70 70 70 70 70 70 68 68 68 66 66 66 66 65 65 65 65 65 oomcaa³ 70 64 69 68 70 66 55 16 20 20 20 16 21 20 15 16 23 26 26 mcaa⁴ A V Y Y C A R A P G Y C S G — — — — — rel. oomcaa⁵ 100% 91% 99% 97% 100% 94% 79% 24% 29% 29% 30% 24% 32% 30% 23% 25% 35% 40% 40% pos  1  5  2  2  1  3  8 10 14 18 15 18 15 15 17 17 15 12 11 occupied⁶ Framework IV amino acid¹ G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113 sum A  1  1  1  2  1 670 B C 165 D  1 14 59  1  1 308 E  1  1  1 297 F  1 28  2  2 226 G 15  1  1  7 58 59  1  1 928 H  1 14 I  1  3  4 286 K  3  1 325 L  1  1  3  1 40  1 386 M 10  1  3 189 N  1  1  4  1 176 P  4  1  1  1  5  1 238 Q 52 494 R  1 351 S  2  1  2  1 53 51 972 T  1  1 54 11  1 51  1 736 V  1 15  1  1 54 54  1 699 W  1  5  1 59 1 243 X Y  6  9 10  7  1 34  1 542 Z  3 — 31 34 46 39 21 1  1 578 unknown (?)  1  1  2  3  8 not  5  5  5  5  5  5  5  9  9 10 11 14 14 14 15 16 16 17 406 sequenced sum of seq² 65 65 65 65 65 65 65 61 61 60 59 56 56 56 55 54 54 53 oomcaa³ 31 34 46 39 28 59 34 59 58 52 59 54 40 54 51 54 53 51 mcaa⁴ — — — — F D Y W G Q G T L V T V S S rel. oomcaa⁵ 48% 52% 71% 60% 43% 91% 52% 97% 95% 87% 100% 96% 71% 96% 93% 100% 98% 96% pos 11 10  8  7  6  6  9  3  4  7  1  3  5  3  2  1  2  3 occupied⁶

TABLE 6B Analysis of V heavy chain subgroup 1B Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 32 34 B C D E  1  5  1 35 F G 27 35 H  1  1 I K  3  1 34 33 33 L  3 26  1 M  1  1 N P  1 33  1 Q 21 20 26 R  1  1  2 S 27  1 34 T  1  1  2 V  3 21 20 35 35 W X Y Z — unknown (?) not 15 15 15 13 13 13 13 13  6  5  5  5  5  5  5  5  5  5  5 sequenced sum of seq² 25 25 25 27 27 27 27 27 34 35 35 35 35 35 35 35 35 35 35 oomcaa³ 21 21 20 26 20 26 27 27 32 35 35 34 33 33 35 34 34 35 33 mcaa⁴ Q V Q L V Q S G A E V K K P G A S V K rel. oomcaa⁵ 84% 84% 80% 96% 74% 96% 100% 100% 94% 100% 100% 97% 94% 94% 100% 97% 97% 100% 94% pos  3  3  4  2  4  2  1  1  3  1  1  2  2  3  1  2  2  1  2 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 35 36 A 30  2  6 B C 35 D  1  5  1 E  3  1 F  2 39  2  2 G  1 40  1 14  1 H  3  1 34 I  1  1  1  9 K 28 L  1  1  5 M 23 N  1  1  3  1  3 P  1 Q  2  1  1  1 R  2  2  1 S 35 40  5  2 15  2  1 T  3 32 34  1 V 34  1  1  1  1  2  2 W 40 X Y 36  1 32 19  1 Z — 40 40 unknown (?) not  5  5  5  5  5 sequenced sum of seq² 35 35 35 35 35 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 34 35 35 28 30 40 40 36 32 39 34 15 40 40 32 19 23 34 40 mcaa⁴ V S C K A S G Y T F T S — — Y Y M H W rel. oomcaa⁵ 97% 100% 100% 80% 86% 100% 100% 90% 80% 98% 85% 38% 100% 100% 80% 48% 58% 85% 100% pos  2  1  1  4  4  1  1  4  4  2  6 10  1  1  5 11  5  5  1 occupied⁶ Framework II CDR II amino acid¹ 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A B C A 39  1  1  7 B C D  1  1 E  1 39 F  2  1 G  1 39 28 39  1  1 H I  3 34 K  1 L  2  1 37  1 M 37  2  4 N 35 P  1 34  1 31 Q  1 39 39  1 R 37  1 10  4 S  1  1  2 T  4  1 V 38  1  1 W 40 33 X Y Z — 40 40 unknown (?) not sequenced sum of seq² 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 38 37 39 39 34 39 39 28 37 39 40 37 39 33 34 35 31 40 40 mcaa⁴ V R Q A P G Q G L E W M G W I N P — — rel. oomcaa⁵ 95% 93% 98% 98% 85% 98% 98% 70% 93% 98% 100% 93% 98% 83% 85% 88% 78% 100% 100% pos  2  4  2  2  4  2  2  4  3  2  1  2  2  4  4  5  4  1  1 occupied⁶ CDR II Framework III amino acid¹ 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 A  1  1  2 27  2  1  1  2 B C D  1  1  4 E  1  1  2  2  1  1  1 F  1  4 39  3 G  9  1 39 15  6  1 34 H  2  1  1 I  1  1  1  1 13 K  1  2  2  8 36  1  1 L  1  1  1 M 23 N 20 12  1 17 18  1 P Q 36 37 R  3  1  2  1  2 37 34 S  1 20  1  2 11  1  1 T  3 35  2  1  1 39 40  1 V  1 38 W  3 X Y  2 33 Z — unknown (?) not sequenced sum of seq² 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 20 20 39 17 35 18 33 27 36 36 39 37 34 37 38 39 23 40 34 mcaa⁴ N S G N T N Y A Q K F Q G R V T M T R rel. oomcaa⁵ 50% 50% 98% 43% 88% 45% 83% 68% 90% 90% 98% 93% 85% 93% 95% 98% 58% 100% 85% pos  9  8  2  8  4  8  4  4  4  5  2  3  4  2  3  2  4  1  6 occupied⁶ Framework III amino acid¹ 72 73 74 75 76 77 78 79 80 81 82 A B C 83 84 85 86 87 A 12 35  1  2 B C D 35  1  4 19 40 E 35 19 F  1  2 G  1  1  2 H  1 I 22  1 K  1 L  2 39 39 M  1  1 37  1 N  4  7  1  2 P  3  1 Q R  1  4  2 16 37 S 37 27  1 35 20  1 36 T 38  5  1 39  1  1 40 V  4  1  1 W X Y 39 Z — unknown (?) not sequenced sum of seq² 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 35 38 37 22 27 39 35 39 37 35 39 35 20 39 37 36 19 40 40 mcaa⁴ D T S I S T A Y M E L S S L R S D D T rel. oomcaa⁵ 88% 95% 93% 55% 68% 98% 88% 98% 93% 88% 98% 88% 50% 98% 93% 90% 48% 100% 100% pos  3  3  2  4  5  2  3  2  3  3  2  5  4  2  4  4  3  1  1 occupied⁶ Framework III CDR III amino acid¹ 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F A 40 37  1  6  1  1  2  3  1  3  1 B C 37  1  3  2  1 D  1  7  5  2  3  1  5  4  1  2 E  2  1  1  1  2  1 F  2  1  1  1  3  2  1  1  1  1 G  1  7  7  5  5  9  4  7  1  3  2  2 H  1  2  1  1 I  1  1  1  1  3  1  1  1  1  1  1 K  1  1  1  1  1  1 L  2  1  2  4  4  4  3  1  2  1  1  2 M  2  2  1  1 N  1  1  1  1  1 P  1  6  4  1  1  3  2 Q  1  1  2  1 R  1 31  5  1  1  3  1  1 S  1  1  1  3  3  1  4  3  6  3  2  2  1  1 T  2  1  1  2  2  1  5  1  1  1  1 V 33  1  7  1  1  1  3  1  2  1 W  1  1  2  2  1  1 X Y 38 35  5  5  4  2  3  4  3  3  2  1 Z —  1  1  4  6  8 10 11 14 20 23 25 unknown (?) not  1  1  1  1  1  1  3  3  3  3  3  3  4  4  4  4  4  4 sequenced sum of seq² 40 39 39 39 39 39 39 37 37 37 37 37 37 36 36 36 36 36 36 oomcaa³ 40 33 38 35 37 37 31 7 7 5 5 9 8 10 11 14 20 23 25 mcaa⁴ A V Y Y C A R D G D G G — — — — — — — rel. oomcaa⁵ 100% 85% 97% 90% 95% 95% 79% 19% 19% 14% 14% 24% 22% 28% 31% 39% 56% 64% 69% pos  1  5  2  4  3  3  8 10 12 18 13 13 12 12 17 14 13 10  9 occupied⁶ Framework IV amino acid¹ G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113 sum A  5 340 B C 79 D  2  1  2 27  2 179 E  1  1 159 F  2 15  1 130 G  1  1  3  1 27 26  1 450 H  1 51 I  1  7  3 113 K  1  2 194 L  1  2 12  1 204 M  1  4  2 144 N  3  1  1  1 138 P  1  1  1 128 Q 23 253 R  1  1 247 S  3  1 18 18 432 T  1  1 21  6 16  1 390 V  1  2  1  1  6 21 18 342 W  1  4 29 158 X Y  2  5  6  2 11 294 Z — 25 25 23 18 11  6  3 394 unknown (?)  3 3 not  4  4  4  4  4  4  4 11 13 13 14 19 19 19 20 20 21 22 458 sequenced sum of seq² 36 36 36 36 36 36 36 29 27 27 26 21 21 21 20 20 19 18 oomcaa³ 25 25 23 18 15 27 11 29 27 23 26 21 12 21 16 18 18 18 mcaa⁴ — — — — F D Y W G Q G T L V T V S S rel. oomcaa⁵ 69% 69% 64% 50% 42% 75% 31% 100% 100% 85% 100% 100% 57% 100% 80% 90% 95% 100% pos  8  7  8  8  5  5 10  1  1  4  1  1  4  1  3  3  2  1 occupied⁶

TABLE 6C Analysis of V heavy chain subgroup 2 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A  3 B C D E  1  6  2 F G  6 H I  1 K  3  6  1 L  6  6  6 M N  1 P  1  6  6  1 Q  2  4 R  2 S  4 T  6    2  5  5  6 V  5  1  6 W X Y Z  3 — unknown (?) not  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1 sequenced sum of seq²  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6 oomcaa³  3  5  6  6  3  6  4  6  6  3  6  6  6  6  5  4  6  6 mcaa⁴ Z V T L K E S G P A L V K P T Q T L T rel. oomcaa⁵ 50% 83% 100% 100% 50% 100% 67% 100% 100% 50% 100% 100% 100% 100% 83% 67% 83% 100% 100% pos  3  2  1  1  3  1  3  1  1  3  1  1  1  1  2  2  2  1  1 occupied⁶ Framework I CDRI amino acid¹ 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 35 36 A  1  1  1 B C  7  2 D  1 E F  3  6  1 G  7  4  3  3 H I  1 K L  6  2  1  6 M  5 N  2 P Q R  2  1 S  1  6  6  6  2  4  4 T  6  6  1  3  1 V  2  2  7 W  7 X Y  1 Z — unknown (?) not  1  1 sequenced sum of seq²  6  6  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7 oomcaa³  6  6  7  6  3  6  7  6  6  6  6  3  4  4  5  3  7  4  7 mcaa⁴ L T C T F S G F S L S T S G M G V S W rel. oomcaa⁵ 100% 100% 100% 86% 43% 86% 100% 86% 86% 86% 86% 43% 57% 57% 71% 43% 100% 57% 100% pos  1  1  1  2  3  2  1  2  2  2  2  3  4  3  2  4  1  2  1 occupied⁶ Framework II CDR II amino acid¹ 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A B C A  6  7 B C D  2 E  7 F  2 G  1  7  1 H  2 I  7  6 K  6 L  7  7  2  1  1 M N P  5  7 Q  6 R  7  1  1  2 S  1 T V W  7  1 X  1 Y  1  1 Z —  6  7  7 unknown (?) not sequenced sum of seq²  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7 oomcaa³  7  7  6  5  7  7  6  6  7  7  7  7  7  2  6  2  6  7  7 mcaa⁴ I R Q P P G K A L E W L A H I D — — — rel. oomcaa⁵ 100% 100% 86% 71% 100% 100% 86% 86% 100% 100% 100% 100% 100% 29% 86% 29% 86% 100% 100% pos  1  1  2  3  1  1  2  2  1  1  1  1  1  4  2  5  2  1  1 occupied⁶ CDR II Framework III amino acid¹ 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 A B C D  3  6  5 E  1  1 F  1  1 G H  1  1 I  6 K  1  6  4  6 L  7  7 M N  3 P  2 Q R  2  1  2  7  1 S  2  2  6  7  4  1  5 T  4  3  6  2 V  1 W  4  1 X  1  1  1 Y  3  4 Z — unknown (?) not sequenced sum of seq²  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7 oomcaa³  4  3  6  5  6  3  4  6  4  7  7  4  4  7  7  6  6  5  6 mcaa⁴ W D D D K Y Y S T S L K S R L T I S K rel. oomcaa⁵ 57% 43% 86% 71% 86% 43% 57% 86% 57% 100% 100% 57% 57% 100% 100% 86% 86% 71% 86% pos  3  3  2  3  2  3  4  2  3  1  1  3  2  1  1  2  2  2  2 occupied⁶ Framework III amino acid¹ 72 73 74 75 76 77 78 79 80 81 82 A B C 83 84 85 86 87 A  1 B C D  6  1  6  7 E F  1 G H I  2  1 K  6 L  6 M  7  5 N  1  5  6  1 P  7 Q  7 R  1 S  7  2 T  6  5  5  7 V  7  7  1  6 W X Y Z —  1  1  1 unknown (?) not sequenced sum of seq²  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7  7 oomcaa³  6  6  7  6  5  7  7  7  6  5  7  5  6  5  6  7  6  7  7 mcaa⁴ D T S K N Q V V L T M T N M D P V D T rel. oomcaa⁵ 86% 86% 100% 86% 71% 100% 100% 100% 86% 71% 100% 71% 86% 71% 86% 100% 86% 100% 100% pos  2  2  1  2  2  1  1  1  2  2  1  3  2  3  2  1  2  1  1 occupied⁶ Framework III CDR III amino acid¹ 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F A  5  5  1  2  1 B C  7 D E  2  1 F G  2  1  1  1  2  1  1  1  1 H  1  1 I  3  2 K  1 L  1  1 M  1 N  1  2 P  1  1  1  1 Q  1 R  6  1  1  1 S  1  1  1 T  7  1  1  1 V  2  1  1  1  1  1  1 W  1 X Y  7  7  2  1  2  1  1 Z —  2  2  3  4  4 unknown (?) not  1  1  1  1  1  1  1  1  1  1  1  1 sequenced sum of seq²  7  7  7  7  7  7  7  6  6  6  6  6  6  6  6  6  6  6  6 oomcaa³  5  7  7  7  7  5  6  3  1  2  2  1  2  2  2  2  3  4  4 mcaa⁴ A T Y Y C A R I H N I G E A — — — — — rel. oomcaa⁵ 71% 100% 100% 100% 100% 71% 86% 50% 17% 33% 33% 17% 33% 33% 33% 33% 50% 67% 67% pos  2  1  1  1  1  2  2  4  6  4  5  6  5  5  4  5  3  3  3 occupied⁶ Framework IV amino acid¹ G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113 sum A  1 35 B C 16 D  6 43 E 21 F  3 18 G  6  6 55 H 6 I 29 K  1  1 42 L  1  1  3 78 M  2 20 N  1 23 P  1  1 41 Q  3 23 R  2 41 S  6  3 82 T  6  1  5 102 V  3  6  6 68 W  1  1  6 29 X 4 Y  1  2  1 35 Z 3 —  4  6  5  3 56 unknown (?) not  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  1  4 54 sequenced sum of seq²  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  6  3 oomcaa³  4  6  5  3  3  6  3  6  6  3  6  6  3  6  5  6  6  3 mcaa⁴ — — — — F D V W G Q G T L V T V S S rel. oomcaa⁵ 67% 100% 83% 50% 50% 100% 50% 100% 100% 50% 100% 100% 50% 100% 83% 100% 100% 100% pos  3  1  2  3  3  1  4  1  1  3  1  1  4  1  2  1  1  1 occupied⁶

TABLE 6D Analysis of V heavy chain subgroup 3 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 A 1 1 12 1 3 1 B 1 1 1 C D 1 1 16 E 110 9 15 166 9 8 2 F 4 G 181 193 174 1 202 H 5 4 I 9 K 5 3 26 L 1 5 176 43 140 1 M 12 1 N 1 P 1 194 Q 41 138 1 3 12 162 R 6 4 S 178 2 8 T 1 V 5 147 1 118 62 195 W 1 X Y Z 8 — unknown (?) not sequenced 47 47 45 33 32 32 32 31 10 7 6 6 6 6 6 sum of seq² 165 165 167 179 180 180 180 181 202 205 206 206 206 206 206 oomcaa³ 110 147 138 176 118 166 178 181 193 174 140 195 162 194 202 mcaa⁴ E V Q L V E S G G G L V Q P G rel. oomcaa⁵ 67% 89% 83% 98% 66% 92% 99% 100% 96% 85% 68% 95% 79% 94% 98% pos occupied⁶ 5 4 7 4 5 4 3 1 2 5 3 4 7 4 4 Framework I amino acid¹ 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 A 183 192 1 B C 1 209 D 7 E 8 8 3 1 F 1 1 1 201 201 G 134 2 207 3 H 1 I 2 3 17 1 K 15 4 L 205 201 6 3 M 1 1 N 10 10 P 1 2 Q 1 R 62 191 11 S 206 207 4 2 209 15 174 T 4 1 2 4 4 1 163 V 8 7 9 1 6 W X Y Z — unknown (?) not sequenced 4 4 4 4 3 3 3 3 3 3 1 1 2 1 2 sum of seq² 208 208 208 208 209 209 209 209 209 209 211 211 210 211 210 oomcaa³ 134 206 205 191 201 207 209 183 192 209 207 201 163 201 174 mcaa⁴ G S L R L S C A A S G F T F S rel. oomcaa⁵ 64% 99% 99% 92% 96% 99% 100% 88% 92% 100% 98% 95% 78% 95% 83% pos occupied⁶ 4 3 4 3 2 3 1 7 5 1 3 4 8 4 7 CDRI Framework II amino acid¹ 31 A B 32 33 34 35 36 37 38 39 40 41 42 43 A 1 17 80 1 1 187 1 B C 1 1 D 26 3 7 2 E 1 10 1 1 F 5 G 13 31 1 2 209 H 4 88 I 1 1 15 12 K 7 1 202 L 3 3 2 3 1 2 1 M 193 N 35 8 3 34 P 1 1 4 191 Q 209 1 1 R 7 207 7 8 S 103 17 8 72 3 14 T 9 15 10 4 5 V 2 7 1 197 2 W 30 212 X 1 Y 1 154 19 3 Z — 210 210 unknown (?) not sequenced 2 2 2 1 1 1 sum of seq² 210 210 210 210 210 212 212 212 211 211 211 212 212 212 212 oomcaa³ 103 210 210 154 80 193 88 212 197 207 209 187 191 209 202 mcaa⁴ S — — Y A M H W V R Q A P G K rel. oomcaa⁵ 49% 100% 100% 73% 38% 91% 42% 100% 93% 98% 99% 88% 90% 99% 95% pos occupied⁶ 14 1 1 9 10 4 9 1 3 3 3 9 5 4 4 Framework II CDR II amino acid¹ 44 45 46 47 48 49 50 51 52 A B C 53 54 55 A 1 77 42 1 2 14 7 B 3 1 C 1 D 1 7 94 8 3 E 198 3 2 1 2 1 F 7 1 2 1 1 8 G 207 33 11 10 46 4 163 85 H 6 1 I 3 3 191 1 1 K 1 37 2 30 3 1 L 211 5 12 1 M 1 1 N 13 7 9 2 13 11 1 P 1 1 1 Q 7 7 10 R 1 24 1 17 5 1 2 16 S 3 1 102 11 9 118 43 1 74 17 82 T 3 5 4 2 13 12 3 3 V 3 204 49 2 1 6 W 210 1 8 6 X 4 3 Y 1 22 5 58 8 Z — 14 178 178 2 1 1 unknown (?) not sequenced sum of seq² 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 oomcaa³ 207 211 198 210 204 102 49 191 118 58 178 178 94 163 85 mcaa⁴ G L E W V S V I S Y — — D G G rel. oomcaa⁵ 98% 100% 93% 99% 96% 48% 23% 90% 56% 27% 84% 84% 44% 77% 40% pos occupied⁶ 4 2 5 3 3 3 15 9 11 19 5 5 12 9 12 CDR II Framework III amino acid¹ 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 A 9 1 2 174 33 1 B 1 2 C D 11 17 160 E 8 3 2 1 2 F 1 3 2 207 G 5 1 5 4 5 212 1 H 1 4 I 3 37 2 8 14 208 K 1 61 199 8 L 1 1 1 1 1 1 M 8 2 1 N 51 4 2 2 P 1 1 6 8 18 1 Q 3 2 2 2 R 5 4 5 6 201 S 48 11 4 193 2 7 211 T 42 97 5 7 189 1 V 2 10 2 204 1 3 W 2 X 4 1 1 Y 9 151 210 1 1 1 Z — unknown (?) not sequenced sum of seq² 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 oomcaa³ 51 97 151 210 174 160 193 204 199 212 201 207 189 208 211 mcaa⁴ N T Y Y A D S V K G R F T I S rel. oomcaa⁵ 24% 46% 71% 99% 82% 75% 91% 96% 94% 100% 95% 98% 89% 98% 100% pos occupied⁶ 19 12 15 2 9 8 3 2 6 1 4 5 5 3 2 Framework III amino acid¹ 71 72 73 74 75 76 77 78 79 80 81 82 A B C A 57 1 8 1 B 2 C D 199 38 2 2 1 10 E 6 4 5 F 13 G 1 4 H 1 1 2 2 I 1 2 2 3 1 1 K 186 6 3 L 188 209 3 1 212 M 1 2 10 3 2 205 N 5 170 2 188 3 181 10 P 1 Q 7 199 R 211 1 1 2 8 S 153 8 10 56 3 6 186 T 142 1 4 2 V 1 11 1 1 W X 2 2 4 1 Y 194 Z — unknown (?) not sequenced 1 1 sum of seq² 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 oomcaa³ 211 199 170 153 186 188 142 188 194 209 299 205 181 186 212 mcaa⁴ R D N S K N T L Y L Q M N S L rel. oomcaa⁵ 100% 94% 81% 73% 88% 89% 67% 89% 92% 99% 94% 97% 85% 88% 100% pos occupied⁶ 2 4 4 3 8 7 6 5 5 3 6 4 11 7 1 Framework III CDR III amino acid¹ 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 A 149 1 1 207 173 2 15 9 11 B C 1 210 5 2 1 D 5 15 209 2 54 7 6 E 1 190 11 2 11 F 1 15 1 9 6 G 1 1 6 4 1 2 8 34 26 35 H 1 1 3 11 I 8 2 4 15 10 K 30 60 4 3 5 L 18 1 6 11 7 M 2 1 6 1 N 1 1 2 20 4 3 P 9 1 3 4 29 10 Q 1 5 3 9 2 R 177 103 9 30 19 S 1 1 3 9 8 11 T 3 28 207 1 25 15 7 6 20 V 9 187 10 1 7 7 15 W 1 3 4 3 X 1 Y 211 194 12 9 8 Z — 1 3 4 unknown (?) not sequenced 1 1 1 1 1 1 1 1 7 12 13 sum of seq² 212 212 212 212 211 211 211 211 211 211 211 211 205 200 199 oomcaa³ 177 149 190 209 207 207 187 211 194 210 173 103 54 30 35 mcaa⁴ R A E D T A V Y Y C A R D R G rel. oomcaa⁵ 83% 70% 90% 99% 98% 98% 89% 100% 92% 100% 82% 49% 26% 15% 18% pos occupied⁶ 5 10 4 4 4 2 7 1 4 2 5 14 18 20 21 CDR III amino acid¹ 98 99 100 A B C D E F G H I J K 101 A 7 13 7 9 6 2 3 5 5 9 13 2 B C 13 5 1 2 11 3 2 1 D 11 7 10 4 2 3 10 3 3 1 3 2 146 E 6 3 1 13 1 1 1 F 3 5 4 5 5 6 3 5 7 2 1 1 65 1 G 34 17 35 17 14 23 10 5 1 5 3 2 32 6 H 3 4 3 2 9 2 1 3 1 2 8 1 I 6 11 4 4 3 1 3 10 3 3 2 1 2 K 2 11 3 1 L 26 13 4 12 8 2 6 3 10 3 2 1 M 1 2 1 32 N 4 6 4 3 2 2 6 2 5 2 P 6 5 5 6 9 8 2 3 2 1 3 9 Q 4 1 1 1 1 1 1 R 4 10 9 7 5 5 2 3 1 1 2 4 S 16 28 27 25 24 8 11 9 3 2 3 1 1 1 T 6 12 9 17 17 1 2 5 1 9 3 1 V 13 7 15 4 3 6 2 12 1 1 1 1 W 6 5 6 7 2 4 1 6 10 X 1 1 Y 16 14 17 5 8 18 20 13 20 25 28 32 28 Z — 12 21 35 54 73 87 102 110 126 135 134 120 91 71 21 unknown (?) 3 2 1 1 3 2 not sequenced 14 14 14 14 15 19 21 22 23 23 23 25 25 26 25 sum of seq² 198 198 198 197 196 192 190 189 188 188 188 186 186 185 186 oomcaa³ 34 28 35 54 73 87 102 110 126 135 134 120 91 71 146 mcaa⁴ G S G — — — — — — — — — — — D rel. oomcaa⁵ 17% 14% 18% 27% 37% 45% 54% 58% 67% 72% 71% 65% 49% 38% 78% pos occupied⁶ 20 20 19 20 19 20 17 14 14 12 12 13 12 8 11 Framework IV amino acid¹ 102 103 104 105 106 107 108 109 110 111 112 113 sum A 1 1 2 1767 B 1 13 C 470 D 2 1121 E 1 832 F 2 807 G 140 130 1 2743 H 4 179 I 15 1 1 651 K 13 933 L 10 1 91 2 1881 M 6 496 N 1 1 844 P 17 1 1 568 Q 111 949 R 8 1413 S 7 1 118 110 3009 T 123 27 122 1 1426 V 34 1 1 125 119 1851 W 158 686 X 26 Y 82 1598 Z 8 — 9 2 2 2 2 2 2 2 2 2 1 1 2023 unknown (?) 12 not sequenced 27 50 67 75 78 81 83 84 86 89 92 97 1650 sum of seq² 184 161 144 136 133 130 128 127 125 122 119 114 oomcaa³ 82 158 140 111 120 123 91 125 122 119 118 110 mcaa⁴ Y W G Q G T L V T V S S rel. oomcaa⁵ 45% 98% 97% 82% 98% 95% 71% 98% 98% 98% 99% 96% pos occupied⁶ 12 3 4 6 3 6 6 2 3 3 2 4

TABLE 6E Analysis of V heavy chain subgroup 4 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 A 19 1 1 B C D E 32 44 F G 54 1 53 2 H 4 2 I K 1 54 L 7 54 53 19 1 M N P 33 51 1 Q 52 50 51 20 7 R 1 S 33 52 T 1 52 V 47 1 34 W 20 X Y Z 1 — unknown (?) not sequenced 3 3 3 3 4 4 4 3 3 4 4 3 3 4 4 4 4 sum of seq² 54 54 54 54 53 53 53 54 54 53 53 54 54 53 53 53 53 oomcaa³ 52 47 50 54 51 32 33 54 33 53 53 34 54 51 52 44 52 mcaa⁴ Q V Q L Q E S G P G L V K P S E T rel. oomcaa⁵ 96% 87% 93% 100% 96% 60% 62% 100% 61% 100% 100% 63% 100% 96% 98% 83% 98% pos occupied⁶ 3 2 2 1 2 3 2 1 4 1 1 3 1 3 2 3 2 Framework I CDRI amino acid¹ 18 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 A 1 22 1 B C 53 D 1 4 1 1 1 E F 1 22 1 G 53 53 21 3 4 H 1 2 I 1 1 32 K 1 L 53 50 M N 1 1 2 2 P 2 3 Q 1 R 1 3 2 1 S 52 2 35 51 1 52 25 5 9 1 T 53 29 2 1 V 1 55 1 1 W 1 X Y 19 1 48 Z — 45 39 unknown (?) not sequenced 4 3 4 4 4 2 2 2 2 2 2 1 1 1 1 sum of seq² 53 54 53 53 53 55 55 55 55 55 55 56 56 56 56 56 56 oomcaa³ 53 52 50 53 53 29 55 35 53 53 51 32 52 25 45 39 48 mcaa⁴ L S L T C T V S G G S I S S — — Y rel. oomcaa⁵ 100% 96% 94% 100% 100% 53% 100% 64% 96% 96% 93% 57% 93% 45% 80% 70% 86% pos occupied⁶ 1 3 3 1 1 5 1 3 3 3 3 4 3 7 6 6 7 CDRI Framework II amino acid¹ 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 A 8 1 1 B C 1 D 1 E 1 56 22 F 1 1 1 G 8 55 55 56 1 H 2 I 51 54 1 K 54 L 1 1 55 2 M N 1 P 50 49 2 Q 56 1 1 R 57 3 2 9 S 44 1 3 7 T 3 1 1 V 3 1 W 2 56 57 56 X Y 52 1 15 Z — unknown (?) not sequenced 1 1 sum of seq² 56 56 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 oomcaa³ 52 56 44 57 51 57 56 50 49 55 54 55 55 56 56 54 56 22 mcaa⁴ Y W S W I R Q P P G K G L E W I G E rel. oomcaa⁵ 93% 100% 77% 100% 89% 100% 98% 88% 86% 96% 95% 96% 96% 98% 98% 95% 98% 39% pos occupied⁶ 4 1 5 1 5 1 2 5 2 3 2 2 2 2 2 3 2 8 CDR II amino acid¹ 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 A 1 B C D 1 1 2 E F 1 3 G 1 57 1 H 24 2 I 54 1 1 K 1 53 L 1 55 M N 21 2 40 53 P 54 1 Q R 1 2 3 S 1 52 49 1 2 56 T 8 5 1 54 1 1 1 V 3 1 1 W X Y 32 23 11 54 Z — 57 57 57 unknown (?) not sequenced 1 1 1 1 sum of seq² 57 57 57 57 57 57 57 57 57 57 57 57 56 56 56 56 57 oomcaa³ 54 32 57 57 57 24 52 57 49 54 40 54 53 54 56 55 53 mcaa⁴ I Y — — — H S G S T N Y N P S L K rel. oomcaa⁵ 95% 56% 100% 100% 100% 42% 91% 100% 86% 95% 70% 95% 95% 96% 100% 98% 93% pos occupied⁶ 2 6 1 1 1 5 2 1 7 4 6 2 3 3 1 2 3 CDR II Framework III amino acid¹ 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 A 1 1 1 1 B C D 1 55 1 E 1 1 F 1 54 G 1 H I 1 1 48 3 1 K 1 51 3 46 L 1 3 1 3 1 55 M 7 2 1 N 2 1 54 3 P Q 1 54 1 1 R 56 2 2 S 56 1 56 1 57 1 57 2 T 51 1 52 1 V 53 2 50 1 W X Y Z — unknown (?) not sequenced 1 1 sum of seq² 57 57 56 56 57 57 57 57 57 57 57 57 57 57 57 57 57 oomcaa³ 56 56 53 51 48 56 50 55 52 57 51 54 54 54 57 55 46 mcaa⁴ S R V T I S V D T S K N Q F S L K rel. oomcaa⁵ 98% 98% 95% 91% 84% 98% 88% 96% 91% 100% 89% 95% 95% 95% 100% 96% 81% pos occupied⁶ 2 2 4 5 3 2 4 3 5 1 6 2 2 4 1 3 8 Framework III CDR III amino acid¹ 82 A B C 83 84 85 86 87 88 89 90 91 92 93 94 95 A 55 57 57 56 3 B C 57 D 57 6 E 6 F 1 G 1 25 H 1 I 1 3 K 2 2 L 53 2 1 2 M 1 1 1 N 3 1 P Q R 2 1 54 4 S 1 44 55 1 2 1 1 1 T 4 53 55 1 1 V 2 54 1 55 1 1 4 W 1 X Y 57 56 Z — unknown (?) not sequenced 1 sum of seq² 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 56 oomcaa³ 53 44 55 54 53 55 57 57 55 57 55 57 56 57 56 54 25 mcaa⁴ L S S V T A A D T A V Y Y C A R G rel. oomcaa⁵ 93% 77% 96% 95% 93% 96% 100% 100% 96% 100% 96% 100% 98% 100% 98% 95% 45% pos occupied⁶ 4 7 3 3 3 3 1 1 2 1 3 1 2 1 2 4 12 CDR III amino acid¹ 96 97 98 99 100 A B C D E F G H I J K 101 A 3 3 2 5 4 2 2 4 2 1 1 1 12 B C 1 1 D 5 5 5 4 3 2 4 3 1 1 2 1 41 E 1 1 2 1 1 3 1 2 1 F 4 1 1 2 3 2 2 1 1 31 G 9 10 8 10 11 4 7 7 6 1 1 1 2 1 9 H 1 1 1 2 I 1 2 4 1 3 2 3 1 1 K 1 2 2 1 L 6 7 3 5 3 2 4 1 5 3 3 1 M 1 4 3 1 2 1 9 N 3 2 1 1 5 1 1 2 P 4 5 3 1 1 2 1 1 1 2 3 1 2 1 Q 1 1 1 1 1 3 1 R 12 2 5 5 3 2 3 1 2 2 1 S 4 8 8 1 2 5 7 4 2 1 1 1 T 2 1 3 4 4 3 3 1 1 1 V 2 2 5 4 4 7 3 1 2 1 W 2 1 2 2 4 5 1 1 2 2 1 3 2 X Y 1 4 5 3 6 4 2 3 4 8 4 8 3 5 8 2 Z — 1 2 4 6 9 11 16 23 27 29 34 31 14 4 unknown (?) 1 1 1 1 not sequenced 1 1 1 1 2 3 3 6 7 8 9 9 10 11 11 11 11 sum of seq² 56 56 56 56 55 54 54 51 50 49 48 48 47 46 46 46 46 oomcaa³ 12 10 8 10 11 7 9 11 16 23 27 29 34 31 14 31 41 mcaa⁴ R G G G G V — — — — — — — — — F D rel. oomcaa⁵ 21% 18% 14% 18% 20% 13% 17% 22% 32% 47% 56% 60% 72% 67% 30% 67% 89% pos occupied⁶ 16 16 16 16 16 16 18 18 13 15 13 10 9 8 5 4 4 Framework IV amino acid¹ 102 103 104 105 106 107 108 109 110 111 112 113 sum A 1 1 332 B C 113 D 210 E 176 F 135 G 41 40 1 674 H 1 1 45 I 9 1 282 K 3 278 L 4 19 540 M 9 43 N 1 204 P 3 2 2 281 Q 29 334 R 1 4 1 250 S 1 1 36 33 986 T 1 33 8 34 532 V 12 36 36 488 W 46 267 X Y 16 455 Z 1 — 466 unknown (?) 4 not sequenced 10 11 16 17 17 20 20 21 21 21 21 22 426 sum of seq² 47 46 41 40 40 37 37 36 36 36 36 35 oomcaa³ 16 46 41 29 40 33 19 36 34 36 36 33 mcaa⁴ Y W G Q G T L V T V S S rel. oomcaa⁵ 34% 100% 100% 73% 100% 89% 51% 100% 94% 100% 100% 94% pos occupied⁶ 8 1 1 6 1 5 4 1 3 1 1 2

TABLE 6F Analysis of V heavy chain subgroup 5 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 A 1 1 89 1 1 B C 1 D 2 E 88 1 2 4 93 92 F 1 G 1 92 94 H I K 94 94 L 1 91 2 M 3 N P 1 1 94 Q 3 92 1 90 3 R 1 1 1 1 S 92 94 T V 90 89 1 91 W X Y Z — unknown (?) not sequenced 5 5 5 5 4 4 4 4 2 2 2 2 2 2 2 2 2 sum of seq² 92 92 92 92 93 93 93 93 95 95 95 95 95 95 95 95 95 oomcaa³ 88 90 92 91 89 90 92 92 89 93 91 94 94 94 94 92 94 mcaa⁴ E V Q L V Q S G A E V K K P G E S rel. oomcaa⁵ 96% 98% 100% 99% 96% 97% 99% 99% 94% 98% 96% 99% 99% 99% 99% 97% 99% pos occupied⁶ 3 3 1 2 4 3 2 2 4 2 3 2 2 2 2 2 2 Framework I CDRI amino acid¹ 18 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 A 3 2 4 B C 96 1 1 D 2 2 E 2 1 F 3 6 97 2 G 92 93 1 H 1 4 I 96 4 K 77 89 1 L 95 M 1 1 N 1 2 4 14 2 P 1 Q 1 4 R 17 1 1 2 S 94 1 90 84 10 61 2 T 2 5 75 16 V W X Y 90 87 Z — 97 97 unknown (?) not sequenced 2 1 1 1 1 1 1 1 1 1 sum of seq³ 95 96 96 96 96 96 96 96 96 96 97 97 97 97 97 97 97 oomcaa³ 95 77 96 94 96 89 92 90 93 90 84 97 75 61 97 97 87 mcaa⁴ L K I S C K G S G Y S F T S — — Y rel. oomcaa⁵ 100% 80% 100% 98% 100% 93% 96% 94% 97% 94% 87% 100% 77% 63% 100% 100% 90% pos occupied⁶ 1 4 1 2 1 5 3 4 3 2 7 1 5 8 1 1 5 CDRI Framework II amino acid¹ 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 A 8 1 1 1 B C D 1 E 3 97 F 1 G 72 97 96 95 H 1 I 93 1 75 K 1 94 L 1 2 94 2 2 M 1 1 92 89 N P 1 96 2 Q 97 1 R 1 95 1 1 14 S 2 15 1 T 2 1 1 3 V 1 93 2 5 1 1 W 93 97 94 X Y 3 Z — unknown (?) not sequenced sum of seq² 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 oomcaa¹ 93 93 72 97 93 95 97 92 96 97 94 96 94 97 94 89 95 75 mcaa⁴ W I G W V R Q M P G K G L E W M G I rel. oomcaa⁵ 96% 96% 74% 100% 96% 98% 100% 95% 99% 100% 97% 99% 97% 100% 97% 92% 98% 77% pos occupied⁶ 4 4 5 1 4 3 1 5 2 1 2 2 3 1 2 4 3 7 CDR II amino acid¹ 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 A 1 2 1 6 1 B C 1 1 1 D 14 8 93 77 E 2 3 2 F 2 2 91 G 69 1 1 H 3 1 I 92 4 1 1 K 2 L 1 1 4 M 1 N 2 14 2 P 1 93 1 95 1 1 Q 91 R 1 78 3 S 1 16 96 2 2 95 1 95 1 T 1 1 85 2 1 V 2 1 W X Y 76 12 92 Z — 97 97 unknown (?) not sequenced sum of seq² 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 oomcaa³ 92 76 93 97 97 69 93 96 77 85 78 92 95 95 95 91 91 mcaa⁴ I Y P — — G D S D T R Y S P S F Q rel. oomcaa⁵ 95% 78% 96% 100% 100% 71% 96% 99% 79% 88% 80% 95% 98% 98% 98% 94% 94% pos occupied⁶ 5 6 5 1 1 6 4 2 6 4 5 4 3 3 3 4 4 CDR II Framework III amino acid¹ 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 A 88 1 91 B C 1 D 2 97 1 E 2 1 F 1 3 1 G 94 H 15 3 I 3 88 91 K 93 L 2 96 M 3 1 N 7 P 1 1 Q 81 1 93 R 1 1 1 1 S 1 95 96 1 87 2 1 1 T 96 4 2 94 2 V 93 2 9 2 1 W X Y 94 Z — unknown (?) not sequenced sum of seq² 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 oomcaa³ 94 81 93 96 88 95 88 97 93 96 91 87 94 91 94 96 93 mcaa⁴ G Q V T I S A D K S I S T A Y L Q rel. oomcaa⁵ 97% 84% 96% 99% 91% 98% 91% 100% 96% 99% 94% 90% 97% 94% 97% 99% 96% pos occupied⁶ 3 3 3 2 5 2 2 1 4 2 4 4 3 5 4 2 3 Framework III CDR III amino acid¹ 82 A B C 83 84 85 86 87 88 89 90 91 92 93 94 95 A 1 96 93 92 1 B C 1 95 D 96 E 1 1 F 2 6 G 3 1 4 1 H 10 I 2 9 K 91 1 1 1 L 97 2 11 M 84 N 2 2 2 P 5 Q 1 3 R 1 1 3 3 92 7 S 90 91 96 5 1 1 T 1 1 1 1 88 1 1 1 V 1 2 2 W 95 1 X Y 94 89 Z — unknown (?) not sequenced 1 2 2 2 2 52 sum of seq² 97 97 97 97 97 97 97 97 97 97 97 96 95 95 95 95 45 oomcaa³ 95 90 91 97 91 96 96 96 88 93 84 94 89 95 92 92 11 mcaa⁴ W S S L K A S D T A M Y Y C A R L rel. oomcaa⁵ 98% 93% 94% 100% 94% 99% 99% 99% 91% 96% 87% 98% 94% 100% 97% 97% 24% pos occupied⁶ 3 5 4 1 5 2 2 2 4 2 5 2 2 1 3 4 13 CDR III amino acid¹ 96 97 98 99 100 A B C D E F G H I J K 101 A 1 2 3 4 3 2 1 1 4 2 B C 1 1 1 2 1 D 3 3 3 3 1 2 1 1 2 2 1 1 2 37 E 1 1 2 1 1 1 1 F 1 3 3 2 1 26 G 9 11 12 12 5 2 4 3 10 2 1 5 H 1 2 1 1 1 I 3 2 2 1 1 4 1 1 1 1 K 1 1 3 1 2 L 2 3 1 1 2 5 1 1 1 M 2 1 1 1 1 1 1 10 N 1 2 1 1 2 1 2 P 1 4 3 1 2 1 1 1 1 Q 2 1 1 4 2 1 2 3 R 9 2 2 2 1 2 S 3 2 6 4 4 5 3 5 3 2 2 1 1 T 3 2 1 2 6 3 3 6 1 1 V 4 4 1 1 2 1 W 2 1 1 2 1 1 1 X Y 1 6 3 6 9 8 7 2 1 2 6 8 9 9 10 1 Z — 1 1 2 8 10 16 23 30 30 31 32 30 22 7 2 unknown (?) 1 1 1 1 not sequenced 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 53 52 sum of seq² 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 44 45 oomcaa³ 9 11 12 12 9 8 10 16 23 30 30 31 32 30 22 26 37 mcaa⁴ G G G G Y Y — — — — — — — — — F D rel. oomcaa⁵ 20% 24% 27% 27% 20% 18% 22% 36% 51% 67% 67% 69% 71% 67% 49% 59% 82% pos occupied⁶ 16 14 18 16 15 16 15 14 11 11 9 8 4 6 6 4 5 Framework IV amino acid¹ 102 103 104 105 106 107 108 109 110 111 112 113 sum A 1 611 B C 205 D 1 458 E 1 404 F 2 256 G 41 41 1065 H 44 I 9 2 588 K 3 650 L 2 25 1 549 M 8 303 N 64 P 2 1 1 414 Q 34 612 R 3 351 S 2 40 39 1545 T 1 40 8 39 604 V 11 40 41 594 W 43 432 X Y 13 738 Z — 2 635 unknown (?) 4 not sequenced 52 54 56 56 56 56 56 56 56 56 56 57 1678 sum of seq³ 45 43 41 41 41 41 41 41 41 41 41 40 oomcaa³ 13 43 41 34 41 40 25 40 39 41 40 39 mcaa⁴ Y W G Q G T L V T V S S rel. oomcaa⁵ 29% 100% 100% 83% 100% 98% 61% 98% 95% 100% 98% 98% pos occupied⁶ 10 1 1 4 1 2 3 2 2 1 2 2

TABLE 6G Analysis of V heavy chain subgroup 6 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 A 1 B C D E F G 52 67 H I K 68 L 52 68 1 M N P 68 67 Q 52 52 51 52 68 R 1 1 S 52 1 68 T 68 V 52 66 W X Y Z — unknown (?) not sequenced 22 22 22 22 22 22 22 22 6 6 6 6 6 6 6 6 6 sum of seq² 52 52 52 52 52 52 52 52 68 68 68 68 68 68 68 68 68 oomcaa³ 52 52 52 52 51 52 52 52 68 67 68 66 68 67 68 68 68 mcaa⁴ Q V Q L Q Q S G P G L V K P S Q T rel. oomcaa⁵ 100% 100% 100% 100% 98% 100% 100% 100% 100% 99% 100% 97% 100% 99% 100% 100% 100% pos occupied⁶ 1 1 1 1 2 1 1 1 1 2 1 3 1 2 1 1 1 Framework I CDRI amino acid¹ 18 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 A 1 67 66 B C 68 D 68 1 E F 2 1 G 1 69 3 1 H I 64 2 K 3 L 67 1 68 M N 1 2 66 P 1 Q R 2 1 S 66 1 1 69 69 68 66 67 T 67 2 1 4 V 1 1 4 70 6 W 1 X Y 1 Z — unknown (?) 1 not sequenced 6 6 6 5 5 5 5 5 5 5 5 4 4 sum of seq² 68 68 68 69 69 69 69 69 69 69 69 70 70 74 74 74 74 oomcaa³ 67 66 68 67 68 67 64 69 69 68 69 70 68 66 66 67 66 mcaa⁴ L S L T C A I S G D S V S S N S A rel. oomcaa⁵ 99% 97% 100% 97% 99% 97% 93% 100% 100% 99% 100% 100% 97% 89% 89% 91% 89% pos occupied⁶ 2 3 1 3 2 3 3 1 1 2 1 1 2 5 6 3 4 CDRI Framework II amino acid¹ 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 A 67 1 B C D 1 E 74 F 1 1 G 2 74 74 1 H 1 I 1 70 K 1 1 L 1 74 74 M N 70 P 73 Q 72 R 74 73 73 S 3 1 74 1 73 T 1 V 2 W 74 74 74 X Y 1 Z — unknown (?) not sequenced sum of seq² 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 oomcaa³ 67 74 70 74 70 74 72 74 73 73 73 74 74 74 74 74 74 73 mcaa⁴ A W N W I R Q S P S R G L E W L G R rel. oomcaa⁵ 91% 100% 95% 100% 95% 100% 97% 100% 99% 99% 99% 100% 100% 100% 100% 100% 100% 99% pos occupied⁶ 5 1 5 1 4 1 3 1 2 2 2 1 1 1 1 1 1 2 CDR II amino acid¹ 51 52 A B C 53 54 55 56 57 58 59 60 61 62 63 64 A 1 1 73 1 B C 1 D 68 1 E 1 3 7 1 F 2 1 1 7 G 1 1 1 H 1 1 I 1 K 1 66 1 67 L 1 5 2 M N 1 2 65 1 1 P 1 1 Q 2 R 72 1 1 1 3 S 1 72 2 2 1 1 73 T 73 5 4 V 58 72 W 73 X Y 72 72 60 1 72 Z — 74 unknown (?) not sequenced sum of seq² 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 oomcaa³ 73 72 72 72 74 72 66 73 60 65 68 72 73 58 73 72 67 mcaa⁴ T Y Y R — S K W Y N D Y A V S V K rel. oomcaa⁵ 99% 97% 97% 97% 100% 97% 89% 99% 81% 88% 92% 97% 99% 78% 99% 97% 91% pos occupied⁶ 2 2 3 3 1 3 5 2 7 6 5 3 2 7 2 2 5 CDR II Framework III amino acid¹ 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 A 2 6 1 B C D 2 73 E 2 F 71 G 8 H 1 2 I 65 2 71 1 1 K 1 70 L 4 1 1 74 M 1 N 69 74 P 66 Q 1 72 71 R 73 1 1 S 66 1 2 1 73 74 T 69 1 71 1 2 V 4 2 1 2 W X Y Z — unknown (?) not sequenced sum of seq² 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 oomcaa³ 66 73 65 69 71 69 66 73 71 73 70 74 72 71 74 74 71 mcaa⁴ S R I T I N P D T S K N Q F S L Q rel. oomcaa⁵ 89% 99% 88% 93% 96% 93% 89% 99% 96% 99% 95% 100% 97% 96% 100% 100% 96% pos occupied⁶ 2 2 4 4 3 4 4 2 4 2 3 1 3 3 1 1 3 Framework III CDR III amino acid¹ 82 A B C 83 84 85 86 87 88 89 90 91 92 93 94 95 A 1 74 69 11 B C 73 D 3 73 19 E 73 10 F 1 3 1 1 G 1 1 16 H 1 I 2 K 4 1 1 L 72 1 M 1 1 2 N 63 1 1 P 70 Q 1 R 1 1 69 1 S 1 73 1 3 3 5 T 1 73 74 1 1 V 1 73 70 3 1 4 W 1 X Y 73 70 Z — unknown (?) not sequenced 1 sum of seq² 74 74 74 74 74 73 74 74 74 74 74 74 74 74 74 74 73 oomcaa³ 72 63 73 73 73 70 73 73 74 74 70 73 70 73 69 69 19 mcaa⁴ L N S V T P E D T A V Y Y C A R D rel. oomcaa⁵ 97% 85% 99% 99% 99% 96% 99% 99% 100% 100% 95% 99% 95% 99% 93% 93% 26% pos occupied⁶ 3 7 2 2 2 2 2 2 1 1 3 2 3 2 4 4 14 CDR III amino acid¹ 96 97 98 99 100 A B C D E F G H I J K 101 A 1 3 12 4 3 2 5 8 10 1 B C 1 1 1 1 1 D 4 3 7 4 3 1 6 1 1 1 62 E 4 2 1 2 2 1 2 1 F 1 1 1 2 3 2 1 38 4 G 4 15 15 11 8 6 2 5 1 8 6 1 17 H 1 1 1 1 1 1 1 1 1 I 1 2 2 5 1 K 1 1 1 1 1 1 L 8 4 2 3 2 1 1 5 8 M 1 1 5 11 N 3 1 2 1 1 1 3 2 1 1 3 P 10 4 5 3 5 1 1 Q 1 1 1 1 1 R 7 8 1 8 8 3 1 1 5 1 S 5 5 7 6 7 3 4 2 1 1 T 1 4 3 4 4 6 3 1 1 C 5 1 9 4 9 4 1 1 2 W 6 8 3 2 4 4 4 X Y 6 4 2 2 2 6 6 2 4 2 1 8 8 12 12 Z — 2 3 7 14 23 25 33 41 47 53 54 57 56 50 28 12 4 unknown (?) 6 1 5 not sequenced 1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 sum of seq² 72 71 71 72 72 72 72 72 72 72 72 72 72 72 72 72 72 oomcaa³ 10 15 15 14 23 25 33 41 47 53 54 57 56 50 28 38 62 mcaa⁴ P G G — — — — — — — — — — — — F D rel. oomcaa⁵ 14% 21% 21% 19% 32% 35% 46% 57% 65% 74% 75% 79% 78% 69% 39% 53% 86% pos occupied⁶ 20 19 15 17 16 16 13 14 11 8 8 4 5 7 6 6 5 Framework IV amino acid¹ 102 103 104 105 106 107 108 109 110 111 112 113 sum A 2 494 B C 147 D 1 403 E 186 F 2 2 150 G 49 50 571 H 2 18 I 9 3 1 304 K 1 1 293 L 5 26 632 M 8 31 N 436 P 4 6 1 387 Q 40 539 R 2 495 S 4 1 1 43 46 1271 T 45 4 45 640 V 21 2 46 48 647 W 65 5 398 X Y 19 518 Z — 2 585 unknown (?) 13 not sequenced 5 8 23 24 23 24 25 25 28 25 28 26 580 sum of seq² 68 65 50 49 50 49 48 48 45 48 45 47 oomcaa³ 21 65 49 40 50 45 26 46 45 48 43 46 mcaa⁴ V W G Q G T L V T V S S rel. oomcaa⁵ 31% 100% 98% 82% 100% 92% 54% 96% 100% 100% 96% 98% pos occupied⁶ 9 1 2 4 1 3 7 3 1 1 2 2 Appendix to Tables 1A–C A. References of Rearranged Sequences References of Rearranged Human Kappa Sequences Used for Alignment

-   1 Alescio-Zonta, L. & Baglioni, C. (1970) Eur. J. Biochem.,     15,450–463. -   2 Andrews, D. W. & Capra, J. D. (1981) Biochemistry, 20, 5816–5822. -   3 Andris, J. S., Ehrlich, P. H., Ostberg, L. &     Capra, J. D. (1992) J. Immunol., 149, 4053–4059. -   4 Atkinson, P. M., Lampman, G. W., Furie, B. C., Naparstek, Y.,     Schwartz, R. S., Stollar, B. D. & Furie, B. (1985) J. Clin. Invest.,     75, 1138–1143. -   5 Aucouturier, P., Bauwens, M., Khamlichi, A. A., Denoroy, L.     Spinelli, S., Touchard, G., Preud'homme, J.-L & Cogne, M. (1993) J.     Immunol., 150, 3561–3568. -   6 Avila, M. A., Vazques, J., Danielsson, L, Fernandez De     Cossio, M. E. & Borrebaeck, C. A. K. (1993) Gene, 127, 273–274. -   7 Barbas Iii, C. F., Crowe, Jr., J. E., Cababa, D., Jones, T. M.,     Zebedee, S. L., Murphy, B. R., Chanock, R. M. & Burton, D. R. (1992)     Proc. Natl. Acad. Sci. Usa, 89, 10164–10168. -   8 Barbas, CF., Iii, et al. (1993) J-Mol-Biol., 230, 812–23. -   9 Bentley, D. L. & Rabbitts, T. H. (1980) Nature, 288, 730–733. -   10 Bentley, D. L. & Rabbitts, T. H. (1983) Cell, 32, 181–189. -   11 Bentley, D. L. (1984) Nature, 307, 77–80. -   12 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K. &     Teng, N. N. H. (1993) J. Immunol., 151, 5011–5021. -   13 Blaison, G., Kuntz, J.-L & Pasquali, J.-L (1991) Eur. J.     Immunol., 21, 1221–1227. -   14 Braun, H., Leibold, W., Barnikol, H. U. &     Hilschmann, N. (1971) Z. Physiol. Chem., 352, 647–651; (1972) Z.     Physiol. Chem., 353, 1284–1306. -   15 Capra, J. D. & Kehoe, J. M. (1975) Adv. Immunology, 20, 1–40.;     Andrews, D. W. & Capra, J. D. (1981) Proc. Nat. Acad. Sci. Usa, 78,     3799–3803. -   16 Capra, J. D. & Kehoe, J. M. (1975) Adv. Immunology, 20, 1–40.;     Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C.,     Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322–1325. -   17 Chastagner, P., Theze, J. & Zouali, M. (1991) Gene, 101, 305–306. -   18 Chen, P. P., Robbins, D. L, Jirik, F. R., Kipps, T. J. &     Carson, D. A. (1987) J. Exp. Med, 166, 1900–1905. -   19 Chen, P. P., Robbins, D. L, Jirik, F. R., Kipps, T. J. &     Carson, D. A. (1987) J. Exp. Med, 166, 1900–1905; Liu, M.-F.,     Robbins, D. L., Crowley, J. J., Sinha, S., Kozin, F., Kipps, T. J.,     Carson, D. A. & Chen. P. P. (1989) J. Immunol., 142, 688–694. -   20 Chersi, A. & Natali, P. G. (1978) Immunochemistry, 15, 585–589. -   21 Co, M. S., Deschamps, M., Whitley, R. J. & Queen, C. (1991) Proc.     Natl. Acad. Sci. Usa, 88, 2869–2873. -   22 Cuisinier, A.-M., Fumoux, F., Fougereau, M. & Tonnelle, C. (1992)     Mol. Immunol., 29, 1363–1373. -   23 Davidson, A., Manheimer-Lory, A., Aranow, C., Peterson, R.,     Hannigan, N. & Diamond, B. (1990) J. Clin. Invest., 85, 1401–1409. -   24 Denomme, G. A., Mahmoudi, M., Edwards. J. Y., Massicotte, H.,     Cairns, E. & Bell, D. A. (1993) Hum. Antibod. Hybridomas, 4, 98–103. -   25 Dersimonian, H., Mcadam, K. P. W. J., Mackworth-Young, C. &     Stollar, B. D. (1989) J. Immunol., 142, 4027–4033. -   26 Dreyer, W. J., Gray, W. R. & Hood, L. (1967) Cold Spring Harbor     Symp. Quantitative Biol., 32, 353–367. -   27 Ebeling, S. B., Schutte, M. E. M. & Logtenberg, T. (1993) Eur. J.     Immunol., 23, 1405–1408. -   28 Eulitz, M. & Kley, H.-P. (1977) Immunochem., 14, 289–297. -   29 Eulitz, M. & Linke, R. P. (1982) Z. Physiol. Chem., 363,     1347–1358. -   30 Eulitz, M., Breuer, M., Eblen, A., Weiss, D. T. &     Solomon, A. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O.     Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark,     Kluwer Academic -   31 Eulitz, M., Gotze, D. & Hilschmann, N. (1972) Z. Physiol. Chem.,     353, 487–491; Eulitz, M. & Hilschmann, N. (1974) Z. Physiol. Chem.,     355, 842–866. -   32 Eulitz, M., Kley, H. P. & Zeitler, H. J. (1979) Z. Physiol.     Chem., 360, 725–734. -   33 Ezaki, I., Kanda, H., Sakai, K., Fukui, N., Shingu, M.,     Nobunaga, M. & Watanabe, T. (1991) Arthritis And Rheumatism, 34,     343–350. -   34 Felgenhauer, M., Kohl, J. & Ruker, F. (1990) Nucl. Acids Res.,     18, 4927. -   35 Ferri, G., Stoppini, M., Iadarola, P., Bellotti, V. &     Merlini, G. (1989) Biochim. Biophys. Acta, 995, 103–108. -   36 Gillies, S. D. Dorai, H., Wesolowski, J., Majeau, G., Young, D.,     Boyd, J., Gardner, J. & James, K. (1989) Bio/Tech., 7.799–804. -   37 Goni, F. & Frangione, B. (1983) Proc. Nat. Acad. Sci. Usa, 80,     48374841. -   38 Goni, F. R., Chen, P. P., Mcginnis, D., Arjonilla, M. L.,     Fernandez, J., Carson, D., Solomon, A, Mendez, E. &     Frangione, B. (1989) J. Immunol., 142, 3158–3163. -   39 Gorman, S. D., Clark, M. R., Routledge, E. G., Cobbold, S. P. &     Waldmann, H. (1991) Proc. Natl. Acad. Sci. Usa, 88, 4181–4185. -   40 Gottlieb, P. D., Cunningham, B. A., Rutishauser, U. &     Edelman, G. M. (1970) Biochemistry, 9, 3155–3161. -   41 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M.,     Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P.,     Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R. &     Winter, G. (1993) Embo J., 12, 725–734. -   42 Hieter, P. A., Max, E. E., Seidman, J. G., Maizel, J. V., Jr. &     Leder, P. (1980) Cell, 22, 197–207; Klobeck, H. G, Meindl, A.,     Combriato, G., Solomon, A. & Zachau, H. G. (1985) Nucl. Acids Res.,     13, 6499–6513; Weir, L. & Leder, P. (1986) -   43 Hilschmann, N. & Craig, L. C. (1965) Proc. Nat. Acad. Sci. Usa,     53, 1403–1409; Hilschmann, N. (1967) Z. Physiol. Chem., 348,     1077–1080. -   44 Hilschmann, N. & Craig, L. C. (1965) Proc. Nat. Acad. Sci. Usa,     53, 1403–1409; Hilschmann, N. (1967) Z. Physiol. Chem., 348,     1718–1722; Hilschmann, N. (1969) Naturwissenschaften, 56, 195–205. -   45 Hirabayashi, Y., Munakata, Y., Sasaki, T. & Sano, H. (19921 Nucl.     Acids Res., 20, 2601. -   46 Jaenichen, H.-R., Pech, M., Lindenmaier, W., Wildgruber, N. &     Zachau, H. G. (1984) Nuc. Acids Res., 12, 5249–5263. -   47 Jirik, F. R., Sorge, J., Fong, S., Heitzmann, J. G., Curd, J. G.,     Chen, P. P., Goldfien, R. & Carson, D. A (1986) Proc. Nat. Acad.     Sci. Usa, 83, 2195–2199. -   48 Kaplan, A. P. & Metzger, H. (1969) Biochemistry, 8, 3944–3951.;     Klapper, D. G. & Capra, J. D. (1976) Ann. Immunol. (Inst. Pasteur),     127c, 261–271. -   49 Kennedy, M. A. (1991) J. Exp. Med., 173, 1033–1036. -   50 Kim, H. S. & Deutsch, H. F. (1988) Immunol., 64, 573–579. -   51 Kipps, T. J., Tomhave, E., Chen, P. P. & Carson, D. A. (1988) J.     Exp. Med., 167, 840–852. -   52 Kipps, T. J., Tomhave, E., Chen, P. P. & Fox, R. I. (1989) J.     Immunol., 142, 4261–4268. -   53 Klapper, D. G. & Capra, J. D. (1976) Ann. Immunol. (Inst.     Pasteur), 127c, 261–271. -   54 Klein, U., Kuppers, R. & Rajewsky, K. (1993) Eur. J. Immunol.,     23, 3272–3277. -   55 Klobeck, H. G, Meindl, A., Combriato, G., Solomon, A. &     Zachau, H. G. (1985) Nucl. Acids Res., 13, 6499–6513. -   56 Klobeck, H. G., Bornkammm, G. W., Combriato, G., Mocikat, R.,     Pohlenz, H. D. & Zachau, H. G. (1985) Nucl. Acids Res., 13,     6515–6529. -   57 Klobeck, H. G., Combriato, G. & Zachau, H. G. (1984) Nuc. Acids     Res., 12, 6995–7006. -   58 Klobeck, H. G., Solomon, A. & Zachau, H. G. (1984) Nature, 309,     73–76. -   59 Knight, G. B., Agnello, V., Bonagura, V., Barnes, J. L.,     Panka, D. J. & Zhang, Q.-X. (1993) J. Exp. Med., 178, 1903–1911. -   60 Kohler, H., Shimizu, A., Paul, C. & Putnam, F. W. (1970) Science,     169, 56–59. (Kaplan, A. P. & Metzger, H. (1969) Biochemistry, 8,     3944–3951.) -   61 Kratzin, H., Yang, C. Y., Krusche, J. U. &     Hilschmann, N. (1980) Z. Physiol. Chem., 361, 1591–1598. -   62 Kunicki, T. J., Annis, D. S., Gorski, J. &     Nugent, D. J. (1991) J. Autoimmunity, 4, 433–446. -   63 Larrick, J. W., Wallace, E. F., Coloma, M. J., Bruderer, U.,     Lang, A. B. & Fry, K. E. (1992) Immunological Reviews, 130, 69–85. -   64 Laure, C. J., Watanabe, S. & Hilschmann, N. (1973) Z. Physiol.     Chem., 354, 1503–1504. -   65 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C.,     Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322–1325. -   66 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C.,     Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322–1325. -   67 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C.,     Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322–1325.     Pons-Estel, B., Goni, F., Solomon, A. & Frangione, B. (1984) J. Exp.     Med., 160, 893. -   68 Levy, S., Mendel, E., Kon, S., Avnur, Z. & Levy, R. (1988) J.     Exp. Med., 168, 475–489. -   69 Liepnieks, J. J., Dwulet, F. E. & Benson, M. D. (1990) Mol.     Immunol., 27, 481–485. -   70 Manheimer-Lory, A., Katz, J. B., Pillinger, M., Ghossein, C.,     Smith, A. & Diamond, B. (1991) J. Exp. Med., 174, 1639–1652. -   71 Mantovani, L, Wilder, R. L. & Casali, P. (1993) J. Immunol., 151,     473–488. -   72 Mariette, X., Tsapis, A. & Brouet, J.-C. (1993) Eur. J. Immunol.,     23, 846–851. -   73 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J.,     Griffiths, A. D. & Winter, G. (1991) J. Mol. Biol., 222, 581–597. -   74 Marsh, P., Mills, F. & Gould, H. (1985) Nuc. Acids Res., 13,     6531–6544. -   75 Middaugh, C. R. & Litman, G. W. (1987) J. Biol. Chem., 262,     3671–3673. -   76 Milstein, C. & Deverson, E. V. (1971) Biochem., 123, 945–958. -   77 Milstein, C. (1969) Febs Letters, 2, 301–304. -   78 Milstein, C. (1969) Febs Letters, 2, 301–304. -   79 Milstein, C. P. & Deverson, E. V. (1974) Eur. J. Biochem., 49,     377–391. -   80 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D. &     Hersh, E. M. (1993) Mol. Immunol., 30, 1543–1551. -   81 Nakatani, T., Nomura, N., Horigome, K., Ohtsuka, H. &     Noguchi, H. (1989) Bio/Tech., 7, 805–810. -   82 Newkirk, M., Chen, P. P., Carson, D., Posnett, D. &     Capra, J. D. (1986) Mol. Immunol., 23, 239–244. -   83 Newkirk, M. M., Gram, H., Heinrich, G. F., Ostberg, L.,     Capra, J. D. & Wasserman, R. L. (1988) J. Clin. Invest., 81,     1511–1518. -   84 Newkirk, M. M., Mageed, R. A., Jefferis, R., Chen, P. P. &     Capra, J. D. (1987) J. Exp. Med., 166, 550–564. -   85 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos,     M., Kozin, F., Carson, D. A. & Chen, P. P. (1992) J. Exp. Med., 175,     831–842. -   86 Palm, W. & Hilschmann, N. (1973) Z. Physiol. Chem., 354,     1651–1654; (1975) Z. Physiol. Chem., 356, 167–191. -   87 Pascual, V., Victor, K., Lelsz, D., Spellerberg, M. B.,     Hamblin, T. J., Thompson, K. M., Randen, I., Natvig, J.,     Capra, J. D. & Stevenson, F. K. (1991) J. Immunol., 146, 4385–4391. -   88 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M.,     Forre, O., Fu, S.-M., Natvig, J. B. & Capra, J. D. (1992) Scand. J.     Immunol., 36, 349–362. -   89 Pech, M. & Zachau, H. G. (1984) Nuc. Acids Res., 12, 9229–9236. -   90 Pech, M., Jaenichen, H.-R., Pohlenz, H.-D., Neumaier, P. S.,     Klobeck, H.-G. & Zachau, H. G. (1984) J. Mol. Biol., 176, 189–204. -   91 Pons-Estel, B., Goni, F., Solomon, A & Frangione, B. (1984) J.     Exp. Med., 160, 893–904. -   92 Portolano, S., Mclachlan, S. M. & Rapoport, B. (1993) J.     Immunol., 151, 2839–2851. -   93 Portolano, S., Seto, P., Chazenbalk, G. D., Nagayama, Y.,     Mclachlan, S. M. & Rapoport, B. (1991) Biochem. Biophys. Res.     Commun., 179, 372–377. -   94 Pratt, L. F., Rassenti, L, Larrick. J., Robbins, B., Banks, P. M.     & Kipps, T. J. (1989) J. Immunol., 143,699–705. -   95 Prelli, F., Tummolo, D., Solomon, A & Frangione, B. (1986) J.     Immunol., 136, 4169–4173. -   96 Putnam, F. W., Whitley, E. J., Jr., Paul, C. &     Davidson, J. N. (1973) Biochemistry, 12, 3763–3780. -   97 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O.,     Capra, J. D. & Natvig, J. B. (1993) Eur. J. Immunol., 23, 1220–1225. -   98 Rassenti, L. Z., Pratt, L. F., Chen, P. P., Carson, D. A. &     Kipps, T. J. (1991) J. Immunol., 147, 1060–1066. -   99 Reidl, L. S., Friedman, D. F., Goldman, J., Hardy, R. R.,     Jefferies, L. C. & Silberstein, L. E. (1991) J. Immunol., 147,     3623–3631. -   100 Riechmann, L., Clark, M., Waldmann, H. & Winter, G. (1988)     Nature, 332, 323–327. -   101 Riesen, W., Rudikoff, S., Oriol, R. & Potter, M. (1975)     Biochemistry, 14, 1052–1057; Riesen, W. F., Braun, D. G. &     Jaton, J. C. (1976) Proc. Nat. Acad. Sci. Usa, 73, 2096–2100;     Riesen, W. F. & Jaton, J. C. (1976) Biochemistry, 15, 3829. -   102 Rodilla Sala, E., Kratzin, D. H., Pick, A. I. &     Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B.     Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P.     Westermark, Kluwer Academic -   103 Schiechl, H. & Hilschmann, N. (1971) Z. Physiol. Chem., 352,     111–115; (1972) Z. Physiol. Chem., 353, 345–370. -   104 Schneider, M. & Hilschmann, N. (1974) Z. Physiol. Chem., 355,     1164–1168. -   105 Shearman, C. W., Pollock, D., White, G., Hehir, K., Moore, G.     P., Kanzy, E. J. & Kurrle, R. (1991) J. Immunol., 147, 4366–4373. -   106 Shinoda, T. (1973) J. Biochem., 73, 433–446. -   107 Shinoda, T. (1975) J. Biochem., 77, 1277–1296. -   108 Shinoda, T., Takenawa, T., Hoshi, A. & Isobe, T. (1990) In     Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A.     Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic     Publishers, Dordrecht/Boston/London, Pp. 157- -   109 Silberstein, L. E., Litwin, S. & Carmack, C. E. (1989) J. Exp.     Med., 169, 1631–1643. -   110 Sims, M. J., Hassal, D. G., Brett, S., Rowan, W., Lockyer, M.     J., Angel, A., Lewis, A. P., Hale, G., Waldmann, H. &     Crowe, J. S. (1993) J. Immunol., 151, 2296–2308. -   111 Spatz, L. A., Wong, K. K., Williams, M., Desai, R., Golier, J.,     Berman, J. E., Alt, F. W. & Latov, N. (1990) J. Immunol., 144,     2821–2828. -   112 Stavnezer, J., Kekish, O., Batter, D., Grenier, J., Balazs, I.,     Henderson, E. & Zegers, B. J. M. (1985) Nucl. Acids Res., 13,     3495–3514. -   113 Straubinger, B., Thiebe, R., Pech, M. & Zachau, H. G. (1988)     Gene, 69, 209–214. -   114 Suter, L, Barnikol, H. U., Watanabe, S. &     Hilschmann, N. (1969) Z. Physiol. Chem., 350, 275–278; (1972) Z.     Physiol. Chem., 353, 189–208. -   115 Tempest, P. R., Bremner, P., Lambert, M., Taylor, G., Furze, J.     M., Carr, F. J. & Harris, W. J. (1991) Bio/Tech., 9, 266–271. -   116 Titani, K., Shinoda, T. & Putnam, F. W. (1969) J. Biol. Chem.,     244, 3550–3560. -   117 Toft, K. G., Olstad, O. K., Sletten, K. & Westermark, P. (1990)     In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G.     Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer     Academic. -   118 Van Es, J. H., Aanstoot, H., Gmelig-Meyling, F. H. J.,     Derksen, R. H. W. M. & Logtenberg, T. (1992) J. Immunol., 149,     2234–2240. -   119 Victor, K. D., Pascual, V., Lefvert, A. K. & Capra, J. D. (1992)     Mol. Immunol., 29, 1501–1506. -   120 Victor, K. D., Pascual, V., Williams, C. L., Lennon, V. A. &     Capra, J. D. (1992) Eur. J. Immunol., 22, 2231–2236. -   121 Victor, K. D., Randen, I., Thompson, K., Forre, O., Natvig, J.     B., Fu, S. M. & Capra, J. D. (1991) J. Clin. Invest., 87, 1603–1613. -   122 Wagner, S. D. & Luzzatto, L. (1993) Eur. J. Immunol., 23,     391–397. -   123 Watanabe, S. & Hilschmann, N. (1970) Z. Physiol. Chem., 351,     1291–1295. -   124 Weisbart, R. H., Wong, A. L., Noritake, D., Kacena, A., Chan,     G., Ruland, C., Chin, E., Chen, I. S. Y. &     Rosenblatt, J. D. (1991) J. Immunol., 147, 2795–2801. -   125 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M. &     Marcus, D. M. (1992) J. Immunol., 149, 2518–2529. -   126 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur J. Immunol.,     22, 1719–1728.     References of Rearranged Human Lambda Sequences Used for Alignment -   1 Alexandre, D., Chuchana, P., Brockly, F., Blancher, A.,     Lefranc, G. & Lefranc, M.-P. (1989) Nuc. Acids Res., 17, 3975. -   2 Anderson, M. L. M., Brown, L., Mckenzie, E., Kellow, J. E. &     Young, B. D. (1985) Nuc. Acids Res, 13, 2931–2941. -   3 Andris, J. S., Brodeur, B. R. & Capra, J. D. (1993) Mol. Immunol.,     30, 1601–1616. -   4 Andris, J. S., Ehrlich, P. H., Ostberg, L. &     Capra, J. D. (1992) J. Immunol., 149, 4053–4059. -   5 Baczko, K., Braun, D. G., Hess, M. & Hilschmann, N. (1970) Z.     Physiol. Chem., 351, 763–767; Baczko, K., Braun, D. G. &     Hilschmann, N. (1974) Z. Physiol. Chem., 355, 131–154. -   6 Berinstein, N., Levy, S. & Levy, R. (1989) Science, 244, 337–339. -   7 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K. &     Teng, N. N. H. (1993) J. Immunol., 151, 5011–5021. -   8 Cairns, E., Kwong, P. C., Misener, V., Ip, P., Bell, D. A. &     Siminovitch, K. A. (1989) J. Immunol., 143, 685–691. -   9 Carroll, W. L., Yu, M., Link, M. P. & Korsmeyer, S. J. (1989) J.     Immunol., 143, 692–698. -   10 Chen, B. L. & Poljak, R. J. (1974) Biochemistry, 13, 1295–1302. -   11 Chen, B. L., Chiu, Y. Y. H., Humphrey, R. L. &     Polijak, R. J. (1978) Biochim. Biophys. Acta, 537, 9–21. -   12 Combriato, G. & Klobeck, H. G. (1991) Eur. J. Immunol., 21,     1513–1522. -   13 Cuisinier, A.-M., Fumoux, F., Fougereau, M. & Tonnelle, C. (1992)     Mol. Immunol., 29, 1363–1373. -   14 Dwulet, F. E., Strako, K. & Benson, M. D. (1985) Scand. J.     Immunol., 22, 653–660. -   15 Elahna, P., Livneh, A., Manheimer-Lory, A. J. &     Diamond, B. (1991) J. Immunol., 147, 2771–2776. -   16 Engelhard, M., Hess, M. & Hilschmann, N. (1974) Z. Physiol.     Chem., 355, 85–88; Engelhard, M. & Hilschmann, N. (1975) Z. Physiol.     Chem., 356, 1413–1444. -   17 Eulitz, M. (1974) Eur. J. Biochem., 50, 49–69. -   18 Eulitz, M., Breuer, M. & Linke, R. P. (1987) Biol. Che.     Hoppe-Seyler, 368, 863–870. -   19 Eulitz, M., Murphy, C., Weiss, D. T. & Solomon, A. (1991) J.     Immunol., 146, 3091–3096. -   20 Fett, J. W. & Deutsch, H. F. (1974) Biochemistry, 13, 4102–4114. -   21 Fett, J. W. & Deutsch, H. F. (1976) Immunochem., 13, 149–155.;     Jabusch, J. R. & Deutsch, H. F. (1982) Mol. Immunol., 19, 901–906. -   22 Furey, W. Jr., Wang, B. C., Yoo, C. S. & Sax, M. (1983) J. Mol.     Biol., 167, 661–692. -   23 Fykse, E.-M., Sletten, K., Husby, G. & Cornwell, G. G.,     Iii (1988) Biochem. J., 256, 973–980. -   24 Garver, F. A. & Hilschmann, N. (1971) Febs Letters, 16,     128–132; (1972) Eur. J. Biochem., 26, 10–32. -   25 Gawinowicz, M. A., Merlini, G., Birken, S., Osserman, E. F. &     Kabat, E. A. (1991) J. Immunol., 147, 915–920. -   26 Ghiso, J., Solomon, A. & Frangione, B. (1986) J. Immunol., 136,     716–719. -   27 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M.,     Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P.,     Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R. &     Winter, G. (1993) Embo J., 12, 725–734. -   28 Gullasken, N., Idso, H., Nilsen, R., Sletten, K., Husby, G. &     Cornwell, G. G. (1990) In Amyloid And Amyloidosis, Eds. J. B.     Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P.     Westermark, Kluwer Academic -   29 Harindranath, N., Goldfarb, I. S., Ikematsu, H., Burastero, S.     E., Wilder, R. L, Notkins, A. L. & Casali, P. (1991) Int. Immunol.,     3, 865–875. -   30 Holm, E., Sletten, K. & Husby, G. (1986) Biochem. J., 239,     545–551. -   31 Hughes-Jones, N. C., Bye, J. M., Beale, D. & Coadwell, J. (1990)     Biochem. J., 268, 135–140. -   32 Kametani, F., Yoshimura, K., Tonoike, H., Hoshi, A., Shinoda, T.     & Isobe, T. (1985) Biochem. Biophys. Res. Commun., 126, 848–852. -   33 Kiefer, C. R., Mcguire, B. S., Jr., Osserman, E. F. &     Garver, F. A. (1983) J. Immunol., 131, 1871–1875. -   34 Kiefer, C. R., Patton, H. M., Jr., Mcquire, B. S., Jr. &     Garver, F. A. (1980) J. Immunol., 124, 301–306. -   35 Kishimoto, T., Okajima, H., Okumoto, T. & Taniguchi, M. (1989)     Nucl. Acids Res., 17, 4385. -   36 Klafki, H.-W., Kratzin, H. D., Pick, A. I., Eckart, K. &     Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B.     Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P.     Westermark, Kluwer Academic -   37 Kohler, H., Rudofsky, S. & Kluskens, L. (1975) J. Immunology,     114, 415–421. -   38 Kojima, M., Odani, S. & Ikenaka, T. (1980) Mol. Immunol., 17,     1407–1414. -   39 Komori, S., Yamasaki, N., Shigeta, M., Isojima, S. &     Watanabe, T. (1988) Clin. Exp. Immunol., 71, 508–516. -   40 Kratzin, H. D., Palm, W., Stangel, M., Schmidt, W. E.,     Friedrich, J. & Hilschmann, N. (1989) Biol. Chem. Hoppe-Seyler, 370,     263–272. -   41 Kratzin, H. D., Pick, A. I., Stangel, M. & Hilschmann, N. (1990)     In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G.     Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer     Academic Publishers, Dordrecht/Boston/London, Pp. 181- -   42 Langer, B., Steinmetz-Kayne, M. & Hilschmann, N. (1968) Z.     Physiol. Chem., 349, 945–951. -   43 Larrick. J. W., Danielsson, L., Brenner, C. A., Wallace, E. F.,     Abrahamson, M., Fry, K. E. & Borrebaeck, C. A. K. (1989) Bio/Tech.,     7, 934–938. -   44 Levy, S., Mendel, E., Kon, S., Avnur, Z. & Levy, R. (1988) J.     Exp. Med., 168, 475–489. -   45 Lewis, A. P., Lemon, S. M., Barber, K. A., Murphy, P., Parry, N.     R., Peakman, T. C., Sims, M. J., Worden, J. & Crowe, J. S. (1993) J.     Immunol., 151, 2829–2838. -   46 Liu, V. Y. S., Low, T. L. K, Infante, A. & Putnam, F. W. (1976)     Science, 193, 1017–1020; Infante, A. & Putnam, F. W. 11979) J. Biol.     Chem., 254, 9006–9016. -   47 Lopez De Castro, J. A., Chiu, Y. Y. H. & Poljak, R. J. (1978)     Biochemistry, 17, 1718–1723. -   48 Mantovani, L., Wilder, R. L. & Casali, P. (1993) J. Immunol.,     151, 473–488. -   49 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J.,     Griffiths, A. D. & Winter, G. (1991) J. Mol. Biol., 222, 581–597. -   50 Mihaesco, E., Roy, J.-P., Congy, N., Peran-Rivat, L. &     Mihaesco, C. (1985) Eur. J. Biochem., 150, 349–357. -   51 Milstein, C., Clegg, J. B. & Jarvis, J. M. (1968) Biochem. J.,     110, 631–652. -   52 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D. &     Hersh, E. M. (1993) Mol. Immunol., 30, 1543–1551. -   53 Nabeshima, Y. & Ikenaka, T. (1979) Mol. Immunol., 16, 439–444. -   54 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos,     M., Kozin, F., Carson, D. A. & Chen, P. P. (1992) J. Exp. Med., 175,     831–842. -   55 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M.,     Forre, O., Fu, S.-M., Natvig, J. B. & Capra, J. D. (1992) Scand. J.     Immunol., 36.349–362. -   56 Paul, E., Iliev, A. A., Livneh, A. & Diamond, B. (1992) J.     Immunol., 149, 3588–3595. -   57 Pick, A. I., Kratzin, H. D., Barnikol-Watanabe, S. &     Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B.     Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten a P.     Westermark, Kluwer Academic -   58 Ponstingl. H. & Hilschmann, N. (1969) Z. Physiol. Chem., 350,     1148–1152; (1971) Z. Physiol. Chem., 352, 859–877. -   59 Ponstingl, H., Hess, M. & Hilschmann, N. (1968) Z. Physiol.     Chem., 349, 867–871; (1971) Z. Physiol. Chem., 352.247–266. -   60 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O.,     Capra, J. D. & Natvig, J. B. (1993) Eur. J. Immunol., 23, 1220–1225. -   61 Scholz, R. & Hilschmann, N. (1975) Z. Physiol. Chem., 356,     1333–1335. -   62 Settmacher, U., Jahn, S., Siegel, P., Von Baehr, R. &     Hansen, A. (1993) Mol. Immunol., 30, 953–954. -   63 Shinoda, T., Titani, K. & Putnam, F. W. (1970) J. Biol. Chem.,     245, 4475–4487. -   64 Sletten, K., Husby, G. & Natvig, J. B. (1974) Scand J. Immunol.,     3, 833–836.; Sletten, K., Natvig, J. B., Husby, G. & Juul, J. (1981)     Biochem J., 195, 561–572. -   65 Solomon, A, Frangione, B. & Franklin, E. C. (1982) J. Clin.     Invest., 70, 453–460.; Frangione, B., Moloshok, T. & Solomon,     A (1983) J. Immunol., 131, 2490–2493. -   66 Takahashi, N., Takayasu, T., Isobe, T., Shinoda, T., Okuyama, T.     & Shimizu, A (1979) J. Biochem., 86, 1523–1535. -   67 Takahashi, N., Takayasu, T., Shinoda, T., Ito, S., Okuyama, T. &     Shimizu, A. (1980) Biomed. Res., 1, 321–333. -   68 Takahashi, Y., Takahashi, N., Tetaert, D. & Putnam, F. W. (1983)     Proc. Nat. Acad. Sci. Usa, 80, 3686–3690. -   69 Takayasu, T., Takahashi, N., Shinoda, T., Okuyama, T. &     Tomioka, H. (1980) J. Biochem., 89, 421–436. -   70 Titani, K., Wikler, M., Shinoda, T. & Putnam, F. W. (1970) J.     Biol. Chem., 245, 2171–2176. -   71 Toft, K. G., Sletten, K. & Husby, G. (1985) Biol. Chem.     Hoppe-Seyler, 366, 617–625. -   72 Tonoike, H., Kametani, F., Hoshi, A, Shinoda, T. &     Isobe, T. (1985) Biochem. Biophys. Res. Commun., 126, 1228–1234. -   73 Tonoike, H., Kametani, F., Hoshi, A., Shinoda, T. &     Isobe, T. (1985) Febs Letters, 185, 139–141. -   74 Tsujimoto, Y. & Croce, C. M. (1984) Nucl. Acids Res., 12,     8407–8414. -   75 Tsunetsugu-Yokota, Y., Minekawa, T., Shigemoto, K., Shirasawa, T.     & Takemori, T. (1992) Mol. Immunol., 29, 723–728. -   76 Tveteraas, T., Sletten, K. & Westermark, P. (1985) Biochem. J.,     232, 183–190. -   77 Vasicek, T. J. & Leder, P. (1990) J. Exp. Med., 172, 609–620. -   78 Victor, K. D., Randen, I., Thompson, K., Forre, O., Natvig, J.     B., Fu, S. M. & Capra, J. D. (1991) J. Clin. Invest., 87, 1603–1613. -   79 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M. &     Marcus, D. M. (1992) J. Immunol., 149, 2518–2529. -   80 Wikler, M. & Putnam, F. W. (1970) J. Biol. Chem., 245, 4488–4507. -   81 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur. J. Immunol.,     22, 1719–1728. -   82 Yago, K., Zenita, K., Ohwaki, I., Harada, Y., Nozawa, S.,     Tsukazaki, K., Iwamori, M., Endo, N., Yasuda, N., Okuma, M. &     Kannagi, R. (1993) Mol. Immunol., 30, 1481–1489. -   83 Yamasaki, N., Komori, S. & Watanabe, T. (1987) Mol. Immunol., 24,     981–985. -   84 Zhu, D., Kim, H. S. & Deutsch, H. F. (1983) Mol. Immunol., 20,     1107–1116. -   85 Zhu, D., Zhang, H., Zhu, N. & Luo, X. (1986) Scientia Sinica, 29,     746–755.     References of Rearranged Human Heavy Chain Sequences Used for     Alignment -   1 Adderson, E. E., Azmi, F. H., Wilson, P. M., Shackelford, P. G. &     Carroll, W. L. (1993) J. Immunol., 151, 800–809. -   2 Adderson, E. E., Shackelford, P. G., Quinn, A. &     Carroll, W. L. (1991) J. Immunol., 147, 1667–1674. -   3 Akahori, Y., Kurosawa, Y., Kamachi, Y., Torii, S. &     Matsuoka, H. (1990) J. Clin. Invest., 85, 1722–1727. -   4 Andris, J. S., Brodeur, B. R. & Capra, J. D. (1993) Mol. Immunol.,     30, 1601–1616. -   5 Andris, J. S., Ehrlich, P. H., Ostberg, L. &     Capra, J. D. (1992) J. Immunol., 149, 4053–4059. -   6 Andris, J. S., Johnson, S., Zolla-Pazner, S. & Capra, J. D. (1991)     Proc. Natl. Acad. Sci. Usa, 88, 7783–7787. -   7 Anker, R., Conley, M. E. & Pollok, B. A. (1989) J. Exp. Med., 169,     2109–2119. -   8 Atkinson, P. M., Lampman, G. W., Furie, B. C., Naparstek, Y.,     Schwartz, R. S., Stollar, B. D. & Furie, B. (1985) J. Clin. Invest.,     75, 1138–1143.; Lampman, G. W., Furie, B., Schwartz, R. S.,     Stollar, B. D. & Furie, B. C. (1989) -   9 Avila, M. A., Vazques, J., Danielsson, L., Fernandez De     Cossio, M. E. & Borrebaeck, C. A. K. (1993) Gene, 127, 273–274. -   10 Bakkus, M. H. C., Heirman, C., Van Riet, I., Van Camp, B. &     Thielemans, K. (1992) Blood, 80, 2326–2335. -   11 Barbas Iii, C. F., Crowe, Jr., J. E., Cababa, D., Jones, T. M.,     Zebedee, S. L., Murphy, B. R., Chanock, R. M. & Burton, D. R. (1992)     Proc. Natl. Acad. Sci. Usa, 89, 10164–10168. -   12 Barbas, C. F., Iii, Collet, T. A., Amberg, W., Roben, P.,     Binley, J. M., Hoekstra, D., Cababa, D., Jones, T. M.,     Williamson, R. A., Pilkington, G. R., Haigwood, N. L., Cabezas, E.,     Satterthwait, A. C., Sanz, I. & Burton, D. R. (1993) J. Mol. Biol.,     230, 812–823. -   13 Berman, J. E., Humphries, C. G., Barth, J., Alt, F. W. &     Tucker, P. W. (1991) J. Exp. Med., 173, 1529–1535. -   14 Berman, J. E., Mellis, S. J., Pollock, R., Smith, C. L., Suh, H.,     Heinke, B., Kowal, C., Surti, U., Chess, L, Cantor, C. R &     Alt, F. W. (1988) Embo J., 7, 727–738. -   15 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K. &     Teng, N. N. H. (1993) J. Immunol., 151, 5011–5021. -   16 Bird, J., Galili, N., Link, M., Stites, D. & Sklar, J. (1988) J.     Exp. Med., 168, 229–245. -   17 Cai, J., Humphries, C., Richardson, A. & Tucker, P. W. (1992) J.     Exp. Med., 176, 1073–1081. -   18 Cairns, E., Kwong, P. C., Misener, V., Ip, P., Bell, D. A. &     Siminovitch, K. A. (1989) J. Immunol., 143, 685–691. -   19 Capra, J. D. & Hopper, J. E. (1976) Immunochemistry, 13, 995–999;     Hopper, J. E., Noyes, C., Heinrikson, R. & Kessel, J. W. (1976) J.     Immunol., 116, 743–746. -   20 Capra, J. D. & Kehoe, J. M. (1974) Proc. Nat. Acad. Sci. Usa, 71,     845–848. -   21 Carroll, W. L., Yu, M., Link, M. P. & Korsmeyer, S. J. (1989) J.     Immunol., 143, 692–698. -   22 Chen, P. P., Liu, M.-F., Glass, C. A., Sinha, S., Kipps, T. J. &     Carson, D. A. (1989) Arthritis & Rheumatism, 32, 72–76; Kipps, T.     J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P. &     Carson, D. A. (1989) Proc. Natl. Acad. Sci. Usa, 86, 5913–5917. -   23 Chiu, Y. Y. H., Lopez De Castro, J. A. Poljak, R. J. (1979)     Biochemistry, 18, 553–560. -   24 Cleary, M. L., Meeker, T. C., Levy, S., Lee, E., Trela, M.,     Sklar, J. & Levy, R. (1986) Cell, 44, 97–106. -   25 Cuisinier, A.-M., Fumoux, F., Fougereau, M. & Tonnelle, C. (1992)     Mol. Immunol., 29, 1363–1373. -   26 Cuisinier, A.-M., Gauthier, L., Boubli, L., Fougereau, M. &     Tonnelle, C. (1993) Eur. J. Immunol., 23, 110–118. -   27 Cunningham, B. A., Gottlieb. P. D., Pflumm, M. N. &     Edelman, G. M. (1971) Progress in Immunology (B. Amos, Ed.),     Academic Press, N. Y., Pp. 3–24. -   28 Cunningham, B. A., Rutishauser, U., Gall, W. E., Gottlieb, P. D.,     Waxdal, M. J. & Edelman, G. M. (1970) Biochemistry, 9, 3161–3170. -   29 Deane, M. & Norton, J. D. (1990) Eur. J. Immunol., 20, 2209–2217. -   30 Deane, M. & Norton, J. D. (1991) Leukemia, 5, 646–650. -   31 Dersimonian, H., Schwartz, R. S., Barrett, K. J. &     Stollar, B. D. (1987) J. Immunol., 139, 2496–2501. -   32 Dersimonian, H., Schwartz, R. S., Barrett, K. J. &     Stollar, B. D. (1987) J. Immunol., 139, 2496–2501; Chen, P. P., Liu,     M.-F., Sinha, S. & Carson, D. A. (1988) Arth. Rheum., 31, 1429–1431. -   33 Desai, R., Spatz, L., Matsuda, T., Ilyas, A. A., Berman, J. E.,     Alt, F. W., Kabat, E. A. & Latov, N. (1990) J. Neuroimmunol., 26,     35–41. -   34 Ezaki, I., Kanda, H., Sakai, K., Fukui, N., Shingu, M.,     Nobunaga, M. & Watanabe, T. (1991) Arthritis And Rheumatism, 34,     343–350. -   35 Felgenhauer, M., Kohl, J. & Ruker, F. (1990) Nucl. Acids Res.,     18, 4927. -   36 Florent, G., Lehman, D. & Putnam, F. W. (1974) Biochemistry, 13,     2482–2498. -   37 Friedlander, R. M., Nussenzweig, M. C. & Leder, P. (1990) Nucl.     Acids Res., 18, 4278. -   38 Gawinowicz, M. A., Merlini, G., Birken, S., Osserman, E. F. &     Kabat, E. A. (1991) J. Immunol., 147,915–920. -   39 Gillies, S. D., Dorai, H., Wesolowski, J., Majeau, G., Young, D.,     Boyd, J., Gardner, J. & James, K. (1989) Bio/Tech., 7, 799–804. -   40 Goni F. & Frangione, B. (1983) Proc. Nat. Acad. Sci. Usa, 80,     4837–4841. -   41 Gorman, S. D., Clark, M. R., Routledge, E. G., Cobbold, S. P. &     Waldmann, H. (1991) Proc. Natl. Acad. Sci. Usa, 88, 4181–4185. -   42 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M.,     Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P.,     Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R. &     Winter, G. (1993) Embo J., 12, 725–734. -   43 Grillot-Courvalin, C., Brouet, J.-C., Piller, F., Rassenti, L.     Z., Labaume, S., Silverman, G. J., Silberstein, L. &     Kipps, T. J. (1992) Eur. J. Immunol., 22, 1781–1788. -   44 Guillaume, T., Rubinstein, D. B., Young, F., Tucker, L.,     Logtenberg, T., Schwartz, R. S. & Barrett, K. L. (1990) J. Immunol.,     145, 1934–1945; Young, F., Tucker, L., Rubinstein, D., Guillaume,     T., Andre-Schwartz, J., Barrett, K. J., Schwartz, R. S. &     Logtenberg, T. (1990) -   45 Harindranath, N., Goldfarb, I. S., Ikematsu, H., Burastero, S.     E., Wilder, R. L., Notkins, A. L. & Casali, P. (1991) Int. Immunol.,     3, 865–875. -   46 Hillson, J. L., Oppliger, I. R., Sasso, E. H., Milner, E. C. B. &     Wener, M. H. (1992) J. Immunol., 149, 3741–3752. -   47 Hirabayashi, Y., Munakata, Y., Sasaki, T. & Sano, H. (1992) Nucl.     Acids Res., 20, 2601. -   48 Hoch, S. & Schwaber, J. (1987) J. Immunol., 139, 1689–1693. -   49 Huang, C., Stewart, A. K., Schwartz, R. S. &     Stollar, B. D. (1992) J. Clin. Invest., 89, 1331–1343. -   50 Hughes-Jones, N. C, Bye, J. M., Beale, D. & Coadwell, J. (1990)     Biochem J., 268, 135–140. -   51 Ikematsu, H., Harindranath, N., Ueki, Y., Notkins, A. L. &     Casali, P. (1993) J. Immunol., 150, 1325–1337. -   52 Ikematsu, H., Kasaian, M. T., Schettino, E. W. &     Casali, P. (1993) J. Immunol., 151, 3604–3616. -   53 Kelly, P. J., Pascual, V., Capra, J. D. & Lipsky, P. E. (1992) J.     Immunol., 148, 1294–1301. -   54 Kipps, T. J. & Duffy, S. F. (1991) J. Clin. Invest., 87,     2087–2096. -   55 Kipps, T. J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P. &     Carson, D. A. (1989) Proc. Natl. Acad. Sci. Usa, 86, 5913–5917. -   56 Kishimoto, T., Okajima, H., Okumoto, T. & Taniguchi, M. (1989)     Nucl. Acids Res., 17, 4385. -   57 Knight, G. B., Agnello, V., Bonagura, V., Barnes, J. L.,     Panka, D. J. & Zhang, Q. X. (1993) J. Exp. Med., 178, 1903–1911. -   58 Kohler, H., Shimizu, A, Paul, C., Moore, V. &     Putnam, F. W. (1970) Nature, 227, 1318–1320; Florent, G., Lehman, D.     & Putnam, F. W. (1974) Biochemistry, 13, 2482–2498 -   59 Komori, S., Yamasaki, N., Shigeta, M., Isojima, S. &     Watanabe, T. (1988) Clin. Exp. Immunol., 71, 508–516. -   60 Kon, S., Levy, S. & Levy, R. (1987) Proc. Natl. Acad. Sci. Usa,     84, 5053–5057. -   61 Kratzin, H., Altevogt, P., Ruban, E., Kortt, A., Staroscik, K. &     Hilschmann, N. (1975) Z. Physiol. Chem., 356, 1337–1342; Kratzin,     H., Altevogt, P., Kortt, A, Ruban, E. & Hilschmann, N. (1978) Z.     Physiol. Chem., 359, 1717–1745. -   62 Kudo, A., Ishihara, T., Nishimura, Y. & Watanabe, T. (1985) Gene,     33, 181–189. -   63 Kunicki, T. J., Annis, D. S., Gorski, J. &     Nugent, D. J. (1991) J. Autoimmunity, 4, 433–446. -   64 Larrick, J. W., Wallace, E. F., Coloma, M. J., Bruderer, U.,     Lang, A. B. & Fry, K. E. (1992) Immunological Reviews, 130, 69–85. -   65 Lehman, D. W. & Putnam, F. W. (1980) Proc. Nat. Acad. Sci. Usa,     77, 3239–3243. -   66 Lewis, A. P., Lemon, S. M., Barber. K. A., Murphy, P., Parry, N.     R., Peakman, T. C., Sims, M. J., Worden, J. & Crowe, J. S. (1993) J.     Immunol., 151, 2829–2838. -   67 Liu, V. Y. S., Low, T. L. K., Infante, A. & Putnam, F. W. (1976)     Science, 193, 1017–1020. -   68 Logtenberg, T., Young, F. M., Van Es, J., Gmelig-Meyling, F. H.     J., Berman, J. E. & Alt, F. W. (1989) J. Autoimmunity, 2, 203–213. -   69 Logtenberg, T., Young, F. M., Van Es, J. H.,     Gmelig-Meyling, F. H. J. & Alt, F. W. (1989) J. Exp. Med., 170,     1347–1355. -   70 Manheimer-Lory, A., Katz, J. B., Pillinger, M., Ghossein, C.,     Smith, A. & Diamond, B. (1991) J. Exp. Med., 174, 1639–1652. -   71 Mantovani, L., Wilder, R. L. & Casali, P. (1993) J. Immunol.,     151, 473–488. -   72 Mariette, X., Tsapis, A. & Brouet, J.-C. (1993) Eur. J. Immunol.,     23, 846–851. -   73 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J.,     Griffiths, A. D. & Winter, G. (1991) J. Mol. Biol., 222, 581–597. -   74 Meeker, T. C., Grimaldi, J., O'rourke, R., Loeb, J. Juliusson, G.     & Einhorn, S. (1988) J. Immol., 141, 3994–3998. -   75 Milili, M., Fougereau, M., Guglielmi, P. & Schiff, C. (1991) Mol.     Immunol., 28, 753–761. -   76 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D. &     Hersh, E. M. (1993) Mol. Immunol., 30, 1543–1551. -   77 Mortari, F., Wang, J.-Y. & Schroeder, Jr., H. W. (1993) J.     Immunol., 150, 1348–1357. -   78 Newkirk, M. M., Gram, H., Heinrich, G. F., Ostberg, L,     Capra, J. D. & Wasserman, R. L. (1988) J. Clin. Invest., 81,     1511–1518. -   79 Newkirk, M. M., Mageed, R. A., Jefferis, R., Chen, P. P. &     Capra, J. D. (1987) J. Exp. Med., 166, 550–564. -   80 Nickerson, K. G., Berman, J., Glickman, E., Chess, L. &     Alt, F. W. (1989) J. Exp. Med., 169, 1391–1403. -   81 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos,     M., Kozin, F., Carson, D. A. & Chen, P. P. (1992) J. Exp. Med., 175,     831–842. -   82 Pascual, V., Randen, I., Thompson, K., Sioud, M. Forre, O.,     Natvig, J. & Capra, J. D. (1990) J. Clin. Invest., 86, 1320–1328. -   83 Pascual, V., Randen, I., Thompson, K., Sioud, M. Forre, O.,     Natvig, J. & Capra, J. D. (1990) J. Clin. Invest., 86, 1320–1328;     Randen, I., Brown, D., Thompson, K. M., Hughes-Jones, N., Pascual,     V., Victor, K., Capra, J. D., Forre, O. & Natvig, J. B. (1992) -   84 Pascual, V., Victor, K., Lelsz, D., Spellerberg, M. B.,     Hamblin, T. J., Thompson, K. M., Randen, I., Natvig, J.,     Capra, J. D. & Stevenson, F. K. (1991) J. Immunol., 146, 4385–4391. -   85 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M.,     Forre, O., Fu, S.-M., Natvig, J. B. & Capra, J. D. (1992) Scand J.     Immunol., 36, 349–362. -   86 Pascual, V., Victor. K., Spellerberg, M., Hamblin, T. J.,     Stevenson, F. K. & Capra. J. D. (1992) J. Immunol., 149, 2337–2344. -   87 Ponstingl, H., Schwarz, J., Reichel, W. &     Hilschmann, N. (1970) Z. Physiol. Chem., 351, 1591–1594.;     Ponstingl, H. & Hilschmann, N. (1976) Z. Physiol. Chem., 357,     1571–1604. -   88 Portolano, S., Mclachlan, S. M. & Rapoport, B. (1993) J.     Immunol., 151, 2839–2851. -   89 Portolano, S., Seto, P., Chazenbalk, G. D., Nagayama, Y.,     Mclachlan, S. M. & Rapoport, B. (1991) Biochem. Biophys. Res.     Commun., 179,372–377. -   90 Pratt, L. F., Szubin, R., Carson, D. A. & Kipps, T. J. (1991) J.     Immunol., 147, 2041–2046. -   91 Press, E. M. & Hogg, N. M. (1970) Biochem J., 117, 641–660. -   92 Putnam, F. W., Shimizu, A, Paul., C., Shinoda, T. &     Kohler, H. (1971) Ann. N.Y. Acad. Sci., 190, 83–103. -   93 Putnam, F. W., Takahashi, N., Tetaert, D., Debuire, B. &     Lin, L. C. (1981) Proc. Nat. Acad. Sci. Usa; 78, 6168–6172.;     Takahashi, N., Tetaert, D., Debuire, B., Lin, L. &     Putnam, F. W. (1982) Proc. Nat. Acad. Sci. Usa, 79, 2850–2854. -   94 Raaphorst, F. M., Timmers, E., Kenter, M. J. H., Van Tol, M. J.     D., Vossen, J. M. & Schuurman, R. K. B. (1992) Eur. J. Immunol., 22,     247–251. -   95 Rabbitts, T. H., Bentley, D. L., Dunnick, W., Forster, A.,     Matthyssens, G. & Milstein, C. (1980) Cold Spring Harb. Symp.     Quanti. Biol., 45, 867–878; Matthyssens, G. & Rabbitts, T. H. (1980)     Proc. Nat. Acad. Sci. Usa, 77, 6561–6565. -   96 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O.,     Capra, J. D. & Natvig, J. B. (1993) Eur J. Immunol., 23, 1220–1225. -   97 Rassenti, L. Z. & Kipps, T. J. (1993) J. Exp. Med., 177,     1039–1046. -   98 Reidl, L. S., Friedman, D. F., Goldman, J., Hardy, R. R.,     Jefferies, L. C. & Silberstein, L. E. (1991) J. Immunol., 147,     3623–3631. -   99 Roudier, J., Silverman, G. J., Chen, P. P., Carson, D. A. &     Kipps, T. J. (1990) J. Immunol., 144, 1526–1530. -   100 Sanz, I., Casali, P., Thomas, J. W., Notkins, A. L. &     Capra, J. D. (1989) J. Immunol., 142, 4054–4061. -   101 Sanz, I., Dang, H., Takei, M., Talal, N. &     Capra, J. D. (1989) J. Immunol., 142, 883–887. -   102 Schmidt, W. E., Jung, H-.D., Palm, W. & Hilschmann, N. (1983) Z.     Physiol. Chem., 364, 713–747. -   103 Schroeder, H. W., Jr. & Wang, J. Y. (1990) Proc. Natl. Acad.     Sci. Usa, 87, 6146–6150. -   104 Schroeder, H. W., Jr., Hillson, J. L. & Perlmutter, R. M. (1987)     Science, 238, 791–793. -   105 Schroeder, H. W., Jr., Hillson, J. L. & Perlmutter, R. M. (1987)     Science, 238, 791–793; Chen, P. P., Liu, M.-F., Glass, C. A, Sinha,     S., Kipps, T. J. & Carson, D. A. (1989) Arthritis & Rheumatism, 32,     72–76. -   106 Schroeder, H. W., Jr., Hillson, J. L. & Perlmutter, R. M. (1987)     Science, 238, 791–793; Chen, P. P., Liu, M.-F., Sinha, S. &     Carson, D. A. (1988) Arth. Rheum., 31, 1429–1431. -   107 Schutte, M. E., Ebeling, S. B., Akkermans, K. E.,     Gmelig-Meyling, F. H. & Logtenberg, T. (1991) Eur. J. Immunol., 21,     1115–1121. -   108 Schutte, M. E., Ebeling, S. B., Akkermans, K. E.,     Gmelig-Meyling, F. H. J. & Logtenberg, T. (1991) Eur. J. Immunol.,     21, 1115–1121. -   109 Settmacher, U., Jahn, S., Siegel, P., Von Baehr, R. &     Hansen, A. (1993) Mol. Immunol., 30, 953–954. -   110 Shen, A., Humphries, C, Tucker, P. & Blattner, F. (1987) Proc.     Natl. Acad. Sci. Usa, 84, 8563–8567. -   111 Shimizu, A., Nussenzweig, M. C., Mizuta, T.-R., Leder, P. &     Honjo, T. (1989) Proc. Natl. Acad. Sci. Usa, 86, 8020–8023. -   112 Shin, E. K., Matsuda, F., Fujikura, J., Akamizu, T., Sugawa, H.,     Mori, T. & Honjo, T. (1993) Eur. J. Immunol., 23, 2365–2367. -   113 Silberstein, L. E., Litwin, S. & Carmack, C. E. (1989) J. Exp.     Med., 169, 1631–1643. -   114 Singal, D. P., Frame, B., Joseph, S., Blajchman, M. A. &     Leber, B. F. (1993) Immunogenet., 38, 242. -   115 Spatz, L. A., Wong, K. K., Williams, M., Desai, R., Golier, J.,     Berman, J. E., Alt, F. W. & Latov, N. (1990) J. Immunol., 144,     2821–2828. -   116 Steiner, L. A., Garcia-Pardo, A. & Margolies, M. N. (1979)     Biochemistry, 18, 4068–4080. -   117 Stewart, A. K., Huang, C., Stollar, B. D. &     Schwartz, R. S. (1993) J. Exp. Med., 177, 409–418. -   118 Thomas, J. W. (1993) J. Immunol., 150, 1375–1382. -   119 Torano, A. & Putnam, F. W. (1978) Proc. Nat. Acad. Sci. Usa, 75,     966–969. -   120 Van Der Heijden, R. W. J., Bunschoten, H., Pascual, V.,     Uytdehaag, F. G. C. M., Osterhaus, A. D. M. E. &     Capra, J. D. (1990) J. Immunol., 144, 2835–2839. -   121 Van Der Stoep, N., Van Der Linden, J. & Logtenberg, T. (1993) J.     Exp. Med., 177, 99–107. -   122 Van Es, J. H., Gmelig-Meyling, F. H. J. & Logtenberg, T. (1992)     Eur. J. Immunol., 22, 2761–2764. -   123 Varade, W. S., Marin, E., Kittelberger, A. M. &     Insel, R. A. (1993) J. Immunol., 150, 4985–4995. -   124 Victor, K. D., Pascual, V., Lefvert, A. K. & Capra, J. D. (1992)     Mol. Immunol., 29, 1501–1506. -   125 Victor, K. D., Pascual, V., Williams, C. L., Lennon, V. A. &     Capra, J. D. (1992) Eur. J. Immunol., 22, 2231–2236. -   126 Watanabe, S., Barnikol, H. U., Horn, J., Bertram, J. &     Hilschmann, N. (1973) Z. Physiol. Chem., 354, 1505–1509. -   127 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M. &     Marcus, D. M. (1992) J. Immunol., 149, 2518–2529. -   128 White, M. B., Word, C. J., Humphries, C. G., Blattner, F. R. &     Tucker, P. W. (1990) Mol. Cell. Biol., 10, 3690–3699. -   129 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur. J.     Immunol., 22, 1719–1728. -   130 Yago, K., Zenita, K., Ohwaki, I., Harada, Y., Nozawa, S.,     Tsukazaki, K., Iwamori, M., Endo, N., Yasuda, N., Okuma, M. &     Kannagi, R. (1993) Mol. Immunol., 30, 1481–1489. -   131 Zelenetz, A. D., Chen, T. T. & Levy, R. (1992) J. Exp. Med.,     176, 1137–1148.     B. References of Germline Sequences     References of Human Germline Kappa Sequences -   1 Cox, J. P. L, Tomlinson, I. M. & Winter, G. (1994) Eur. J.     Immunol., 24, 827–836. -   2 Huber, C., Et. Al. (1993) Eur. J. Immunol., 23, 2868. -   3 Klobeck, H. G., Bornkammm, G. W., Combriato, G., Mocikat, R.,     Pohlenz, H. D. & Zachau, H. G. (1985) Nucl. Acids Res., 13,     6515–6529. -   4 Lautner-Rieske, A., Huber, C., Meindl, A., Pargent, W.,     Schäble, K. F., Thiebe, R., Zocher, I. & Zachau, H. G. (1992)     Eur. J. Immunol. 22, 1023. -   5 Lorenz, W., Schäble, K. F., Thiebe, R., Stavnezer, J. &     Zachau, H. G. (1988) Mol. Immunol., 25, 479. -   6 Pargent, W., Meindl, A, Thiebe, R., Mitzel, S. &     Zachau, H. G. (1991) Eur. J. Immunol., 21, 1821–1827. -   7 Pech, M. & Zachau, H. G. (1984) Nuc. Acids Res., 12, 9229–9236. -   8 Pech, M., Jaenichen, H.-R., Pohlenz, H.-D., Neumaier, P. S.,     Klobeck, H.-G. & Zachau, H. G. (1984) J. Mol. Biol., 176, 189–204. -   9 Scott, M. G., Crimmins, D. L., Mccourt, D. W., Chung, G.,     Schäble, K. F., Thiebe, R., Quenzel, E.-M., Zachau, H. G. &     Nahm, M. H. (1991) J. Immunol., 147, 4007–4013. -   10 Stavnezer, J., Kekish, O., Batter, D., Grenier, J., Balazs, I.,     Henderson, E. & Zegers, B. J. M. (1985) Nucl. Acids Res., 13,     3495–3514. -   11 Straubinger, B. Huber, E., Lorenz, W., Osterholzer, E., Pargent,     W., Pech, M., Pohlenz, H.-D., Zimmer, F.-J. &     Zachau, H. G. (1988) J. Mol. Biol., 199, 23–34. -   12 Straubinger, B., Thiebe, R., Huber, C., Osterholzer, E. &     Zachau, H. G. (1988) Biol. Chem. Hoppe-Seyer, 369, 601–607.     References of Human Germline Lambda Sequences -   1 Williams, S. C. & Winter, G. (1993) Eur. J. Immunol., 23,     1456–1461. -   2 Siminovitch, K. A., Misener, V., Kwong, P. C., Song, Q.-L. &     Chen, P. P. (1989) J. Clin. Invest., 84, 1675–1678. -   3 Brockly, F., Alexandre, D., Chuchana, P., Huck, S., Lefranc, G. &     Lefranc, M.-P. (1989) Nuc. Acids. Res., 17, 3976. -   4 Daley, M. D., Peng, H.-Q., Misener, V., Liu, X.-Y., Chen, P. P. &     Siminovitch, K. A. (1992) Mol. Immunol., 29, 1515–1518. -   5 Deftos, M., Soto-Gil, R., Quan, M., Olee, T. & Chen, P. P. (1994)     Scand. J. Immunol., 39, 95. -   6 Stiernholm, N. B. J., Kuzniar, B. & Berinstein, N. L. (1994) J.     Immunol., 152, 4969–4975. -   7 Combriato, G. & Klobeck, H. G. (1991) Eur. J. Immunol., 21,     1513–1522. -   8 Anderson, M. L. M., Szajnert, M. F., Kaplan, J. C., Mccoll, L. &     Young, B. D. (1984) Nuc. Acids Res., 12, 6647–6661.     References of Human Germline Heavy Chain Sequences -   1 Adderson, E. E., Azmi, F. H., Wilson, P. M., Shackelford, P. G. &     Carroll, W. L. (1993) J. Immunol., 151, 800–809. -   2 Andris, J. S., Brodeur, B. R. & Capra, J. D. (1993) Mol. Immunol.,     30, 1601–1616. -   3 Berman, J. E., Mellis, S. J., Pollock, R., Smith, C. L., Suh, H.,     Heinke, B., Kowal, C., Surti, U., Chess, L, Cantor. C. R. &     Alt, F. W. (1988) Embo J., 7, 727–738. -   4 Buluwela, L. & Rabbitts, T. H. (1988) Eur. J. Immunol., 18,     1843–1845.; Buluwela, L., Albertson, D. G., Sherrington, P.,     Rabbitts, P. H., Spurr, N. & Rabbitts, T. H. (1988) Embo J., 7,     2003–2010. -   5 Chen, P. P., Liu, M.-F., Sinha, S. & Carson, D. A. (1988) Arth.     Rheum., 31, 1429–1431. -   6 Chen, P. P., Liu, M.-F., Glass, C. A., Sinha, S., Kipps, T. J. &     Carson, D. A. (1989) Arthritis & Rheumatism, 32, 72–76. -   7 Cook, G. P. et al. (1994) Nature Genetics 7, 162–168. -   8 Haino, M. et al., (1994). J. Biol. Chem. 269, 2619–2626 -   9 Humphries, C. G., Shen, A, Kuziel, W. A., Capra, J. D.,     Blattner, F. R. & Tucker, P. W. (1988) Nature, 331, 446–449. -   10 Kodaira, M., Kinashi, T., Umemura, I., Matsuda, F., Noma, T.,     Ono, Y. & Honjo, T. (1986) J. Mol. Biol., 190, 529–541. -   11 Lee, K. H., Matsuda, F., Kinashi, T., Kodaira, M. &     Honjo, T. (1987) J. Mol. Biol., 195,761–768. -   12 Matsuda, F., Lee, K. H., Nakai, S., Sato, T., Kodaira, M.,     Zong, S. Q., Ohno, H., Fukuhara, S. & Honjo, T. (1988) Embo J., 7,     1047–1051. -   13 Matsuda, F., Shin, E. K., Hirabayashi, Y., Nagaoka, H.,     Yoshida, M. C., Zong, S. Q. & Honjo, T. (1990) Embo J., 9,     2501–2506. -   14 Matsuda, F., Shin, E. K., Nagaoka, H., Matsumura, R., Haino, M.,     Fukita, Y., Taka-Ishi, S., Imai, T., Riley, J. H., Anand, R. Et,     Al. (1993) Nature Genet. 3, 88–94 -   15 Nagaoka, H., Ozawa, K., Matsuda, F., Hayashida, H., Matsumura,     R., Haino, M., Shin, E. K., Fukita, Y., Imai, T., Anand, R.,     Yokoyama, K., Eki, T., Soeda, E. & Honjo, T. (1993). (Temporal) -   16 Rechavi, G., Bienz, B., Ram, D., Ben-Neriah, Y., Cohen, J. B.,     Zakut, R. & Givol, D. (1982) Proc. Nat. Acad. Sci. Usa, 79,     4405–4409. -   17 Sanz, I., Kelly, P., Williams, C., Scholl, S., Tucker, P. &     Capra, J. D. (1989) Embo J., 8, 3741–3748. -   18 Shin, E. K., Matsuda, F., Fujikura, J., Akamizu, T., Sugawa, H.,     Mori, T. & Honjo, T. (1993) Eur. J. Immunol., 23, 2365–2367. -   19 Tomlinson, Im., Walter, G., Marks, Jd., Llewelyn, Mb. &     Winter. G. (1992) J. Mol. Biol. 227, 776–798. -   20 Van Der Maarel. S., Van Dijk, K. W., Alexander, C. M., Sasso, E.     H., Bull, A. & Milner, E. C. B. (1993) J. Immunol., 150, 2858–2868. -   21 Van Dijk, K. W., Mortari, F., Kirkham, P. M., Schroeder,     Jr., H. W. & Milner, E. C. B. (1993) Eur. J. Immunol., 23, 832–839. -   22 Van Es, J. H., Aanstoot, H., Gmelig-Meyling, F. H. J.,     Derksen, R. H. W. M. & Logtenberg, T. (1992) J. Immunol., 149,     2234–2240. -   23 Weng, N.-P., Snyder, J. G., Yu-Lee, L-Y. & Marcus, D. M. (1992)     Eur J. Immunol., 22, 1075–1082. -   24 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur J. Immunol.,     22, 1719–1728. -   25 Olee, T., Yang, P. M., Siminovitch, K. A., Olsen, N. J.,     Hillson, J. L., Wu, J., Kozin, F., Carson, D. A. &     Chen, P. P. (1991) J. Clin. Invest 88, 193–203. -   26 Chen, P. P. & Yang, P. M. (1990) Scand. J. Immunol. 31, 593–599. -   27 Tomlinson, M., Walter, G., Cook&Winter, G. (Unpublished). 

1. A modular replicable vector, comprising a plurality of vector modules, wherein each vector module is (a) flanked by DNA cleavage sites unique within said vector, and (b) essentially devoid of DNA cleavage sites comprised in a nucleotide sequence selected from the group consisting of V-kappa-1 (SEQ ID NO: 42), V-kappa-2 (SEQ ID NO: 44), V-kappa-3 (SEQ ID NO: 46), V-kappa-4 (SEQ ID NO: 48), V-lambda-1 (SEQ ID NO: 50), V-lambda-2 (SEQ ID NO: 52), V-lambda-3 (SEQ ID NO: 54), VH1A (SEQ ID NO: 56), VH1B (SEQ ID NO: 58), VH2 (SEQ ID NO: 60), VH3 (SEQ ID NO: 62), VH4 (SEQ ID NO: 64), VH5 (SEQ ID NO: 66), and VH6 (SEQ ID NO: 68) at the boundaries between each consensus framework region and each complementarity determining region.
 2. The vector according to claim 1, wherein said vector is selected from the group consisting of pCAL 4 (SEQ ID NO: 274), pCALO-1 (SEQ ID NO: 294), pCALO-2 (SEQ ID NO: 296), pCALO-3 (SEQ ID NO: 299) and pMCS (SEQ ID NO: 264).
 3. The vector according to claim 1, wherein said vector is a phagemid vector.
 4. The vector according to claim 1, comprising (a) an origin of replication selected from the group consisting of an origin of single-stranded replication, an origin of double-stranded replication for a low copy number plasmid and an origin of double-stranded replication for a high copy number plasmid; and (b) a plurality of vector modules selected from the group consisting of a promoter element, an operator element, a repressor element, a terminator element, a resistance gene, a recombination site, a filamentous phage gene III, a truncated filamentous phage gene III, a signal sequence, a purification tag, a detection tag, and a sequence encoding an additional (poly)peptide moiety.
 5. A modular replicable vector, comprising (i) a nucleotide sequence encoding an immunoglobulin variable region, comprising a modular sequence of four consensus framework regions interspaced by three complementarity determining regions CDR1, CDR2, and CDR3, wherein said nucleotide sequence comprises DNA cleavage sites at the boundary of each consensus framework region and each complementarity determining region, and (ii) a plurality of vector modules, wherein each vector module is flanked by DNA cleavage sites, wherein each of said DNA cleavage sites of (i) and (ii) is unique within said vector, and wherein said immunoglobulin variable region is a heavy chain or a light chain.
 6. The vector according to claim 5, wherein said framework regions correspond to the framework regions contained in a sequence selected from the group consisting of V-kappa-1 (SEQ ID NO: 42), V-kappa-2 (SEQ ID NO: 44), V-kappa-3 (SEQ ID NO: 46), and V-kappa-4 (SEQ ID NO: 48), V-lambda-1 (SEQ ID NO: 50), V-lambda-2 (SEQ ID NO: 52), and V-lambda-3 (SEQ ID NO: 54).
 7. The vector according to claim 5, wherein said framework regions correspond to the framework regions contained in a sequence selected from the group consisting of VH1A (SEQ ID NO: 56), VH1B (SEQ ID NO: 58), VH2 (SEQ ID NO: 60), VH3 (SEQ ID NO: 62), VH4 (SEQ ID NO: 64), VH5 (SEQ ID NO: 66), and VH6 (SEQ ID NO: 68).
 8. The vector according to claim 5, comprising (a) an origin of replication selected from the group consisting of an origin of double-stranded replication for a low copy number plasmid and an origin of double-stranded replication for a high copy number plasmid; and (b) a plurality of vector modules selected from the group consisting of a promoter element, an operator element, a repressor element, a terminator element, a resistance gene, a recombination site, a filamentous phage gene III, a truncated filamentous phage gene III, a signal sequence, a purification tag, a detection tag, and a sequence encoding an additional (poly)peptide moiety.
 9. The vector according to claim 5, wherein said additional moiety is selected from the group consisting of a toxin, a cytokine, a reporter enzyme, a metal-binding moiety, a peptide, a tag suitable for detection and/or purification, a homo-association domain and a hetero-association domain.
 10. The vector according to claim 5, wherein said vector is a phagemid vector.
 11. The vector according to claim 5, wherein said nucleotide sequence is selected from the group consisting of V-kappa-1 (SEQ ID NO: 42), V-kappa-2 (SEQ ID NO: 44), V-kappa-3 (SEQ ID NO: 46), and V-kappa-4 (SEQ ID NO: 48).
 12. The vector according to claim 5, wherein said nucleotide sequence is selected from the group consisting of V-lambda-1 (SEQ ID NO: 50), V-lambda-2 (SEQ ID NO: 52), and V-lambda-3 (SEQ ID NO: 54).
 13. The vector according to claim 5, wherein said nucleotide sequence is selected from the group consisting of VH1A (SEQ ID NO: 56), VH1B (SEQ ID NO: 58), VH2 (SEQ ID NO: 60), VH3 (SEQ ID NO: 62), VH4 (SEQ ID NO: 64), VH5 (SEQ ID NO: 66), and VH6 (SEQ ID NO: 68). 